US20170044136A1 - Pyridinoylpiperidines As 5-HT1F Agonists - Google Patents

Pyridinoylpiperidines As 5-HT1F Agonists Download PDF

Info

Publication number
US20170044136A1
US20170044136A1 US15/091,776 US201615091776A US2017044136A1 US 20170044136 A1 US20170044136 A1 US 20170044136A1 US 201615091776 A US201615091776 A US 201615091776A US 2017044136 A1 US2017044136 A1 US 2017044136A1
Authority
US
United States
Prior art keywords
alkyl
substituted
hydrogen
methyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/091,776
Inventor
Michael Philip Cohen
Daniel Timothy Kohlman
Sidney Xi Liang
Frantz Victor
Yao-Chang Xu
Bai-Ping Ying
DeAnna Piatt Zacherl
Deyi Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to US15/091,776 priority Critical patent/US20170044136A1/en
Publication of US20170044136A1 publication Critical patent/US20170044136A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • Sumatriptan and similar compounds previously advanced for the treatment of migraine had tended to be selected on the basis of this vasoconstrictive activity under the premises of the prior art models for migraine.
  • Serotonin (5-HT) exhibits diverse physiological activity mediated by at least seven receptor classes, the most heterogeneous of which appears to be 5-HT 1 .
  • a human gene which expresses one of these 5-HT 1 receptor subtypes, named 5-HT 1F was isolated by Kao and coworkers. Proc. Natl. Acad. Sci. USA, 90:408-412, 1993.
  • This 5-HT 1F receptor exhibits a pharmacological profile distinct from any serotonergic receptor yet described. It was found that sumatriptan, in addition to the above mentioned strong affinities for the 5-HT 1B and 5-HT 1D receptors, also has affinity for this receptor subtype, with a K i of about 23 nM. This suggests a possible role of the 5-HT 1F receptor in migraine.
  • 5-HT 1F receptor agonists include compounds disclosed in the following:
  • the compounds of the present invention may provide improved solubility, which facilitates suitability in preferred formulations, such as sublingual, buccal, and/or nasal formulations.
  • the present invention relates to pyridinoylpiperidine compounds of the general formula I:
  • R 1 is C 1 -C 6 alkyl, substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, substituted C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, substituted C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;
  • R 2 is hydrogen, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl-C 1 -C 3 alkyl, or a group of formula II
  • R 3 is hydrogen or C 1 -C 3 alkyl
  • R 4 is hydrogen, halo, or C 1 -C 3 alkyl
  • R 5 is hydrogen or C 1 -C 3 alkyl
  • R 6 is hydrogen or C 1 -C 6 alkyl
  • n is an integer from 1 to 6 inclusively.
  • the present invention relates to pyridinoylpiperidine compounds of the general formula I:
  • R 1 is phenyl, substituted phenyl, heterocycle or substituted heterocycle
  • R 2 is hydrogen or C 1 -C 2 alkyl
  • R 3 is hydrogen or methyl
  • R 4 and R 5 are both hydrogen.
  • This invention also relates to pharmaceutical formulations comprising a compound of formula I, or a pharmaceutically acceptable acid addition salt thereof, and a pharmaceutical carrier, diluent, or excipient.
  • pharmaceutical formulations containing a compound of formula I, or a pharmaceutically acceptable salt thereof adapted for the activation of 5-HT 1F receptors, for the inhibition of neuronal protein extravasation, for the treatment or prevention of migraine, and/or the treatment or prevention of anxiety in mammals, particularly humans.
  • the present invention relates to a method for activating 5-HT 1F receptors in mammals, particularly humans, comprising administering to a mammal in need of such activation an effective amount of a compound of formula I, or a pharmaceutically acceptable acid addition salt thereof.
  • the current invention relates to a method for inhibiting neuronal protein extravasation in mammals, particularly humans, comprising administering to a mammal in need of such inhibition an effective amount of a compound of formula I, or a pharmaceutically acceptable acid addition salt thereof.
  • the present invention relates to a method for treating or preventing migraine in mammals, particularly humans, comprising administering to a mammal in need of such treatment or prevention, an effective amount of a compound of formula I, or a pharmaceutically acceptable acid addition salt thereof.
  • the present invention relates to a method for treating anxiety in mammals, particularly humans, comprising administering to a mammal in need of such treatment or prevention, an effective amount of a compound of formula I, or a pharmaceutically acceptable acid addition salt thereof.
  • the present invention relates to a compound of formula I, or a pharmaceutically acceptable acid addition salt thereof, for use in the activation of 5-HT 1F receptors, in the inhibition of neuronal protein extravasation, in the treatment or prevention of migraine, and/or in the treatment of anxiety in mammals, particularly humans. That is to say, the present invention relates to the use of a compound of formula I as a medicament for the activation of 5-HT 1F receptors, for the inhibition of neuronal protein extravasation, for the treatment or prevention of migraine, and/or for the treatment of anxiety in mammals, particularly humans.
  • the present invention relates to the use of one or more compounds of formula I in the manufacture of a medicament for the activation of 5-HT 1F receptors, for the inhibition of neuronal protein extravasation, for the treatment or prevention of migraine, and/or for the treatment of anxiety in mammals, particularly humans.
  • the present invention provides for methods for the treatment of 5-HT 1F mediated disorders comprising administering to a mammal in need of such treatment, particularly a human, an effective amount of a compound of formula I, or a pharmaceutically acceptable acid addition salt thereof.
  • the present invention provides a process for the synthesis of compounds of formula I and of novel intermediates in the synthesis.
  • the present invention provides a process for preparing a 2-halo-6-(piperidin-4-carbonyl)pyridine compound of formula III
  • R 8 is an amino protecting group, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl-C 1 -C 3 alkyl, or a group of formula II
  • R 6 is hydrogen or C 1 -C 6 alkyl
  • n is an integer from 1 to 6 inclusively;
  • R 9 and R 10 are each methyl, or R 9 and R 10 , together with the nitrogen to which they are attached, combine to form azetidinyl, pyrrolidinyl, or piperidinyl.
  • R 7 is C1-C3 n-alkyl, or an amino protecting group; comprising reacting 2,6-dibromopyridine with n-butyl lithium to form 2-bromo-6-lithium pyridine, and then reacting the 2-bromo-6-lithium pyridine with a 4-(N,N′-dimethylamino)carbonyl piperidine compound of formula IV
  • One embodiment of the present invention is a method for increasing activation of 5-HT 1F receptors, while avoiding vasoconstrictive activity, for treating a variety of disorders that have been linked to decreased neurotransmission of serotonin in mammals. Included among these disorders are migraine, general pain, trigeminal neuralgia, dental pain or temperomandibular joint dysfunction pain, anxiety, general anxiety disorder, panic disorder, depression, disorders of sleep, chronic fatigue syndrome, premenstrual syndrome or late luteal phase syndrome, post-traumatic syndrome, memory loss, dementia including dementia of aging, social phobia, autism, attention deficit hyperactivity disorder, disruptive behavior disorders, impulse control disorders, borderline personality disorder, obsessive compulsive disorder, premature ejaculation, erectile dysfunction, bulimia, anorexia nervosa, alcoholism, tobacco abuse, mutism, and trichotillomania.
  • the compounds of this invention are also useful as a prophylactic treatment for migraine. Any of these methods employ a compound of formula I.
  • DSM-IVTM Diagnostic and Statistical Manual of Mental Disorders
  • ICD-10 International Classification of Diseases, Tenth Revision
  • a compound of formula I or a combination of more than one compound of formula I, in the manufacture of a medicament for the activation of the 5-HT 1F receptor, for the inhibition of neuronal peptide extravasation, in general or due to stimulation of the trigeminal ganglia specifically, and/or for the treatment of any of the disorders described above, are also all embodiments of the present invention.
  • alkyl refers to a branched or unbranched saturated hydrocarbon group.
  • n-alkyl refers to an unbranched alkyl group.
  • C x -C y alkyl refers to an alkyl group having between x and y carbon atoms, inclusively, in the branched or unbranched hydrocarbon group.
  • C 1 -C 4 alkyl refers to a straight chain or branched hydrocarbon moiety having from 1 to 4 carbon atoms, including methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl.
  • C 1 -C 4 n-alkyl refers to straight chain hydrocarbon moieties having from 1 to 4 carbon atoms including methyl, ethyl, n-propyl, and n-butyl.
  • C 3 -C 6 cycloalkyl refers to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • C 3 -C 7 cycloalkyl also includes cycloheptyl.
  • Cycloalkylalkyl refers to cycloalkyl moieties linked through an alkyl linker chain, as for example, but without limitation, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclohexylmethyl, cyclohexylethyl, and cyclohexylpropyl.
  • Each alkyl, cycloalkyl, and cycloalkylalkyl group may be optionally substituted as specified herein.
  • alkoxy refers to an alkyl group, phenyl group, benzyl group, or pyrimidinyl group, respectively, each optionally substituted, that is bonded through an oxygen atom.
  • alkylthio refers to an alkyl group, phenyl group, or benzyl group, respectively, each optionally substituted, that is bonded through a sulfur atom.
  • C 1 -C 4 acyl refers to a formyl group or a C 1 -C 3 alkyl group bonded through a carbonyl moiety.
  • C 1 -C 4 alkoxycarbonyl refers to a C 1 -C 4 alkoxy group bonded through a carbonyl moiety.
  • halo refers to fluoro, chloro, bromo, or iodo.
  • Preferred halo groups are fluoro, chloro, and bromo. More preferred halo groups are fluoro and chloro.
  • heterocycle is taken to mean a saturated or unsaturated 5- or 6-membered ring containing from 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, said ring optionally being benzofused.
  • exemplary heterocycles include furanyl, thiophenyl (thienyl), pyrrolyl, pyrrolidinyl, pyridinyl, N-methylpyrrolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, triazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, thiazolidinyl, N-acetylthiazolidinyl, pyrimidinyl, pyrazinyl, pyridazinyl, and the like.
  • Benzofused heterocyclic rings include isoquinolinyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, quinolinyl, benzofuranyl, benzothiophenyl, indolyl, and the like, all of which may be optionally substituted, which also of course includes optionally substituted on the benzo ring when the heterocycle is benzofused.
  • Preferred heterocycles include pyridinyl, indolyl, furanyl, benzofuranyl, thiophenyl, benzodioxolyl, and thiazolidinyl, all of which may be optionally substituted.
  • Substituted alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, or alkylthio means an alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, or alkythio group, respectively, substituted one or more times independently with a substituent selected from the group consisting of halo, hydroxy, and C 1 -C 3 alkoxy.
  • examples include trifluoromethyl, pentafluoroethyl, 5-fluoro-2-bromopentyl, 3-hydroxypropyloxy, 4-hydroxycyclohexyloxy, 2-bromoethylthio, 3-ethoxypropyloxy, 3-ethoxy-4-chlorocyclohexyl, and the like.
  • substitutions include substitution 1-5 times with halo, each independently selected, or substituted 1-3 times with halo and 1-2 times independently with a group selected from hydroxy and C 1 -C 3 alkoxy, or substituted 1-3 times independently with a group selected from hydroxy and C 1 -C 3 alkoxy, provided that no more than one hydroxy and/or alkoxy substituent may be attached through the same carbon.
  • substituted phenyl and “substituted heterocycle” are taken to mean that the cyclic moiety in either case is substituted with one or more halo substituents, preferably one to five, each independently selected; or substituted with one or more substituents, preferably one to two substituents, independently selected from the group consisting of halo, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, and C 1 -C 4 alkylthio, wherein each alkyl, alkoxy and alkylthio substituent can be further substituted independently with C 1 -C 2 alkoxy or with one to five halo groups selected from fluoro and chloro; or substituted with one substituent selected from the group consisting of phenyloxy, benzyloxy, phenylthio, benzylthio, and pyrimidinyloxy, wherein the phenyloxy, benzyloxy, phenylthio, benzylthio
  • Pd 2 (dba) 3 means tris(dibenzylidineacetone)-dipalladium(0).
  • BINAP means 2,2′-bis(diphenylphosphino)-1,1′binaphthyl.
  • DMF means N,N-dimethylformamide.
  • HATU O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate.
  • Collidine means trimethylpyridine.
  • APCI MS means Atmospheric Pressure Chemical Ionization Mass Spectrum.
  • amino protecting group refers to a substituents commonly employed to block or protect the amino functionality while reacting other functional groups on the compound.
  • amino-protecting groups include the formyl group, the trityl group, the phthalimido group, the acetyl group, the trichloroacetyl group, the chloroacetyl, bromoacetyl, and iodoacetyl groups, urethane-type blocking groups such as benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl (“FMOC”), and the like; and like amino protecting groups.
  • FMOC 9-fluorenylmethoxycarbonyl
  • the species of amino protecting group employed is not critical so long as the derivatized amino group is stable to the conditions of subsequent reactions on other positions of the molecule and can be removed at the appropriate point without disrupting the remainder of the molecule. Further examples of groups referred to by the above terms are described by T. W. Greene, “Protective Groups in Organic Synthesis”, John Wiley and Sons, New York, N.Y., 1991, Chapter 7 hereafter referred to as “Greene”.
  • pharmaceutical or “pharmaceutically acceptable” when used herein as an adjective, means substantially non-toxic and substantially non-deleterious to the recipient.
  • pharmaceutical formulation it is further meant that the carrier, solvent, excipients and salt must be compatible with the active ingredient of the formulation (e.g. a compound of formula I). It is understood by those of ordinary skill in this art that the terms “pharmaceutical formulation” and “pharmaceutical composition” are generally interchangeable, and they are so used for the purposes of this application.
  • acid addition salt refers to a salt of a compound of formula I prepared by reaction of a compound of formula I with a mineral or organic acid.
  • acid addition salts see, e.g., Berge, S. M, Bighley, L. D., and Monkhouse, D. C., J. Pharm. Sci., 66:1, 1977.
  • the compounds of this invention are amines, they are basic in nature and accordingly react with any of a number of inorganic and organic acids to form pharmaceutically acceptable acid addition salts. Since some of the free amines of the compounds of this invention are typically oils at room temperature, it is preferable to convert the free amines to their pharmaceutically acceptable acid addition salts for ease of handling and administration, since the latter are routinely solid at room temperature.
  • the pharmaceutically acceptable acid addition salts of the invention are typically formed by reacting a compound of formula I with an equimolar or excess amount of acid.
  • hemi-salts can be formed by reacting a compound of formula I with the desired acid in a 2:1 ratio, compound to acid.
  • the reactants are generally combined in a mutual solvent such as diethylether, tetrahydrofuran, methanol, ethanol, isopropanol, benzene, or the like.
  • the salts normally precipitate out of solution within about one hour to about ten days and can be isolated by filtration or other conventional methods.
  • Inorganic acids commonly employed to form such salts include hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like.
  • Organic acids commonly employed to form such salts include p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid and the like.
  • salts thus are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, hemisuccinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylprop
  • an effective amount means an amount of a compound of formula I which is capable of activating 5-HT 1F receptors and/or inhibiting neuronal protein extravasation.
  • suitable solvent refers to any solvent, or mixture of solvents, inert to the ongoing reaction that sufficiently solubilizes the reactants to afford a medium within which to effect the desired reaction.
  • the compounds of formula I wherein R 5 is other than hydrogen contain two chiral centers, one at the 4-position of the piperidine ring, and one where R 5 attaches to the piperidine ring.
  • the four stereoisomers of N-[6-(1,2-dimethylpiperidine-4-carbonyl)-pyridin-2-yl]-isonicotinamide are as follows, wherein the chiral centers are indicated with asterisks, “*”, and the R and S designations are as indicated.
  • the mammal to be treated by the administration of compounds of this invention is human.
  • the compounds of the present invention may be synthesized through a condensation of a 6-lithio anion of 2-chloropyridine with 1-substituted- or N-protected piperidine-4-carboxylic acid methoxy-methylamide, followed by conversion of the 2-halo group to an amino group, and subsequent condensation with the appropriate R 1 -acylhalide compound. (see Scheme 1.)
  • 2-chloropyridine is activated by reaction with a mixture of n-butyl lithium and 2-dimethylamino-ethanol in a suitable solvent, such as hexane, at ⁇ 78° C. The reaction is generally complete within about an hour.
  • a suitable solvent such as hexane
  • 1-R 7 -substituted-piperidine-4-caboxylic acid methoxy-methyl-amide in an organic solvent, such as hexane is added and stirred to form the 2-chloropyridinoyl-piperidine intermediate.
  • the reaction is generally complete within about an hour.
  • the desired final R 2 substituent is hydrogen
  • the piperidinyl nitrogen should first be protected with an amino protecting group, the addition and later removal of which are accomplished by standard procedures well known in the art.
  • the first condensation reaction is quenched by the addition of water and the mixture is extracted multiple times with a suitable solvent, such as ethyl acetate.
  • a suitable solvent such as ethyl acetate.
  • This 2-chloropyridinoyl-piperidine intermediate can then be dried, as for example with anhydrous sodium sulfate, evaporated, and then partially purified, as for example, by chromatography on a silica gel column.
  • the 2-chloropyridinoyl-piperidine intermediate is reacted with benzophenone imine in the presence of tris(dibenzylidineacetone)-dipalladium(0) Pd 2 (dba) 3 ) as a catalyst, and 2,2′-bis(diphenylphosphino)-1,1′binaphthyl (BINAP) and sodium t-butoxide in a suitable solvent, such as toluene, at reflux, to substitute the halo group with the benzophenone imino group.
  • this intermediate is typically reacted with hydrochloric acid in a suitable solvent, such as tetrahydrofuran, and then purified to give the corresponding 2-aminopyridinoyl-piperidine intermediate.
  • the R 1 moiety is added by amide bond formation by reacting the 2-aminopyridinoyl-piperidine intermediate with the desired R 1 -acylhalide.
  • a strong base such as sodium hydroxide, may then be added to neutralize the reaction mixture, and the final product purified by normal work-up procedures.
  • piperidinyl nitrogen is protected by an amino protecting group, this group is removed after the condensation reaction with the acylhalide.
  • the piperidinyl nitrogen can then remain as a secondary amine for compounds of the present invention wherein R 2 is hydrogen, or it may be further alkylated by known procedures for compounds of the present invention wherein R 2 is C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl-C 1 -C 3 alkyl, or a group of formula II
  • one typical alkylation reaction proceeds by reductive alkylation of the secondary amine with an appropriate aldehyde, an organic acid such as glacial acetic acid or trifluoroacetic acid, and a reducing agent such as sodium cyanoborohydride or sodium triacetoxyborohydride, in an appropriate solvent, such as methanol or dichloromethane, wherein the appropriate aldehyde is one that will react to provide the desired R 2 substituent.
  • the R 3 -aminocarbonyl-R 1 reagents are easily prepared by reacting the corresponding R 1 acylhalide with the desired amine (methylamine, ethylamine, propylamine, or isopropylamine, as for example a 2 M solution thereof) in an appropriate solvent, as for example methanol.
  • an appropriate solvent as for example methanol.
  • the 2-bromopyridinoyl-piperidine intermediate is synthesized by first reacting 2,6-dibromopyridine in a suitable organic solvent, such as dichloromethane, preferably under a nitrogen atmosphere, with 1.1 equivalent of n-butyllithium in a suitable solvent, such as hexanes, preferably at low temperatures, such as ⁇ 78° C.
  • a suitable organic solvent such as dichloromethane
  • a suitable solvent such as hexanes
  • the 2-bromopyridinoyl-piperidine intermediate is reacted under N 2 in a mixture with the desired methylaminocarbonyl-R 1 , ethylaminocarbonyl-R 1 , or propylaminocarbonyl-R 1 , respectively, tris(dibenzylidineacetone)-dipalladium(0) (Pd 2 (dba) 3 ), 2,2′-bis(diphenylphosphino)-1,1′binaphthyl (BINAP), and sodium t-butoxide, in a suitable solvent, such as suitably anhydrous toluene.
  • the reaction is typically heated for several hours, as for example at about 85° C. for 16 hours.
  • Additional C 1 -C 2 alkylaminocarbonyl-R 1 , tris(dibenzylidineacetone)-dipalladium(0) (Pd 2 (dba) 3 ), 2,2′-bis(diphenylphosphino)-1,1′binaphthyl (BINAP), and sodium t-butoxide can be added and the reaction continued for a similar period of time to improve the reaction yield.
  • the final product is then purified by common methods.
  • a novel condensation reaction is used to synthesize the 2-bromopyridinoyl-piperidine intermediate to provide highly selective mono-addition, as well as higher yields of the desired intermediate product with fewer impurities.
  • a more favorable reaction is used to convert the 2-bromopyridinoyl-piperidine intermediate to the 2-aminopyridinoyl-piperidine intermediate in preparation for the final condensation reaction. (See Scheme 3.)
  • the novel N,N-dimethylaminocarbonylpiperidine intermediate is made in high yield from an R 7 -isonipicotic acid derivative by reacting the acid with oxalyl chloride in the presence of a catalytic amount of dimethylformamide (DMF) in a suitable solvent, such as dichloromethane, tetrahydrofuran, dichloroethane, diethylether, or the like, and concentrating to yield an isonipecotyl chloride derivative.
  • DMF dimethylformamide
  • a suitable solvent such as tetrahydrofuran, dichloromethane, dichloroethane, diethylether, or the like
  • a proton scavenger such as triethylamine, diisopropylethylamine, or the like, and then purified to give the N,N-dimethylaminocarbonylpiperidine intermediate.
  • N,N-dimethylcarbonylpiperidine intermediates of the present invention have the distinct advantages over the N-protected piperidine-4-caboxylic acid methoxy-methylamide reagents (Weinreb reagents) of the prior art, in that they are non-hygroscopic and surprisingly provide significantly improved chemoselectivity and yield in the subsequent condensation reaction as compared to the condensation reaction using the corresponding Weinreb reagent. This is particularly the case when, as in a preferred embodiment, toluene or methyl-tert-butylether (MTBE) is used as the solvent. In a yet more preferred embodiment, MTBE is used as the solvent.
  • MTBE methyl-tert-butylether
  • 2,6-dibromopyridine is activated by reaction with n-butyllithium in cold MTBE or toluene, preferably MTBE, to produce a bromolithiumpyridine intermediate.
  • n-butyllithium in cold MTBE or toluene, preferably MTBE
  • the N,N-dimethylaminocarbonylpiperidine intermediate is added and the mixture stirred, as for example for about an hour at between about ⁇ 100° C. to about ⁇ 60° C., preferably about ⁇ 75° C.
  • the coupling reaction is run with a ratio of the 2,6-dibromopyridine to the N,N-dimethylaminocarbonylpiperidine intermediate of about a 1.0 to about 2.0, more preferably with a ratio of between about 1.3 to about 1.7, most preferably with a ratio of about 1.5.
  • the reaction is then quenched with saturated ammonium chloride at about ⁇ 20° C. to about 10° C., and then neutralized with hydrochloric acid and additional water.
  • the product can then be isolated by typical work-up procedures, as for example, but without limitation, by extraction of the aqueous phase with dichloromethane, washing the organic fractions with acidified water (as for example, pH 2), neutralizing the aqueous extract with sodium hydroxide, followed by extraction with ethyl acetate, drying the organic phase, as for example with magnesium sulfate, and concentrating, as for example, by evaporation, rotoevaporation, etc.
  • acidified water as for example, pH 2
  • ethyl acetate drying the organic phase, as for example with magnesium sulfate
  • concentrating as for example, by evaporation, rotoevaporation, etc.
  • R 8 , R 9 , and R 10 are as defined above.
  • Preferred compounds of formula IV are those wherein R 9 and R 10 are each methyl, or wherein R 9 and R 10 , together with the nitrogen to which they are attached, combine to form pyrrolidinyl. Particularly preferred are those compounds wherein R 9 and R 10 , together with the nitrogen to which they are attached, combine to form pyrrolidinyl.
  • the 4-(pyrrolidinylcarbonyl)piperidine reagents have the added advantage over the 4-(N,N′-dimethylamino)carbonyl piperidine reagents in that they tend to be even less hygroscopic and tend to produce more stable crystals, improving the handling characteristics of the reagents.
  • the 4-(pyrrolidinylcarbonyl)piperidine reagents provide unexpected significantly improved chemoselectivity and yield in the subsequent condensation reaction over reactions run using the corresponding Weinreb reagents.
  • 1-methyl-4-(N,N′-dimethylamino)carbonyl piperidine is a low melting point solid that crystallizes easily and has relatively low hygroscopicity, particularly as compared to the corresponding Weinreb reagent. However, when the crystalline form does absorb water, it converts to an oil.
  • 1-methyl-4-(pyrrolidinylcarbonyl)piperidine is also a low melting point solid that crystallizes easily, but is even less hygroscopic than 1-methyl-4-(N,N′-dimethylamino)carbonyl piperidine and produces more stable crystals, such that they retain their crystalline form even if some water is absorbed.
  • 1-methyl-4-(piperidin-1-yl)carbonylpiperidine generally remains an oil.
  • 2,6-dichloropyridine can be used instead of 2,6-dibromopyridine in scheme 3, above under similar reaction conditions, to provide the corresponding 2-chloropyridinoylpiperidine intermediate.
  • MTBE or toluene is used as the solvent, resulting in further improved chemoselectivity in the condensation reaction.
  • MTBE as solvent is most preferred.
  • the next step of the synthesis provides for the exchange of the halo group for an amino group by reaction of a 2-bromo-6-(piperidinylcarbonyl)pyridine intermediate, as described above, with ammonia and ethylene glycol, in the presence of copper(I) oxide as a catalyst.
  • this reaction is run in an autoclave, with typical conditions being about 80° C. to about 110° C., preferably about 100° C., and from about 45 to about 60 psi (about 310 to about 414 kPa), typically about 50 psi (about 345 kPa)
  • Ammonia is then removed from the organic fraction by evacuation.
  • Aqueous sodium hydroxide is then added and the mixture extracted with a suitable organic solvent, as for example, methyl-tert-butylether or dichloromethane, and then dried, as for example, with magnesium sulfate.
  • the crude 2-amino-6-(1-R 7 -piperidine-4-ylcarbonyl)pyridine intermediate is further purified by crystallization of the hydrochloric salt and then neutralizing the salt with sodium hydroxide, organic solvent extraction and solvent removal.
  • Recombinant chemistry compounds are characterized by liquid chromatography/mass spectroscopy on a Shimadzu QP8000TM.
  • Examples 24-45 and 55-58 are run with a MetachemTM C18 column (monochrom 3 micron, 2.5 ⁇ 25 cm) using a 10-90% solvent B gradient in 4.5 min., where solvent A is 0.1% trifluoroacetic acid in water and solvent B is 0.1% trifluoroacetic acid in acetonitrile.
  • Examples 46-54 and 59-71 are run with a MetachemTM C18 column (monochrom 5 micron, 4.6 ⁇ 50 cm) using a 10-80% solvent B gradient in 9 min, where solvent A is 0.1% trifluoroacetic acid in water and solvent B is 0.08% trifluoroacetic acid in acetonitrile.
  • the compounds of this invention are useful for increasing activation of the 5-HT 1F receptor.
  • An increase in the activation of the 5-HT 1F is useful for treating a variety of disorders which have been linked to decreased neurotransmission of serotonin in mammals, e.g., migraine headaches.
  • U.S. Pat. No. 5,708,008 demonstrating the nexus between activation of the 5-HT 1F receptor and migraine.
  • To demonstrate the use of the compounds of the present invention in the treatment of migraine, their ability to bind to the 5-HT 1F receptor subtype was determined. The ability of the compounds of this invention to bind to the 5-HT 1F receptor subtype was measured essentially as described in N. Adham, et al., Proceedings of the National 15 Academy of Sciences ( USA ), 90:408-412, 1993.
  • Membranes were prepared from transfected Ltk-cells (transfected with the human 5-HT 1F receptor sequence) which were grown to 100% confluency. The cells were washed twice with phosphate-buffered saline, scraped from the culture dishes into 5 mL of ice-cold phosphate-buffered saline, and centrifuged at 200 ⁇ g for 5 minutes at 4° C. The pellet was resuspended in 2.5 mL of ice-cold Tris buffer (20 mM Tris HCl, pH 7.4 at 23° C., 5 mM EDTA) and homogenized with a Wheaton tissue grinder. The lysate was subsequently centrifuged at 200 ⁇ g for 5 minutes at 4° C.
  • [ 3 H] 5-HT binding was performed using slight modifications of the 5-HT 1D assay conditions reported by Herrick-Davis and Knickeer ( J. Neurochem., 50:1624-1631, 1988) with the omission of masking ligands.
  • Radioligand binding studies were achieved at 37° C. in a total volume of 250 ⁇ L of buffer (50 mM Tris, 10 mM MgCl 2 , 0.2 mM EDTA, 10 ⁇ M pargyline, 0.1% ascorbate, pH 7.4 at 37° C.) in 96 well microtiter plates. Saturation studies were conducted using [ 3 H] 5-HT at 12 different concentrations ranging from 0.5 nM to 100 nM.
  • Representative compounds of the present invention were found to have high affinity for the 5-HT 1F receptor as measured by the procedure described above, as for example K i 's of less than or equal to 300 nM.
  • Preferred compounds of the present invention have K i 's of less than or equal to 100 nM.
  • a yet more preferred embodiment provides compounds having a K i of less than or equal to 50 nM.
  • Compounds of the prevent invention are relatively selective for the 5-HT 1F receptor, particularly in comparison to other 5-HT receptor subtypes, specifically other receptors in the 5-HT 1 subclass, as for example, but without limitation, the 5-HT 1A , 5-HT 1B , 5-HT 1D , and 5-HT 1E receptor subtypes. Affinity for these other receptor subtypes can readily be determined by slight modification of the above described radioligand receptor binding assays using cells transfected with the desired receptor subtype in place of cells transfected with the 5-HT 1F receptor subtype.
  • the binding affinities of representative compounds of the present invention were determined by such assays and were found to be selective for the 5-HT 1F receptor; that is the affinities of the compounds for the 5-HT 1F receptor were on the whole, higher than for other receptor subtypes, particular for the 5-HT 1B and 5-HT 1D receptor subtypes.
  • the 5-HT 1F receptor is functionally coupled to a G-protein as measured by the ability of serotonin and serotonergic drugs to inhibit forskolin stimulated cAMP production in NIH3T3 cells transfected with the 5-HT 1F receptor.
  • Adenylate cyclase activity was determined using standard techniques. A maximal effect is achieved by serotonin. An E max is determined by dividing the inhibition of a test compound by the maximal effect and determining a percent inhibition.
  • Drug dose-effect curves were then conducted by adding 6 different final concentrations of drug, followed immediately by the addition of forskolin (10 ⁇ M). Subsequently, the cells were incubated for an additional 10 minutes at 37° C., 5% CO 2 .
  • the femoral vein was exposed and a dose of the test compound was injected intravenously (1 mL/kg). Approximately 7 minutes later, a 50 mg/kg dose of Evans Blue, a fluorescent dye, was also injected intravenously. The Evans Blue complexed with proteins in the blood and functioned as a marker for protein extravasation. Exactly 10 minutes post-injection of the test compound, the left trigeminal ganglion was stimulated for 3 minutes at a current intensity of 1.0 mA (5 Hz, 4 msec duration) with a Model 273 potentiostat/galvanostat (EG&G Princeton Applied Research).
  • the animals were killed and exsanguinated with 20 mL of saline.
  • the top of the skull was removed to facilitate the collection of the dural membranes.
  • the membrane samples were removed from both hemispheres, rinsed with water, and spread flat on microscopic slides. Once dried, the tissues were coverslipped with a 70% glycerol/water solution.
  • a fluorescence microscope (Zeiss) equipped with a grating monchromator and a spectrophotometer was used to quantify the amount of Evans Blue dye in each sample.
  • An excitation wavelength of approximately 535 nm was utilized and the emission intensity at 600 nm was determined.
  • the microscope was equipped with a motorized stage and also interfaced with a personal computer. This facilitated the computer-controlled movement of the stage with fluorescence measurements at 25 points (500 ⁇ m steps) on each dural sample. The mean and standard deviation of the measurements were determined by the computer.
  • the extravasation induced by the electrical stimulation of the trigeminal ganglion was an ipsilateral effect (i.e. occurs only on the side of the dura in which the trigeminal ganglion was stimulated). This allows the other (unstimulated) half of the dura to be used as a control.
  • the ratio of the amount of extravasation in the dura from the stimulated side compared to the unstimulated side was calculated. Saline controls yielded a ratio of approximately 2.0 in rats and 1.8 in guinea pigs. In contrast, a compound which effectively prevented the extravasation in the dura from the stimulated side would have a ratio of approximately 1.0.
  • a dose-response curve was generated and the dose that inhibited the extravasation by 50% (ID 50 ) was approximated.
  • Representative compounds of the present invention were assayed by the above procedure and were found to significantly inhibit neuronal protein extravasation. All compounds of the present invention tested had ID 50 's of less than or equal to _ nM/Kg.
  • Representative compounds of the present invention were tested in a rabbit saphenous vein contraction assay to measure their ability to mediate vasoconstriction.
  • PESO polyethylene tubing
  • modified Krebs solution described infra
  • Tissues were mounted in organ baths containing 10 mL of modified Krebs solution of the following composition: 118.2 mMol NaCl, 4.6 mMol KCl, 1.6 mMol CaCl 2 .H 2 O, 1.2 mMol KH 2 PO 4 , 1.2 mMol MgSO 4 , 10.0 mMol dextrose and 24.8 mMol NaHCO 3 .
  • Tissue bath solutions were maintained at 37° C. and aerated with 95% O 2 and 5% CO 2 . An initial optimum resting force of 1 gm was applied to the saphenous vein.
  • Isometric contractions were recorded as changes in grams of force on a Beckman Dynograph with Statham UC-3 transducers and microscale accessory attachments. Tissues were allowed to equilibrate 1 to 2 hours before exposure to drugs. Cumulative agonist concentration-response curves were generated in tissues and no tissue was used to generate more than two agonist concentration-response curves. Results are expressed as a mean EC 50 and the maximal response expressed as a percentage of the maximal tissue contraction response to 67 mM KCl administered initially to each tissue.
  • This vasoconstriction assay measures two important parameters, saphenous vein contraction (EC 50 ) and maximal contraction as a % maximal KCl response (% max KCl).
  • the saphenous vein contraction (EC 50 ) is a measure of the dose required to contract tissue to 50% of the maximal response that the specific compound is capable of mediating.
  • the maximal response that the saphenous vein is capable of exhibiting is measured after administration of a high concentration (67 mM) of KCl.
  • the % maximal KCl contraction is the ratio of the maximal response that the specific compound is capable of mediating divided by the maximal response that the tissue can produce upon stimulation with KCl.
  • a compound may be considered to not have significant vasoconstrictive activity if it produces a maximal contraction of less than or equal to 5% of the contraction produced by the 67 mM KCl positive control at compound concentrations of up to 100 ⁇ M.
  • Representative compounds of the present invention were tested with the above saphenous vein assay and found to not be significantly vasoconstrictive. All compounds of the present invention tested had an EC 50 of less than or equal to _ mM and a % max KCl of less than or equal to _ in this assay. This contrasts greatly with prior art compounds for the treatment of migraine targeting the neural vasoconstrictive model for migraine treatment, which compounds were selected on the basis of strong vasoconstrictive activity, as for example, sumatriptan, which has an EC 50 of 0.66 mM and a % max KCl of 64.20 in this assay.
  • the specificity of compounds of the present invention for 5-HT 1F mediated inhibition of neuronal protein extravasation versus vasoconstrictive activity can be expressed with a Specificity Index, which is the ratio of vasoconstriction to efficacy in inhibiting neuronal protein extravasation:
  • the Corrected Vasoconstriction takes into consideration the maximal contraction relative to KCl for each individual compound, and is defined as the vasoconstriction EC 50 value divided by the % max KCl.
  • sumatriptan has a corrected vasoconstriction EC 50 of 1.03 ⁇ 10 ⁇ 8 M (0.66 mM EC 50 ⁇ 64.20% max KCl) and an extravasation inhibition ID 50 of 2.6 ⁇ 10 ⁇ 8 mMol/Kg, giving a Specificity Index of 0.40.
  • Compounds of the present invention have Specificity Indexes of greater than or equal to 10. (10 picked for being a lower number in dependent claim of X09150.)
  • the compound is shown to be an agonist or partial agonist with an E max of at least about 50%, measure efficacy of the compound in inhibition of protein extravasation and saphenous vein contraction using the above described assays;
  • preferred compounds have a Specificity Index of greater than or equal to 10 (at least 10), preferably greater than or equal to 100 (at least 100). More preferred compounds have a Specificity Index of greater than or equal to 1000 (at least 1000), and yet more preferred compounds have Specificity Indexes greater than or equal to 5000 (at least 5000).
  • the type of formulation used for the administration of the compounds employed in the methods of the present invention may be dictated by the particular compounds selected, the type of pharmacokinetic profile desired from the route of administration, and the state of the patient.
  • Formulations amenable to oral, sublingual, nasal or injectable administration are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound. See, e.g., R EMINGTON'S P HARMACEUTICAL S CIENCES , (16th ed. 1980).
  • a formulation of the present invention includes an active ingredient (a compound of formula I) and is usually mixed with an excipient, diluted by an excipient or enclosed within such a carrier which can be in the form of a capsule, sachet, paper or other container.
  • an excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
  • the formulations can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing for example up to 10% by weight of the active compound, soft and hard gelatin capsules, gels, suppositories, sterile injectable solutions, and sterile packaged powders.
  • the active compound In preparing a formulation, it may be necessary to mill the active compound to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it ordinarily is milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size is normally adjusted by milling to provide a substantially uniform distribution in the formulation, e.g., about 40 mesh. In one embodiment of the present invention, the particle size range is between about 0.1 ⁇ m to about 100 ⁇ m.
  • excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose.
  • the formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxybenzoates; sweetening agents; and flavoring agents.
  • the compounds of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
  • active ingredient refers to a compound of formula I.
  • the above ingredients are mixed and filled into hard gelatin capsules in 340 mg quantities.
  • the components are blended and compressed to form tablets, each weighing 240 mg.
  • the active ingredient is mixed with the lactose and the mixture is added to a dry powder inhaling appliance.
  • the active ingredient, starch and cellulose are passed through a No. 20 mesh U.S. sieve and mixed thoroughly.
  • the solution of polyvinylpyrrolidone is mixed with the resultant powders, which are then passed through a 16 mesh U.S. sieve.
  • the granules so produced are dried at 50° C.-60° C. and passed through a 16 mesh U.S. sieve.
  • the sodium carboxymethyl starch, magnesium stearate, and talc previously passed through a No. 30 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 120 mg.
  • the active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 150 mg quantities.
  • Suspensions Ingredient Amount 4-Fluoro-N-[6-(1-methyl-piperidine-4-carbonyl)- 50.0 mg pyridin-2-yl]-2-trifluoromethyl-benzamide mono-hydrochloric acid salt LY586554 Xanthan gum 4.0 mg Sodium carboxymethyl cellulose (11%) 50.0 mg Microcrystalline cellulose (89%) Sucrose 1.75 g Sodium benzoate 10.0 mg Flavor and color q.v. Purified water to 5.0 ml
  • the active ingredient, sucrose and xanthan gum are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of the microcrystalline cellulose and sodium carboxymethyl cellulose in water.
  • the sodium benzoate, flavor, and color are diluted with some of the water and added with stirring. Sufficient water is then added to produce the required volume.
  • the active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 425 mg quantities.
  • Intravenous Formulation Ingredient Quantity 2-Ethoxy-N-[6-(1-methyl-piperidine- 250.0 mg 4-carbonyl)-pyridin-2-yl]-benzamide DZ14 Isotonic saline 1000 ml
  • Sublingual or Buccal Tablets Ingredient Quantity (mg/tablet) 2,4,6-Trifluoro-N-[6-(1-methyl-piperidine- 10.0 4-carbonyl)-pyridin-2-yl]-benzamide hemi-succinnic acid salt LY683974 Glycerol 210.5 Water 143.0 Sodium citrate 4.5 Polyvinyl alcohol 26.5 Polyvinylpyrrolidone 15.5 Total 410.0 mg
  • the glycerol, water, sodium citrate, polyvinyl alcohol, and polyvinylpyrrolidone are admixed together by continuous stirring and maintaining the temperature at about 90° C.
  • the solution is cooled to about 50-55° C. and the active ingredient is slowly admixed.
  • the homogenous mixture is poured into forms made of an inert material to produce a drug-containing diffusion matrix having a thickness of about 2-4 mm. This diffusion matrix is then cut to form individual tablets having the appropriate size.
  • Sublingual or Buccal Tablets Ingredient Quantity (mg/tablet) 2,4,6-Trifluoro-N-[6-(1-methyl-piperidine- 5.0 (freebase equivalent) 4-carbonyl)-pyridin-2-yl]-benzamide hemi-succinnic acid salt LY683974 Mannitol 20 Gelatine 2.0 Water add to total volume of 100 ⁇ L Total 27.0 mg
  • the compound was dissolved in water containing 20% mannitol and 2% gelatine to provide a stock solution at a concentration of 50 mg/mL (free base equivalent).
  • the solution was aliquoted into forms holding 100 ⁇ L solution each.
  • the formulation was then frozen at ⁇ 20° C. for 3 hours and freeze dried.
  • Intravenous Formulation Quantity per Ingredient 1.0 mL Formulation 2,4,6-Trifluoro-N-[6-(1-methyl-piperidine- 1.16 mg 4-carbonyl)-pyridin-2-yl]-benzamide hemi-succinnic acid salt DZ14 Mannitol parenteral 50.0 mg Water for injection: q.s. to 1.0 mL
  • the compound and mannitol are dissolved in water and then water is added to obtain the desired final volume.
  • the solution is then sterile filtered and aseptically filled into suitable vials.
  • the compounds are usually administered in the form of pharmaceutical formulations comprising a pharmaceutically acceptable excipient and at least one active ingredient.
  • These formulations can be administered by a variety of routes including oral, buccal, rectal, intranasal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal.
  • Many of the compounds employed in the methods of this invention are effective as both injectable and oral compositions.
  • transdermal delivery device In order to administer transdermally, a transdermal delivery device (“patch”) is needed. Such transdermal patches may be used to provide continuous or discontinuous infusion of a compound of the present invention in controlled amounts.
  • the construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Pat. No. 5,023,252. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
  • Direct techniques usually involve placement of a drug delivery catheter into the host's ventricular system to bypass the blood-brain barrier.
  • a drug delivery catheter into the host's ventricular system to bypass the blood-brain barrier.
  • One such implantable delivery system used for the transport of biological factors to specific anatomical regions of the body, is described in U.S. Pat. No. 5,011,472, which is herein incorporated by reference.
  • the delivery of hydrophilic drugs may be enhanced by intra-arterial infusion of hypertonic solutions which can transiently open the blood-brain barrier.
  • a pharmaceutical formulation comprising at least one active compound as described above in a formulation adapted for buccal and/or sublingual, or nasal administration.
  • This embodiment provides administration of the active compound in a manner that avoids gastric complications, such as first pass metabolism by the gastric system and/or through the liver. This administration route may also reduce adsorption times, providing more rapid onset of therapeutic benefit.
  • the compounds of the present invention may provide particularly favorable solubility profiles to facilitate sublingual/buccal formulations.
  • Such formulations typically require relatively high concentrations of active ingredients to deliver sufficient amounts of active ingredients to the limited surface area of the sublingual/buccal mucosa for the relatively short durations the formulation is in contact with the surface area, to allow the absorption of the active ingredient.
  • the very high activity of the compounds of the present invention combined with their high solubilities, facilitate their suitability for sublingual/buccal formulation.
  • a compound of formula I is preferably formulated in a unit dosage form, each dosage containing from about 0.001 to about 100 mg, more usually about 1.0 to about 30 mg, of the active ingredient.
  • unit dosage form refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient as described above.
  • the compounds are generally effective over a wide dosage range.
  • dosages per day normally fall within the range of about 0.0001 to about 30 mg/kg of body weight. In the treatment of adult humans, the range of about 0.1 to about 15 mg/kg/day, in single or divided dose, is especially preferred.
  • the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way. In some instances dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several smaller doses for administration throughout the day.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention relates to compounds of formula I:
Figure US20170044136A1-20170216-C00001
or pharmaceutically acceptable acid addition salts thereof, where;
    • R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;
    • R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II
Figure US20170044136A1-20170216-C00002
    • R3 is hydrogen or C1-C3 alkyl;
    • R4 is hydrogen, halo, or C1-C3 alkyl;
    • R5 is hydrogen or C1-C3 alkyl;
    • R6 is hydrogen or C1-C6 alkyl; and
    • n is an integer from 1 to 6 inclusively.
The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.

Description

    RELATED APPLICATIONS
  • This application is a continuation and claims the benefit of priority under 35 U.S.C. 120 to U.S. application Ser. No. 13/363,895, filed Feb. 1, 2012, which is a continuation of U.S. application Ser. No. 12/221,919, filed Aug. 7, 2008, which is a continuation of U.S. application Ser. No. 10/509,770, filed Sep. 28, 2004, now U.S. Pat. No. 7,423,050, which is a U.S. national stage application, filed under 35 U.S.C. 371, of International Application PCT/US03/08455, filed Mar. 27, 2003, which claims priority to U.S. provisional Application No. 60/369,088, filed Mar. 29, 2002, the disclosures of each of which are incorporated by reference herein in their entireties.
    • BACKGROUND OF THE INVENTION
  • Until recently, theories regarding the pathophysiology of migraine have been dominated since 1938 by the work of Graham and Wolff. Arch. Neurol. Psychiatry, 39:737-63, 1938. They proposed that the cause of migraine headache was vasodilatation of extracranial vessels. This view was supported by knowledge that ergot alkaloids and sumatriptan, a hydrophilic 5-HT1 agonist which does not cross the blood-brain barrier, induce contraction of cephalic vascular smooth muscle and are effective in the treatment of migraine. Humphrey, et al., Ann. NY Acad. Sci., 600:587-600, 1990. Recent work by Moskowitz has shown, however, that the occurrence of migraine headaches is independent of changes in vessel diameter. Cephalalgia, 12:5-7, 1992.
  • Moskowitz has proposed that currently unknown triggers for pain stimulate trigeminal ganglia that innervate vasculature within the cephalic tissue, giving rise to release of vasoactive neuropeptides from axons on the vasculature. These released neuropeptides then activate a series of events, a consequence of which is pain. This neurogenic inflammation is blocked by sumatriptan and ergot alkaloids by mechanisms involving 5-HT receptors, believed to be closely related to the 5-HT1D subtype, located on the trigeminovascular fibers. Neurology, 43(suppl. 3):S16-S20 1993. Sumatriptan, in fact, has high affinity for the 5-HT1B and 5-HT1D receptors, Ki=10.3 nM and 5.1 nM, respectively, which activity may be indicative of vasoconstrictive activity. Sumatriptan and similar compounds previously advanced for the treatment of migraine had tended to be selected on the basis of this vasoconstrictive activity under the premises of the prior art models for migraine.
  • Serotonin (5-HT) exhibits diverse physiological activity mediated by at least seven receptor classes, the most heterogeneous of which appears to be 5-HT1. A human gene which expresses one of these 5-HT1 receptor subtypes, named 5-HT1F, was isolated by Kao and coworkers. Proc. Natl. Acad. Sci. USA, 90:408-412, 1993. This 5-HT1F receptor exhibits a pharmacological profile distinct from any serotonergic receptor yet described. It was found that sumatriptan, in addition to the above mentioned strong affinities for the 5-HT1B and 5-HT1D receptors, also has affinity for this receptor subtype, with a Ki of about 23 nM. This suggests a possible role of the 5-HT1F receptor in migraine.
  • Various 5-HT1F receptor agonists have subsequently been developed which have shown relative selectivity for the 5-HT1F receptor subclass and it has been shown that such selectivity generally reduces the vasoconstrictive activity characteristic of other compounds advanced as potential agents for the treatment of migraine and associated disorders.
  • Included among these 5-HT1F receptor agonists are compounds disclosed in the following:
      • X-09763 U.S. Pat. Nos. 5,708,187 and 5,814,653, describing a family of 6-substituted-3-amino(alkyl)-tetrahydrocarbazoles and 7-substituted-4-amino(alkyl)cyclohepta[7,6b]Indoles;
      • X-9801 U.S. Pat. No. 5,521,196, U.S. Pat. No. 5,721,252, X-9850 U.S. Pat. No. 5,521,197, and X-10054A WO 96/29075, describing various families of 5-substituted piperidin-3-yl-indoles and 5-substituted 1,2,3,6 tetrahydropyridin-3-yl-indoles;
      • X-10224 WO 97/13512 describing a family of 5-substituted 3-aminoethylindoles;
      • X-10252 WO 98/46570 describing a family of 5-substituted indoles, pyrrolo[3,2-b]pyridines, benzofurans, and benzothiophenes, having the 3-position substituted with octahydroindolizinyl, octahydro-2H-quinolizinyl, decahydropyrido[1,2-a]azepinyl, 1,2,3,5,8,8a-hexahydroindolizinyl, 1,3,4,6,9,9a-hexahydro-2H-quinolizinyl, or 1,4,6,7,8,9,10,10a-octahydropyrido[1,2-a]azepinyl;
      • X-10612 WO 98/20875 and X-11700 WO 99/25348 describing two families of 5-substituted piperidin-3-yl-azaindoles and 5-substituted 1,2,3,6-tetrahydropyridin-3-yl-azaindoles;
      • X-10810 WO 00/00487 describing a family of 5-substituted (piperidin-3-yl or 1,2,3,6-tetrahydropyridin-3-yl)indoles, azaindoles, benzofurans, and benzothiophenes;
      • X-10830 WO 98/08502 describing a family of 8-substituted-1,2,3,4-tetrahydro-2-dibenzofuranamines and 9-substituted-2-aminocyclohepta[b]benzofurans;
      • X-10833 WO 98/55115 describing a family of 3-amino-1,2,3,4-tetrahydro-9H-carbazole-6-carboxamides and 4-amino-10H-cyclohepta[7,6-b]indole-7-carboxamides;
      • X-11000 WO 98/15545 describing a select family of 3,5-disubstituted indoles and benzofurans;
      • X-11044 WO 00/00490 describing a family of 5-allyl-substituted (piperidin-3-yl or 1,2,3,6-tetrahydropyridin-3-yl)indoles, azaindoles, benzofurans, and benzothiophenes;
      • X-11704 WO 00/47559 describing a family of 4-(3-substituted-benzoyl)piperidines;
      • X-11818 WO 00/50426 describing a family of 3,5-disubstituted azabenzofurans; and
      • X-12288 WO 00/34266 describing a family of 3-heteroaryl-5-[2-(aryl or heteroaryl)-2-oxoethyl]indoles.
  • Continued research has now surprisingly yielded a new and unexpected class of novel selective 5-HT1F agonists having distinct chemical and receptor binding properties, which inhibit peptide extravasation, while avoiding significant vasoconstrictive activity, and are therefore useful for the treatment of migraine and other 5-HT1F receptor associated disorders. Furthermore, the compounds of the present invention may provide improved solubility, which facilitates suitability in preferred formulations, such as sublingual, buccal, and/or nasal formulations.
    • SUMMARY OF THE INVENTION
  • The present invention relates to pyridinoylpiperidine compounds of the general formula I:
  • Figure US20170044136A1-20170216-C00003
  • and pharmaceutically acceptable acid addition salts thereof, where;
  • R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;
  • R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II
  • Figure US20170044136A1-20170216-C00004
  • R3 is hydrogen or C1-C3 alkyl;
  • R4 is hydrogen, halo, or C1-C3 alkyl;
  • R5 is hydrogen or C1-C3 alkyl;
  • R6 is hydrogen or C1-C6 alkyl; and
  • n is an integer from 1 to 6 inclusively.
  • In one preferred embodiment, the present invention relates to pyridinoylpiperidine compounds of the general formula I:
  • Figure US20170044136A1-20170216-C00005
  • and pharmaceutically acceptable acid addition salts thereof, wherein;
  • R1 is phenyl, substituted phenyl, heterocycle or substituted heterocycle;
  • R2 is hydrogen or C1-C2 alkyl;
  • R3 is hydrogen or methyl; and
  • R4 and R5 are both hydrogen.
  • Other preferred compounds are those of formula I wherein R3 is hydrogen.
  • This invention also relates to pharmaceutical formulations comprising a compound of formula I, or a pharmaceutically acceptable acid addition salt thereof, and a pharmaceutical carrier, diluent, or excipient. In preferred embodiments of this aspect of the present invention, there are provided pharmaceutical formulations containing a compound of formula I, or a pharmaceutically acceptable salt thereof, adapted for the activation of 5-HT1F receptors, for the inhibition of neuronal protein extravasation, for the treatment or prevention of migraine, and/or the treatment or prevention of anxiety in mammals, particularly humans.
  • In addition, the present invention relates to a method for activating 5-HT1F receptors in mammals, particularly humans, comprising administering to a mammal in need of such activation an effective amount of a compound of formula I, or a pharmaceutically acceptable acid addition salt thereof.
  • Moreover, the current invention relates to a method for inhibiting neuronal protein extravasation in mammals, particularly humans, comprising administering to a mammal in need of such inhibition an effective amount of a compound of formula I, or a pharmaceutically acceptable acid addition salt thereof.
  • Additionally, the present invention relates to a method for treating or preventing migraine in mammals, particularly humans, comprising administering to a mammal in need of such treatment or prevention, an effective amount of a compound of formula I, or a pharmaceutically acceptable acid addition salt thereof.
  • Additionally, the present invention relates to a method for treating anxiety in mammals, particularly humans, comprising administering to a mammal in need of such treatment or prevention, an effective amount of a compound of formula I, or a pharmaceutically acceptable acid addition salt thereof.
  • In another aspect, the present invention relates to a compound of formula I, or a pharmaceutically acceptable acid addition salt thereof, for use in the activation of 5-HT1F receptors, in the inhibition of neuronal protein extravasation, in the treatment or prevention of migraine, and/or in the treatment of anxiety in mammals, particularly humans. That is to say, the present invention relates to the use of a compound of formula I as a medicament for the activation of 5-HT1F receptors, for the inhibition of neuronal protein extravasation, for the treatment or prevention of migraine, and/or for the treatment of anxiety in mammals, particularly humans.
  • Additionally, the present invention relates to the use of one or more compounds of formula I in the manufacture of a medicament for the activation of 5-HT1F receptors, for the inhibition of neuronal protein extravasation, for the treatment or prevention of migraine, and/or for the treatment of anxiety in mammals, particularly humans.
  • Furthermore, the present invention provides for methods for the treatment of 5-HT1F mediated disorders comprising administering to a mammal in need of such treatment, particularly a human, an effective amount of a compound of formula I, or a pharmaceutically acceptable acid addition salt thereof.
  • In another aspect of the present invention, there is provided a process for the synthesis of compounds of formula I and of novel intermediates in the synthesis. In one embodiment, the present invention provides a process for preparing a 2-halo-6-(piperidin-4-carbonyl)pyridine compound of formula III
  • Figure US20170044136A1-20170216-C00006
  • where X is bromo or chloro;
  • R8 is an amino protecting group, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II
  • Figure US20170044136A1-20170216-C00007
  • R6 is hydrogen or C1-C6 alkyl; and
  • n is an integer from 1 to 6 inclusively;
  • comprising
  • 1) reacting a 2,6-dihalopyridine selected from the group consisting of 2,6-dibromopyridine and 2,6-dichloropyridine, with n-butyl lithium to form 2-halo-6-lithium-pyridine; and then
  • 2) reacting the 2-halo-6-lithium-pyridine with a substituted aminocarbonylpiperidine compound of formula IV
  • Figure US20170044136A1-20170216-C00008
  • wherein R9 and R10 are each methyl, or R9 and R10, together with the nitrogen to which they are attached, combine to form azetidinyl, pyrrolidinyl, or piperidinyl.
  • In a particular embodiment of this aspect of the present invention, there is provided a process for preparing a 2-bromo-6-(piperidin-4-carbonyl)pyridine compound of formula III
  • Figure US20170044136A1-20170216-C00009
  • wherein R7 is C1-C3 n-alkyl, or an amino protecting group;
    comprising reacting 2,6-dibromopyridine with n-butyl lithium to form 2-bromo-6-lithium pyridine, and then reacting the 2-bromo-6-lithium pyridine with a 4-(N,N′-dimethylamino)carbonyl piperidine compound of formula IV
  • Figure US20170044136A1-20170216-C00010
  • in a methyl tert-butyl ether solvent.
    • DETAILED DESCRIPTION OF THE INVENTION
  • One embodiment of the present invention is a method for increasing activation of 5-HT1F receptors, while avoiding vasoconstrictive activity, for treating a variety of disorders that have been linked to decreased neurotransmission of serotonin in mammals. Included among these disorders are migraine, general pain, trigeminal neuralgia, dental pain or temperomandibular joint dysfunction pain, anxiety, general anxiety disorder, panic disorder, depression, disorders of sleep, chronic fatigue syndrome, premenstrual syndrome or late luteal phase syndrome, post-traumatic syndrome, memory loss, dementia including dementia of aging, social phobia, autism, attention deficit hyperactivity disorder, disruptive behavior disorders, impulse control disorders, borderline personality disorder, obsessive compulsive disorder, premature ejaculation, erectile dysfunction, bulimia, anorexia nervosa, alcoholism, tobacco abuse, mutism, and trichotillomania. The compounds of this invention are also useful as a prophylactic treatment for migraine. Any of these methods employ a compound of formula I.
  • In those instances where the disorders which can be treated by serotonin agonists are known by established and accepted classifications, their classifications can be found in various sources. For example, at present, the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV™) (1994, American Psychiatric Association, Washington, D.C.), provides a diagnostic tool for identifying many of the disorders described herein. Also, the International Classification of Diseases, Tenth Revision (ICD-10), provides classifications for many of the disorders described herein. The skilled artisan will recognize that there are alternative nomenclatures, nosologies, and classification systems for disorders described herein, including those as described in the DSM-IV and ICD-10, and that terminology and classification systems evolve with medical scientific progress.
  • The use of a compound of formula I for the activation of the 5-HT1F receptor, for the inhibition of neuronal peptide extravasation, in general or due to stimulation of the trigeminal ganglia specifically, and/or for the treatment of any of the disorders described above, are all embodiments of the present invention.
  • Likewise, the use of a compound of formula I, or a combination of more than one compound of formula I, in the manufacture of a medicament for the activation of the 5-HT1F receptor, for the inhibition of neuronal peptide extravasation, in general or due to stimulation of the trigeminal ganglia specifically, and/or for the treatment of any of the disorders described above, are also all embodiments of the present invention.
  • The general chemical terms used throughout have their usual meanings. For example, the term alkyl refers to a branched or unbranched saturated hydrocarbon group. The term “n-alkyl” refers to an unbranched alkyl group. The term “Cx-Cy alkyl” refers to an alkyl group having between x and y carbon atoms, inclusively, in the branched or unbranched hydrocarbon group. By way of illustration, but without limitation, the term “C1-C4 alkyl” refers to a straight chain or branched hydrocarbon moiety having from 1 to 4 carbon atoms, including methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl. The term “C1-C4 n-alkyl” refers to straight chain hydrocarbon moieties having from 1 to 4 carbon atoms including methyl, ethyl, n-propyl, and n-butyl. The term “C3-C6 cycloalkyl” refers to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. The term “C3-C7 cycloalkyl” also includes cycloheptyl. Cycloalkylalkyl refers to cycloalkyl moieties linked through an alkyl linker chain, as for example, but without limitation, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclohexylmethyl, cyclohexylethyl, and cyclohexylpropyl. Each alkyl, cycloalkyl, and cycloalkylalkyl group may be optionally substituted as specified herein.
  • The terms “alkoxy”, “phenyloxy”, “benzoxy” and “pyrimidinyloxy” refer to an alkyl group, phenyl group, benzyl group, or pyrimidinyl group, respectively, each optionally substituted, that is bonded through an oxygen atom.
  • The terms “alkylthio”, “phenylthio”, and “benzylthio” refer to an alkyl group, phenyl group, or benzyl group, respectively, each optionally substituted, that is bonded through a sulfur atom.
  • The term “C1-C4 acyl” refers to a formyl group or a C1-C3 alkyl group bonded through a carbonyl moiety. The term “C1-C4 alkoxycarbonyl” refers to a C1-C4 alkoxy group bonded through a carbonyl moiety.
  • The term “halo” refers to fluoro, chloro, bromo, or iodo. Preferred halo groups are fluoro, chloro, and bromo. More preferred halo groups are fluoro and chloro.
  • The term “heterocycle” is taken to mean a saturated or unsaturated 5- or 6-membered ring containing from 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, said ring optionally being benzofused. Exemplary heterocycles, for the purposes of the present invention, include furanyl, thiophenyl (thienyl), pyrrolyl, pyrrolidinyl, pyridinyl, N-methylpyrrolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, triazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, thiazolidinyl, N-acetylthiazolidinyl, pyrimidinyl, pyrazinyl, pyridazinyl, and the like. Benzofused heterocyclic rings include isoquinolinyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, quinolinyl, benzofuranyl, benzothiophenyl, indolyl, and the like, all of which may be optionally substituted, which also of course includes optionally substituted on the benzo ring when the heterocycle is benzofused.
  • Preferred heterocycles include pyridinyl, indolyl, furanyl, benzofuranyl, thiophenyl, benzodioxolyl, and thiazolidinyl, all of which may be optionally substituted.
  • Substituted alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, or alkylthio, means an alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, or alkythio group, respectively, substituted one or more times independently with a substituent selected from the group consisting of halo, hydroxy, and C1-C3 alkoxy. By way of illustration, but without limitation, examples include trifluoromethyl, pentafluoroethyl, 5-fluoro-2-bromopentyl, 3-hydroxypropyloxy, 4-hydroxycyclohexyloxy, 2-bromoethylthio, 3-ethoxypropyloxy, 3-ethoxy-4-chlorocyclohexyl, and the like. Preferred substitutions include substitution 1-5 times with halo, each independently selected, or substituted 1-3 times with halo and 1-2 times independently with a group selected from hydroxy and C1-C3 alkoxy, or substituted 1-3 times independently with a group selected from hydroxy and C1-C3 alkoxy, provided that no more than one hydroxy and/or alkoxy substituent may be attached through the same carbon.
  • The terms “substituted phenyl” and “substituted heterocycle” are taken to mean that the cyclic moiety in either case is substituted with one or more halo substituents, preferably one to five, each independently selected; or substituted with one or more substituents, preferably one to two substituents, independently selected from the group consisting of halo, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 alkylthio, wherein each alkyl, alkoxy and alkylthio substituent can be further substituted independently with C1-C2 alkoxy or with one to five halo groups selected from fluoro and chloro; or substituted with one substituent selected from the group consisting of phenyloxy, benzyloxy, phenylthio, benzylthio, and pyrimidinyloxy, wherein the phenyloxy, benzyloxy, phenylthio, benzylthio, and pyrimidinyloxy moiety can be further substituted with one to two substituents selected from the group consisting of halo, C1-C2 alkyl, and C1-C2 alkoxy; or substituted with one substituent selected from the group consisting of C1-C4 acyl and C1-C4 alkoxycarbonyl, and further substituted with zero to one substituent selected from the group consisting of halo, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 alkylthio. When a substituent is halo, preferred halo groups are fluoro, chloro, and bromo.
  • Pd2(dba)3 means tris(dibenzylidineacetone)-dipalladium(0).
  • BINAP means 2,2′-bis(diphenylphosphino)-1,1′binaphthyl.
  • DMF means N,N-dimethylformamide.
  • HATU means O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate.
  • Collidine means trimethylpyridine.
  • HRMS means High Resolution Mass Spectrum.
  • CIMS means Chemical Ionization Mass Spectrum.
  • APCI MS means Atmospheric Pressure Chemical Ionization Mass Spectrum.
  • The term “amino protecting group” as used in this specification refers to a substituents commonly employed to block or protect the amino functionality while reacting other functional groups on the compound. Examples of such amino-protecting groups include the formyl group, the trityl group, the phthalimido group, the acetyl group, the trichloroacetyl group, the chloroacetyl, bromoacetyl, and iodoacetyl groups, urethane-type blocking groups such as benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl (“FMOC”), and the like; and like amino protecting groups. The species of amino protecting group employed is not critical so long as the derivatized amino group is stable to the conditions of subsequent reactions on other positions of the molecule and can be removed at the appropriate point without disrupting the remainder of the molecule. Further examples of groups referred to by the above terms are described by T. W. Greene, “Protective Groups in Organic Synthesis”, John Wiley and Sons, New York, N.Y., 1991, Chapter 7 hereafter referred to as “Greene”.
  • The term “pharmaceutical” or “pharmaceutically acceptable” when used herein as an adjective, means substantially non-toxic and substantially non-deleterious to the recipient.
  • By “pharmaceutical formulation” it is further meant that the carrier, solvent, excipients and salt must be compatible with the active ingredient of the formulation (e.g. a compound of formula I). It is understood by those of ordinary skill in this art that the terms “pharmaceutical formulation” and “pharmaceutical composition” are generally interchangeable, and they are so used for the purposes of this application.
  • The term “acid addition salt” refers to a salt of a compound of formula I prepared by reaction of a compound of formula I with a mineral or organic acid. For exemplification of pharmaceutically acceptable acid addition salts see, e.g., Berge, S. M, Bighley, L. D., and Monkhouse, D. C., J. Pharm. Sci., 66:1, 1977. Since the compounds of this invention are amines, they are basic in nature and accordingly react with any of a number of inorganic and organic acids to form pharmaceutically acceptable acid addition salts. Since some of the free amines of the compounds of this invention are typically oils at room temperature, it is preferable to convert the free amines to their pharmaceutically acceptable acid addition salts for ease of handling and administration, since the latter are routinely solid at room temperature.
  • The pharmaceutically acceptable acid addition salts of the invention are typically formed by reacting a compound of formula I with an equimolar or excess amount of acid. Alternatively, hemi-salts can be formed by reacting a compound of formula I with the desired acid in a 2:1 ratio, compound to acid. The reactants are generally combined in a mutual solvent such as diethylether, tetrahydrofuran, methanol, ethanol, isopropanol, benzene, or the like. The salts normally precipitate out of solution within about one hour to about ten days and can be isolated by filtration or other conventional methods.
  • Inorganic acids commonly employed to form such salts include hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like. Organic acids commonly employed to form such salts include p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid and the like. Examples of such pharmaceutically acceptable salts thus are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, hemisuccinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β-hydroxybutyrate, glycollate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate and the like. Preferred pharmaceutically acceptable salts are those formed with hydrochloric acid and succinic acid.
  • The term “effective amount” means an amount of a compound of formula I which is capable of activating 5-HT1F receptors and/or inhibiting neuronal protein extravasation.
  • The term “suitable solvent” refers to any solvent, or mixture of solvents, inert to the ongoing reaction that sufficiently solubilizes the reactants to afford a medium within which to effect the desired reaction.
  • All enantiomers, diastereomers, and mixtures thereof, are included within the scope of the present invention. For example, the compounds of formula I wherein R5 is other than hydrogen contain two chiral centers, one at the 4-position of the piperidine ring, and one where R5 attaches to the piperidine ring. By way of illustration, but without limitation, the four stereoisomers of N-[6-(1,2-dimethylpiperidine-4-carbonyl)-pyridin-2-yl]-isonicotinamide are as follows, wherein the chiral centers are indicated with asterisks, “*”, and the R and S designations are as indicated.
  • Figure US20170044136A1-20170216-C00011
  • While all enantiomers, diastereomers, and mixtures thereof, are useful as 5-HT1F agonists, single enantiomers and single diastereomers are preferred. Furthermore, while all of the compounds of this invention are useful as 5-HT1F agonists, certain classes are preferred. The following paragraphs describe such preferred classes.
      • 1) R1 is phenyl, substituted phenyl, heterocycle, or substituted heterocycle;
      • 2) R1 is substituted phenyl;
      • 3) R1 is mono- or di-substituted phenyl wherein the substituents are independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, trifluoromethyl, trifluoromethoxy, trifluoroethoxy, phenyloxy, and benzyloxy;
      • 4) R1 is mono- or di-substituted phenyl wherein the substituents are independently selected from halo, C1-C2 alkoxy, trifluoromethyl, trifluoromethoxy, and trifluoroethoxy;
      • 5) R1 is di- or tri-halo substituted phenyl;
      • 6) R1 is heterocycle or substituted heterocycle;
      • 7) R1 is a substituted or unsubstituted heterocycle selected from the group consisting of furanyl, thiophenyl, pyrrolyl, pyrrolidinyl, pyridinyl, N-methylpyrrolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, triazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, thiazolidinyl, N-acetylthiazolidinyl, pyrimidinyl, pyrazinyl, pyridazinyl, isoquinolinyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, quinolinyl, benzofuranyl, benzothiophenyl, indolyl;
      • 8) R1 is a substituted or unsubstituted heterocycle selected from the group consisting of pyridinyl, indolyl, benzofuranyl, furanyl, thiophenyl, benzodioxolyl, and thiazolidinyl;
      • 9) R1 is a substituted or unsubstituted heterocycle selected from the group consisting of pyridinyl, furanyl, thiophenyl;
      • 10) R1 is mono-, di-, or tri-halo-substituted heterocycle, each halo group being independently selected;
      • 11) R1 is mono- or di-substituted heterocycle, wherein one of the substituents is selected from the group consisting of C1-C2 alkoxy, phenoxy, and phenylthio;
      • 12) R2 is hydrogen or C1-C3 alkyl;
      • 13) R2 is hydrogen or methyl;
      • 14) R2 is C3-C6 cycloalkyl-C1-C3 alkyl;
      • 15) R2 is pyrazolylalkyl or N-substituted pyrazolylalkyl;
      • 16) R2 is pyrazol-4-yl-ethyl;
      • 17) R2 is 1-(C1-C3 alkyl)pyrazol-4-yl-ethyl;
      • 18) R3 is hydrogen;
      • 19) R3 is methyl;
      • 20) R3 is ethyl;
      • 21) R4 is hydrogen;
      • 22) R4 is halo;
      • 23) R4 is fluoro or chloro;
      • 24) R4 is C1-C3 alkyl;
      • 25) R4 is methyl;
      • 26) R5 is hydrogen;
      • 27) R5 is C1-C3 alkyl;
      • 28) R5 is methyl;
      • 29) R2 is hydrogen or methyl, and R3, R4 and R5 are all hydrogen;
      • 30) R2 is hydrogen or methyl, and R3 is methyl, and R4 and R5 are both hydrogen;
      • 31) R1 is mono- or di-substituted phenyl wherein the substituents are independently selected from halo, C1-C2 alkoxy, trifluoromethyl, trifluoromethoxy, and trifluoroethoxy, R2 is hydrogen or methyl, and R3, R4 and R5 are hydrogen;
      • 32) R1 is a substituted or unsubstituted heterocycle selected from the group consisting of pyridinyl, indolyl, benzofuranyl, furanyl, thiophenyl, benzodioxolyl, and thiazolidinyl, R2 is hydrogen or methyl, and R3, R4 and R5 are hydrogen;
      • 33) R1 is substituted phenyl, R2 is hydrogen or methyl, and R3, R4 and R5 are all hydrogen;
      • 34) R1 is substituted phenyl, R2 is hydrogen or methyl, and R3 is methyl, and R4 and R5 are both hydrogen;
      • 35) R1 is mono- or di-substituted phenyl wherein the substituents are independently selected from halo, C1-C2 alkoxy, trifluoromethyl, trifluoromethoxy, and trifluoroethoxy, R2 is hydrogen or methyl, R3 is methyl and R4 and R5 are hydrogen;
      • 36) R1 is di- or tri-halo substituted phenyl, R2 is hydrogen or methyl, and R3, R4 and R5 are all hydrogen;
      • 37) R1 is di- or tri-halo substituted phenyl, R2 is hydrogen or methyl, and R3 is methyl, and R4 and R5 are both hydrogen;
      • 38) R1 is a substituted or unsubstituted heterocycle selected from the group consisting of pyridinyl, indolyl, benzofuranyl, furanyl, thiophenyl, benzodioxolyl, and thiazolidinyl, R2 is hydrogen or methyl, R3 is methyl, and R4 and R5 are hydrogen;
      • 39) any compound exemplified;
      • 40) the compound is an acid addition salt;
      • 41) the compound is a hydrochloride salt;
      • 42) the compound is the dihydrochloride salt.
      • 43) the compound is the hemisuccinate salt;
      • 44) the compound is the succinate salt; and
      • 45) the compound is the disuccinate salt.
  • It will be understood that the above classes may be combined to form additional preferred classes, as for example the combination of preferred selections for two or more substituents. Illustrative examples of combinations of preferred classes forming additional preferred classes are:
      • 46) the combination of any one of preferred classes 1), 2), 8) or 9) with preferred classes 21), and 26);
      • 47) the combination of any one of preferred classes 1), 2), 8) or 9) with preferred classes 21), and 27);
      • 48) the combination of any one of preferred classes 1), 2), 8) or 9) with preferred classes 21), and 28);
      • 49) the combination of any one of preferred classes 1), 2), 8) or 9) with preferred classes 23), and 26);
      • 50) the combination of any one of preferred classes 1), 2), 8) or 9) with preferred classes 23), and 28);
      • 51) the combination of any one of preferred classes 1), 2), 8) or 9) with preferred classes 25), and 26);
      • 52) the combination of any one of preferred classes 1), 2), 8) or 9) with preferred classes 25), and 28);
      • 53) the combination of any one of the preferred combinations 46)-52) with preferred classes 12) and 18);
      • 54) the combination of any one of the preferred combinations 46)-52) with preferred classes 12) and 19);
      • 55) the combination of any one of the preferred combinations 46)-52) with preferred classes 13) and 18);
      • 56) the combination of any one of the preferred combinations 46)-52) with preferred classes 13) and 19);
      • 57) the combination of any one of the preferred combinations 46)-52) with preferred classes 14) and 18);
      • 58) the combination of any one of the preferred combinations 46)-52) with preferred classes 14) and 19);
      • 59) the combination of any one of the preferred combinations 46)-52) with preferred classes 15) and 18); and
      • 60) the combination of any one of the preferred combinations 46)-52) with preferred classes 15) and 19).
  • In addition to those compounds presented in the examples, the following compounds further illustrate the scope of the present invention:
    • 1) 4-Fluoro-N-[6(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide;
    • 2) 2,4-Difluoro-N-[6(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 3) N-[6(1-Methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 4) 2-Chloro-4-fluoro-N-[6(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 5) 2-Chloro-N-[6(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 6) 2,4,6-Trifluoro-N-[6-(piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 7) 1H-5-Trifluoromethyl-indole-3-carboxylic acid [6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-amide
    • 8) N-[6-(1-Methyl-piperidine-4-carbonyl)-pyridin-2-yl]-2-trifluoromethoxy-benzamide
    • 9) 3-Bromo-thiophene-2-carboxylic acid [6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-amide
    • 10) 4-Fluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-2-trifluoromethyl-benzamide
    • 11) 2,4,6-Trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 12) 2-Chloro-6-fluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 13) 2,4,6-Trifluoro-N-methyl-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 14) 2,4,6-Trifluoro-N-methyl-N-[6-(piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 15) 2,4,6-Trifluoro-N-methyl-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 16) 2,4,6-Trifluoro-N-ethyl-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 17) 2-Chloro-4-fluoro-N-[6-(piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
    • 18) 2-Chloro-4-fluoro-N-methyl-N-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
    • 19) 1H-5-Fluoro-indole-3-carboxylic acid [6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-amide
    • 20) Cyclopropanecarboxylic acid [6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-amide
    • 21) 3-Methyl-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-butanamide
    • 22) Thiophene-2-carboxylic acid [6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-amide
    • 23) Furan-2-carboxylic acid [6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-amide
    • 24) 2-Chloro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 25) Furan-3-carboxylic acid [6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-amide
    • 26) 3,4-Difluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 27) N-[6-(1-Methyl-piperidine-4-carbonyl)-pyridin-2-yl]-isonicotinamide
    • 28) 2-Methyl-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 29) 2-Bromo-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 30) Thiophene-3-carboxylic acid [6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-amide
    • 31) 2-Fluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-isonicotinamide
    • 32) 4-Chloro-2-methoxy-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 33) 2-Ethoxy-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 34) N-[6-(1-Methyl-piperidine-4-carbonyl)-pyridin-2-yl]-2-phenoxy-benzamide
    • 35) 5-Chloro-2-methoxy-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 36) 2-Methoxy-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-4-methylsulfanyl-benzamide
    • 37) 2,3-Dihydro-benzofuran-7-carboxylic acid [6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-amide
    • 38) 2-Benzyloxy-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 39) N-[6-(1-Methyl-piperidine-4-carbonyl)-pyridin-2-yl]-2-propoxy-benzamide
    • 40) 2,2-Difluoro-benzo[1,3]dioxole-4-carboxylic acid [6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-amide
    • 41) 4-Methoxy-2-(2-methoxy-ethoxy)-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 42) 5-Bromo-2-methoxy-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 43) 2-(4,6-Dimethoxy-pyrimidin-2-yloxy)-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 44) N-[6-(1-Methyl-piperidine-4-carbonyl)-pyridin-2-yl]-butanamide
    • 45) Cyclohexanecarboxylic acid [6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-amide
    • 46) N-[6-(1-Methyl-piperidine-4-carbonyl)-pyridin-2-yl]-3-phenyl-propionamide
    • 47) 2,6-Difluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 48) 2-Ethoxy-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-nicotinamide
    • 49) N-[6-(1-Methyl-piperidine-4-carbonyl)-pyridin-2-yl]-2-phenoxy-nicotinamide
    • 50) 3-Acetyl-thiazolidine-4-carboxylic acid [6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-amide
    • 51) N-[6-(1-Methyl-piperidine-4-carbonyl)-pyridin-2-yl]-2-phenylsulfanyl-nicotinamide
    • 52) 5-Methoxy-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-2-(2,2,2-trifluoro-ethoxy)-benzamide
    • 53) 2-Methoxy-6-methyl-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 54) N-[6-(1-Methyl-piperidine-4-carbonyl)-pyridin-2-yl]-terephthalamic acid methyl ester
    • 55) Cyclobutanecarboxylic acid [6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-amide
    • 56) 2-(2-Chloro-1,1,2-trifluoro-ethoxy)-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 57) 2-Chloro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 58) 2,5-Difluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 59) 3,4-Difluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 60) 4-Fluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-2-trifluoromethyl-benzamide
    • 61) 2-Fluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-6-trifluoromethyl-benzamide
    • 62) 2,3,4-Trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 63) 2,4,5-Trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 64) 3-Chloro-thiophene-2-carboxylic acid [6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-amide
    • 65) 2,6-Dichloro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide
    • 66) 2-Fluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-4-trifluoromethyl-benzamide
    • 67) Cyclopentanecarboxylic acid [6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-amide
    • 69) N-[6-(1-Methyl-piperidine-4-carbonyl)-pyridin-2-yl]-nicotinamide
  • It is preferred that the mammal to be treated by the administration of compounds of this invention is human.
  • The compounds of the present invention may be synthesized through a condensation of a 6-lithio anion of 2-chloropyridine with 1-substituted- or N-protected piperidine-4-carboxylic acid methoxy-methylamide, followed by conversion of the 2-halo group to an amino group, and subsequent condensation with the appropriate R1-acylhalide compound. (see Scheme 1.)
  • Figure US20170044136A1-20170216-C00012
  • Suitable reaction conditions for the steps of this scheme are well known in the art and appropriate substitutions of solvents and reagents are within the skill of the art. See for example, J. C. S. Perkin T. (24), 3597-3600 (1997) for the initial condensation.
  • Typically 2-chloropyridine is activated by reaction with a mixture of n-butyl lithium and 2-dimethylamino-ethanol in a suitable solvent, such as hexane, at −78° C. The reaction is generally complete within about an hour. Next 1-R7-substituted-piperidine-4-caboxylic acid methoxy-methyl-amide in an organic solvent, such as hexane is added and stirred to form the 2-chloropyridinoyl-piperidine intermediate. The reaction is generally complete within about an hour. When the desired final R2 substituent is hydrogen, the piperidinyl nitrogen should first be protected with an amino protecting group, the addition and later removal of which are accomplished by standard procedures well known in the art.
  • Typically the first condensation reaction is quenched by the addition of water and the mixture is extracted multiple times with a suitable solvent, such as ethyl acetate. This 2-chloropyridinoyl-piperidine intermediate can then be dried, as for example with anhydrous sodium sulfate, evaporated, and then partially purified, as for example, by chromatography on a silica gel column.
  • Next, the 2-chloropyridinoyl-piperidine intermediate is reacted with benzophenone imine in the presence of tris(dibenzylidineacetone)-dipalladium(0) Pd2(dba)3) as a catalyst, and 2,2′-bis(diphenylphosphino)-1,1′binaphthyl (BINAP) and sodium t-butoxide in a suitable solvent, such as toluene, at reflux, to substitute the halo group with the benzophenone imino group. After work-up, this intermediate is typically reacted with hydrochloric acid in a suitable solvent, such as tetrahydrofuran, and then purified to give the corresponding 2-aminopyridinoyl-piperidine intermediate.
  • In the final stage of scheme I, the R1 moiety is added by amide bond formation by reacting the 2-aminopyridinoyl-piperidine intermediate with the desired R1-acylhalide. Typically, a mixture of the 2-aminopyridinoyl-piperidine intermediate, the desired R1-acylhalide, a proton scavenger, such as triethylamine, diisopropylethylamine, and the like, in an appropriate solvent, such as dichloromethane, THF, MTBE and the like, is stirred at about room temperature until the reaction is complete, as for example, about 4 hrs. A strong base, such as sodium hydroxide, may then be added to neutralize the reaction mixture, and the final product purified by normal work-up procedures.
  • If the piperidinyl nitrogen is protected by an amino protecting group, this group is removed after the condensation reaction with the acylhalide. The piperidinyl nitrogen can then remain as a secondary amine for compounds of the present invention wherein R2 is hydrogen, or it may be further alkylated by known procedures for compounds of the present invention wherein R2 is C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II
  • Figure US20170044136A1-20170216-C00013
  • Although alternative alkylation methods are well known in the art, one typical alkylation reaction proceeds by reductive alkylation of the secondary amine with an appropriate aldehyde, an organic acid such as glacial acetic acid or trifluoroacetic acid, and a reducing agent such as sodium cyanoborohydride or sodium triacetoxyborohydride, in an appropriate solvent, such as methanol or dichloromethane, wherein the appropriate aldehyde is one that will react to provide the desired R2 substituent. (Michael B. Smith and Jerry March, March's Advanced Organic Chemistry: Reactions, mechanisms and Structure, 5th ed., pgs 1185-1187 (sec. 16-12), John Wiley & Sons, Inc., New York, 2001.) By way of illustration, for the synthesis of compounds having R2=methyl, the desired aldehyde would be formaldehyde, whereas for the synthesis of compounds having R2=3-cyclopentylpropyl, the desired aldehyde would be 3-cyclopentylpropanal.
  • Compounds of the present invention wherein R3 is methyl or ethyl can be synthesized by Scheme 2.
  • Figure US20170044136A1-20170216-C00014
  • The R3-aminocarbonyl-R1 reagents are easily prepared by reacting the corresponding R1 acylhalide with the desired amine (methylamine, ethylamine, propylamine, or isopropylamine, as for example a 2 M solution thereof) in an appropriate solvent, as for example methanol. Such a procedure is trivial and well known in the art.
  • The 2-bromopyridinoyl-piperidine intermediate is synthesized by first reacting 2,6-dibromopyridine in a suitable organic solvent, such as dichloromethane, preferably under a nitrogen atmosphere, with 1.1 equivalent of n-butyllithium in a suitable solvent, such as hexanes, preferably at low temperatures, such as −78° C. An appropriate 1-R7-substituted-N-methoxy-N-methyl-piperidine-4-carboxamide is then added to the reaction mixture. The reaction is subsequently quenched with base, as for example, aqueous NaOH. The resulting intermediate may then be purified by standard workup techniques, such as extraction, solvent removal and subsequent chromatography.
  • The 2-bromopyridinoyl-piperidine intermediate is reacted under N2 in a mixture with the desired methylaminocarbonyl-R1, ethylaminocarbonyl-R1, or propylaminocarbonyl-R1, respectively, tris(dibenzylidineacetone)-dipalladium(0) (Pd2(dba)3), 2,2′-bis(diphenylphosphino)-1,1′binaphthyl (BINAP), and sodium t-butoxide, in a suitable solvent, such as suitably anhydrous toluene. The reaction is typically heated for several hours, as for example at about 85° C. for 16 hours. Additional C1-C2 alkylaminocarbonyl-R1, tris(dibenzylidineacetone)-dipalladium(0) (Pd2(dba)3), 2,2′-bis(diphenylphosphino)-1,1′binaphthyl (BINAP), and sodium t-butoxide can be added and the reaction continued for a similar period of time to improve the reaction yield. The final product is then purified by common methods.
  • Compounds of the present invention wherein R4 or R5 are other than hydrogen can be synthesized by the above schemes utilizing the corresponding substituted 2-halopyridine and substituted piperidinyl starting reagents.
  • In a preferred embodiment, a novel condensation reaction is used to synthesize the 2-bromopyridinoyl-piperidine intermediate to provide highly selective mono-addition, as well as higher yields of the desired intermediate product with fewer impurities. In another preferred embodiment, a more favorable reaction is used to convert the 2-bromopyridinoyl-piperidine intermediate to the 2-aminopyridinoyl-piperidine intermediate in preparation for the final condensation reaction. (See Scheme 3.)
  • Figure US20170044136A1-20170216-C00015
  • The novel N,N-dimethylaminocarbonylpiperidine intermediate is made in high yield from an R7-isonipicotic acid derivative by reacting the acid with oxalyl chloride in the presence of a catalytic amount of dimethylformamide (DMF) in a suitable solvent, such as dichloromethane, tetrahydrofuran, dichloroethane, diethylether, or the like, and concentrating to yield an isonipecotyl chloride derivative. This is then resuspended in a suitable solvent, such as tetrahydrofuran, dichloromethane, dichloroethane, diethylether, or the like, and reacted with dimethylamine in the presence of a proton scavenger, as for example, a non-nucleophilic organic base, such as triethylamine, diisopropylethylamine, or the like, and then purified to give the N,N-dimethylaminocarbonylpiperidine intermediate.
  • The N,N-dimethylcarbonylpiperidine intermediates of the present invention have the distinct advantages over the N-protected piperidine-4-caboxylic acid methoxy-methylamide reagents (Weinreb reagents) of the prior art, in that they are non-hygroscopic and surprisingly provide significantly improved chemoselectivity and yield in the subsequent condensation reaction as compared to the condensation reaction using the corresponding Weinreb reagent. This is particularly the case when, as in a preferred embodiment, toluene or methyl-tert-butylether (MTBE) is used as the solvent. In a yet more preferred embodiment, MTBE is used as the solvent.
  • Next, 2,6-dibromopyridine is activated by reaction with n-butyllithium in cold MTBE or toluene, preferably MTBE, to produce a bromolithiumpyridine intermediate. Subsequently, the N,N-dimethylaminocarbonylpiperidine intermediate is added and the mixture stirred, as for example for about an hour at between about −100° C. to about −60° C., preferably about −75° C. In a preferred embodiment, the coupling reaction is run with a ratio of the 2,6-dibromopyridine to the N,N-dimethylaminocarbonylpiperidine intermediate of about a 1.0 to about 2.0, more preferably with a ratio of between about 1.3 to about 1.7, most preferably with a ratio of about 1.5. The reaction is then quenched with saturated ammonium chloride at about −20° C. to about 10° C., and then neutralized with hydrochloric acid and additional water. The product can then be isolated by typical work-up procedures, as for example, but without limitation, by extraction of the aqueous phase with dichloromethane, washing the organic fractions with acidified water (as for example, pH 2), neutralizing the aqueous extract with sodium hydroxide, followed by extraction with ethyl acetate, drying the organic phase, as for example with magnesium sulfate, and concentrating, as for example, by evaporation, rotoevaporation, etc.
  • In another preferred embodiment, the 4-(N,N′-dimethylamino)carbonyl piperidine compound in Scheme 3 is replaced with a substituted aminocarbonylpiperidine compound of formula IV
  • Figure US20170044136A1-20170216-C00016
  • where R8, R9, and R10 are as defined above. Preferred compounds of formula IV are those wherein R9 and R10 are each methyl, or wherein R9 and R10, together with the nitrogen to which they are attached, combine to form pyrrolidinyl. Particularly preferred are those compounds wherein R9 and R10, together with the nitrogen to which they are attached, combine to form pyrrolidinyl.
  • Compounds where R9 and R10, together with the nitrogen to which they are attached, combine to form azetidinyl, pyrrolidinyl, or piperidinyl, can be synthesized by the same methods as their N,N′-dimethyl analogs, by substituting azetidine, pyrrolidine, or piperidine, respectively, for the dimethylamine reagent described above.
  • The 4-(pyrrolidinylcarbonyl)piperidine reagents have the added advantage over the 4-(N,N′-dimethylamino)carbonyl piperidine reagents in that they tend to be even less hygroscopic and tend to produce more stable crystals, improving the handling characteristics of the reagents. As with the 4-(N,N′-dimethylamino)carbonyl piperidine reagents, the 4-(pyrrolidinylcarbonyl)piperidine reagents provide unexpected significantly improved chemoselectivity and yield in the subsequent condensation reaction over reactions run using the corresponding Weinreb reagents.
  • By way of illustration, but without limitation, 1-methyl-4-(N,N′-dimethylamino)carbonyl piperidine is a low melting point solid that crystallizes easily and has relatively low hygroscopicity, particularly as compared to the corresponding Weinreb reagent. However, when the crystalline form does absorb water, it converts to an oil. In comparison, 1-methyl-4-(pyrrolidinylcarbonyl)piperidine is also a low melting point solid that crystallizes easily, but is even less hygroscopic than 1-methyl-4-(N,N′-dimethylamino)carbonyl piperidine and produces more stable crystals, such that they retain their crystalline form even if some water is absorbed. 1-methyl-4-(piperidin-1-yl)carbonylpiperidine generally remains an oil.
  • In another embodiment of the present inventive process, 2,6-dichloropyridine can be used instead of 2,6-dibromopyridine in scheme 3, above under similar reaction conditions, to provide the corresponding 2-chloropyridinoylpiperidine intermediate.
  • In yet another preferred embodiment of the novel synthetic process, MTBE or toluene is used as the solvent, resulting in further improved chemoselectivity in the condensation reaction. MTBE as solvent is most preferred.
  • In a further embodiment of the present inventive process, the next step of the synthesis provides for the exchange of the halo group for an amino group by reaction of a 2-bromo-6-(piperidinylcarbonyl)pyridine intermediate, as described above, with ammonia and ethylene glycol, in the presence of copper(I) oxide as a catalyst. In a preferred embodiment, this reaction is run in an autoclave, with typical conditions being about 80° C. to about 110° C., preferably about 100° C., and from about 45 to about 60 psi (about 310 to about 414 kPa), typically about 50 psi (about 345 kPa) Ammonia is then removed from the organic fraction by evacuation. Aqueous sodium hydroxide is then added and the mixture extracted with a suitable organic solvent, as for example, methyl-tert-butylether or dichloromethane, and then dried, as for example, with magnesium sulfate.
  • In a preferred embodiment, the crude 2-amino-6-(1-R7-piperidine-4-ylcarbonyl)pyridine intermediate is further purified by crystallization of the hydrochloric salt and then neutralizing the salt with sodium hydroxide, organic solvent extraction and solvent removal.
  • The final condensation reaction is as described in Scheme 1.
  • The following Preparations and Examples are illustrative and should not be interpreted in any way so as to limit the scope of the invention.
    • Preparations
  • Figure US20170044136A1-20170216-C00017
    • 1. 2-Chloro-6-(1-methylpiperidin-4-ylcarbonyl) pyridine (GB2-B8P-055)
  • Figure US20170044136A1-20170216-C00018
  • Add 2-chloropyridine (1 g, 8.8 mmole) to a mixture of n-butyl lithium (1.6 M in hexane) (22 mL, 35.2 mmole) and 2-dimethylamino-ethanol (1.56 g, 17.6 mmole) in hexane (20 mL at −78° C.) and stirred for 1 hour. Then add 1-methyl-piperidine-4-carboxylic acid methoxy-methyl-amide (3.2 g, 17.6 mmole) in hexane (5 mL) and stir the mixture for 1 hour. Quench the reaction mixture with water and extract twice with ethyl acetate, dry the organic layer with anhydrous sodium sulfate, evaporate the solvent and purify the residual product by chromatography on a silica gel column to give about 1 g of the title product.
    • 2. 2-Amino-6-(1-methylpiperidin-4-ylcarbonyl)pyridine (GB2-B8P-056)
  • Figure US20170044136A1-20170216-C00019
  • Heat a mixture of 2-chloro-6-(1-methylpiperidin-4-ylcarbonyl) pyridine (800 mg, 3.35 mmole), benzophenone imine (729 mg, 4.02 mmole), tris(dibenzylidineacetone)-dipalladium(0) (61 mg, 0.067 mmole), racemic-2,2′-bis(diphenylphosphino)-1,1′ binaphthyl (83 mmole, 0.134 mmole) and sodium t-butoxide (451 mg, 4.69 mmole) in toluene (100 mL) at reflux for 2 hours. Evaporate the solvent and re-dissolve the residue in ethyl acetate, wash with water, dry with anhydrous sodium sulfate, evaporate and purify by chromatography on a silica gel column to give about 1 g of a benzophenone-imine intermediate. Add 1N HCl (12 mL) into a solution of the product in THF (50 mL), and stir at room temperature for 2 hours. Then add 25 mL of 1N HCl and extract the mixture twice with (2:1) hexane:ethyl acetate. Basify the aqueous phase, extract with dichloromethane, dry with anhydrous sodium sulfate, evaporate the solvent and purify the residual by chromatography on a silica gel column (ethyl acetate:2M NH3 in methanol, 90:10) to give about 600 mg of the title product.
    • EXAMPLES 1. 4-Fluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide dihydrochloride LY 520728 GB2-B8P-059
  • Figure US20170044136A1-20170216-C00020
  • Stir a mixture of 2-Amino-6-(1-methylpiperidin-4-ylcarbonyl)pyridine (0.150 g), 4-fluorobenzoyl chloride (0.218 g), triethylamine (0.192 mL) and dichloromethane at room temperature for 4 hours. Add 1N aqueous NaOH to basify the reaction mixture. Extract the mixture with dichloromethane, dry the organic phase with anhydrous sodium sulfate, evaporate the solvent, and purify the residue by HPLC to provide the free base of the title compound. Re-dissolve the free base in diethyl ether and add excess 1 M HCl. Evaporate the solvent and dry the residue under vacuum to obtain 80 mg of the title compound. M.p. 75-80° C.; HRMS: 342.1605 (obs.) (Cal. 342.1618).
    • 2. 2,4-Difluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide dihydrochloride
  • Figure US20170044136A1-20170216-C00021
  • Use a method similar to the above example 1, with 2,4-difluorobenzoyl chloride to obtain the title compound. M.p. 108-110° C.; mass spectrum (electric spray) m/z=360.
  • Mono-hydrochloride salt LY 522975 GB2-B8P-069-1
    Di-hydrochloride salt LY 545966 GB2-B8P-127-1 (free base M+1)
    • 3. 2-Chloro-4-fluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide
  • Figure US20170044136A1-20170216-C00022
  • Use a method similar to the above example 1, with 2-chloro-4-fluorobenzoyl chloride to obtain the title compound. Free base (LY 526867, GB2-B8P-87) m.p. 53-55° C.; HRMS: 376.1233 (obs.) (Cal. 376.1228). Di-HCl salt (LY 543057, GB2-B8P-124) m.p. 243-245° C.; HRMS: 376.1238 (obs.) (Cal. 376.1228).
    • 4. 2-Chloro-6-fluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide mono-hydrochloride salt LY622824 GB2-B8P-296 (PX104847)
  • Figure US20170044136A1-20170216-C00023
  • Combine 2-amino-6-(1-methylpiperidin-4-ylcarbonyl)pyridine (0.18 g, 0.85 mmol), 2-chloro-6-fluoro-benzoyl chloride (0.318 g, 1.65 mmol), and 1,4-dioxane (10 mL). Stir and heat the mixture at reflux. After 2 hr., cool the reaction mixture to ambient temperature and concentrate. Load the mixture onto an SCX column (10 g), wash with methanol, and elute with 2M ammonia/methanol. Concentrate the eluent to obtain the free base of the title compound (0.30 g, 94%) as an oil. Dissolve the oil in methanol (5 mL) and treat with ammonium chloride (0.045 g, 0.85 mmol). Concentrate the mixture and dry under vacuum to obtain the title compound. HRMS Obs. m/z 376.1237; Calc. m/z 376.1228; m.p. 155° C. (dec).
    • 5. 2-Bromo-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridine-2-yl]benzamide hydrochloride salt (LY 574243, GJ2-H3K-177)
  • Figure US20170044136A1-20170216-C00024
  • Use a method similar to example 1, with 2-bromobenzoyl chloride to obtain the free base of the title compound. Dissolve the clean material (104.8 mg) in methanol and add 1 equivalent (13.9 mg) of NH4Cl. Sonicate the reaction mixture at room temperature for 15 min and then concentrate and dry the mixture to provide the title compound as a white solid. Mass spectrum (ion spray): m/z=402.1 (M+1); 1H NMR δ (d6-DMSO, ppm) 11.15 (1H, s), 8.37 (1H, bs), 8.07 (1H, t, J=7.69, 8.05, 15.74 Hz), 7.74 (2H, m), 7.58 (3H, m), 3.70 (1H, bs), 2.87 (2H, m), 2.65 (3H, s), 2.12 (3H, m), 1.82 (3H, m)
    • 6. 2-Chloro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide LY 542968 MN4-B6K-251
  • Figure US20170044136A1-20170216-C00025
  • Mix 2-Amino-6-(1-methylpiperidin-4-ylcarbonyl)pyridine (0.223 g) and 2-chlorobenzoyl chloride (0.175 g) in 1,4-dioxane (10 mL) and heat at reflux for 1 hour. Dilute with methanol (10 mL) and load on a SCX column (10 g). Wash the column with methanol, elute the product with 2 M NH3 in methanol, evaporate and purify the product on a silica gel column (CH2Cl2 with 2 M NH3 in methanol) to obtain 0.305 g (84%) of the title compound: mass spectrum (electric spray) m/z=358 (M+1) and 360 (M+2+1); 1H NMR (CDCl3): 8.60 (br s, 1H), 8.54 (d, 1H), 7.90 (dd, 1H), 7.81 (d, 1H), 7.76 (dd, 1H), 7.45 (m, 3H), 3.63 (m, 1H), 2.90 (m, 2H), 2.29 (s, 3H), 2.07 (m 2H), 1.85 (m, 4H). (file: mn4-b6k-251)
  • Dissolve the free base in dichloromethane and add 1N HCl in ether (0.85 mL), evaporate, and dry under vacuum to obtain the monohydrochloride salt (0.354 g). (LY 572158, MN4-B6K-251)
    • 7. N-[6-(1-Methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide hydrochloride
  • Figure US20170044136A1-20170216-C00026
  • Use a method similar to the above example 1, with benzoyl chloride to obtain the free base of the title compound. Re-dissolve the free base in diethyl ether and add 1 M HCl in a 1:1 molar ratio. Evaporate the solvent and dry the residue under vacuum to obtain the title compound. hydrochloric acid salt LY 522976 GB2-B8P-069-2 HRMS: 324.1697 (obs.) (Cal. 324.1712). (There is no other physical data available).
    • 8. 2,4,6-Trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide mono-hydrochloride salt LY587815 GB2-B8P-261 (PX100246)
  • Figure US20170044136A1-20170216-C00027
  • Combine 2-amino-6-(1-methylpiperidin-4-ylcarbonyl)pyridine (0.20 g, 0.92 mmol), 2,4,6-Trifluorobenzoyl chloride (0.357 g, 1.84 mmol), and 1,4-Dioxane (10 mL), and stir while heating at reflux. After 3 hr., cool the reaction mixture to ambient temperature and concentrate. Load the concentrated mixture onto an SCX column (10 g), wash with methanol, and elute with 2M ammonia in methanol. Concentrate the eluent to obtain the free base of the title compound as an oil (0.365 g (>100%)). Dissolve the oil in methanol (5 mL) and treat with ammonium chloride (0.05 g, 0.92 mmol). Concentrate the mixture and dry under vacuum to obtain the title compound. HRMS Obs. m/z 378.1435, Calc. m/z 378.1429; m.p. 255° C. (dec).
    • 9. 2-Trifluoromethyl-4-fluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide mono-hydrochloride salt LY586554 GB2-B8P-254 (PX097276)
  • Figure US20170044136A1-20170216-C00028
  • Combine 2-amino-6-(1-methylpiperidin-4-ylcarbonyl)pyridine (0.19 g, 0.87 mmol), 2-trifluoromethyl-4-fluoro-benzoyl chloride (0.395 g, 1.74 mmol), and 1,4-Dioxane (50 mL). Stir and heat the mixture at reflux. After 3 hr., cool the reaction mixture to ambient temperature and concentrate. Load the mixture onto an SCX column (10 g), wash with methanol, and elute with 2M ammonia/methanol. Concentrate the eluent to obtain the free base of the title compound as an oil (0.241 g, 68%). Dissolve the oil in methanol (5 mL) and treat with ammonium chloride (0.031 g, 0.59 mmol). Concentrate and dry under vacuum to obtain the title compound. HRMS Obs. m/z 410.1490, Calc. 410.1491; m.p. 145-150° C.
    • 10. 2-Trifluoromethoxy-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide mono-hydrochloride salt LY572270 GH8-B8Q-284C (PX097276)
  • Figure US20170044136A1-20170216-C00029
  • Combine 2-amino-6-(1-methylpiperidin-4-ylcarbonyl)pyridine (0.18 g, 0.84 mmol), 2-trifluoromethoxybenzoyl chloride (0.23 g, 1.0 mmol) and 1,4-Dioxane (5 mL). Stir and heat the mixture at reflux. After 3 hr., cool the reaction mixture to ambient temperature. Load on an SCX column (10 g), wash with methanol, and elute with 2M ammonia/methanol. Concentrate the eluent to obtain the free base of the title compound (0.26 g, 76%). Dissolve the free base in methanol (10 mL) and treat with ammonium chloride (0.032 g). Concentrate and dry under vacuum to obtain the title compound. HRMS Obs. m/z 408.1517, Calc. m/z 408.1535; m.p. 155-160° C.
    • 11. 3-Bromo-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-thiophene-2-carboxamide mono-hydrochloride salt LY586552 GB2-B8P-250 (PX099831)
  • Figure US20170044136A1-20170216-C00030
  • Combine 2-amino-6-(1-methylpiperidin-4-ylcarbonyl)pyridine (0.104 g, 0.48 mmol), 3-Bromo-thiophene-2-carbonyl chloride (0.215 g, 0.95 mmol), and 1,4-Dioxane (10 mL). Stir and heat the mixture at reflux. After 2 hr., cool the reaction mixture to ambient temperature and concentrate. Load the mixture onto an SCX column (10 g), wash with methanol, and elute with 2M ammonia/methanol. Concentrate the eluent to obtain the free base of the title compound as an oil (0.152 g, 78%). Dissolve the oil in dichloromethane (10 mL), treat with 1M hydrogen chloride in ether, concentrate and dry under vacuum to obtain the title compound. HRMS Obs. m/z 408.0384, Calc. m/z 408.0381; m.p. 195-200° C.
    • 12. 1-H-indol-3-yl-N-[6-(1-methylpiperidin-4-ylcarbonyl)-pyridin-2-yl]-carboxamide dihydrochloride salt
  • Figure US20170044136A1-20170216-C00031
    • (i) Intermediate: 1-Benzylindol-3-yl-N-[6-(1-methylpiperidin-4-ylcarbonyl)-pyridin-2-yl]-carboxamide
  • Figure US20170044136A1-20170216-C00032
  • Add oxalyl chloride (0.18 mL, 2.1 mmol) dropwise to a solution of 1-benzylindol-3-carboxylic acid (0.48 g, 1.9 mmol) in pyridine and CH3CN (5 mL each) cooled in an ice bath. Stir the reaction mixture for 2.25 hr. and then add a suspension of 2-amino-6-(1-methylpiperidin-4-ylcarbonyl)pyridine (0.56 g, 1.9 mmol) in CH3CN (5 mL) and pyridine (12 mL). Warm the reaction mixture to room temperature overnight. Quench the reaction with cold H2O (20 mL) and dilute with CHCl3. Adjust the pH to 11 with Na2CO3 and separate the layers. Extract the aqueous layer with CHCl3 (2×30 mL). Combine the organic fractions and dry with anhydrous MgSO4, filter and concentrate the mixture in vacuo. Purify the product by chromatography on a silica gel column, eluting with methanol/CH2Cl2 (5:95) followed by methanol/CH2Cl2 (10:90) to afford the sub-title compound (0.44 g, 51%). 1H NMR (CD3OD) □ δ □8.45 (d, J=8 Hz, 1H), 8.32 (s, 1H), 8.26 (m, 1H), 7.95 (t, J=8 Hz, 1H), 7.72 (d, J=8 Hz, 1H), 7.45 (m, 1H), 7.22-7.37 (m, 7H), 5.51 (s, 2H), 3.90 (m, 1H), 2.93-3.01 (m, 2H), 2.33 (s, 3H), 2.21-2.31 (m, 2H), 1.92-1.99 (m, 2H), 1.71-1.84 (m, 2H); CIMS (Methane) m/z 453 [C28H28N4O2+H]+.
    • (ii) 1H-indol-3-yl-N-[6-(1-methylpiperidin-4-ylcarbonyl)-pyridin-2-yl]-carboxamide
  • Figure US20170044136A1-20170216-C00033
  • Add aluminum trichloride (106 mg, 0.795 mmol) to a suspension of 1-benzylindol-3-yl-N-[6-(1-methylpiperidin-4-ylcarbonyl)-pyridin-2-yl]-carboxamide (180 mg, 0.398 mmol) in benzene (6 mL) and heat the mixture at reflux for 1.25 hr. Then add another 2 equivalents of aluminum trichloride (108 mg) and continue heating at reflux for an additional 5.5 hr. Cool the reaction mixture to room temperature. Then pour the reaction into ice cold H2O (50 mL) and then dilute with ethyl acetate. Adjusted the pH of the solution to 11 with saturated Na2CO3, separate the layers and extract the aqueous layer with ethyl acetate (3×50 mL). Combined the organic fractions, dry with Na2SO4, filter and concentrate in vacuo. Purify the intermediate by flash chromatography on a silica gel column, eluting with CHCl3/methanol/NH4OH (93:7:1) to obtain the sub-title compound (96 mg, 67%). 1H NMR (CD3OD) □ δ □8.45 (d, J=8 Hz, 1H), 8.25 (s, 1H), 8.21 (m, 1H), 7.96 (t, J=8 Hz, 1H), 7.72 (d, J=8 Hz, 1H), 7.48 (m, 1H), 7.18-7.27 (m, 2H), 3.90 (m, 1H), 2.94-3.01 (m, 2H), 2.31 (s, 3H), 2.19-2.28 (m, 2H), 1.92-2.02 (m, 2H), 1.71-1.84 (m, 2H). CIMS (Methane) m/z 363 [C21H22N4O2+H]+.
    • (iii) 1-H-indol-3-yl-N-[6-(1-methylpiperidin-4-ylcarbonyl)-pyridin-2-yl]-carboxamide dihydrochloride salt
  • Figure US20170044136A1-20170216-C00034
  • Add 2.0M HCl in diethylether (0.46 mL, 0.93 mmol) to a suspension of 1H-indol-3-yl-N-[6-(1-methylpiperidin-4-ylcarbonyl)-pyridin-2-yl]-carboxamide (free base) (0.16 g, 0.44 mmol) in diethylether (10 mL). After 2 hr. filter the reaction mixture and wash the solid with diethylether to afford the title compound as a yellow solid. Rf 0.29 (93:7:1 CHCl3/methanol/NH4OH); m.p. 200-218° C.; 1H NMR (CD3OD, complex mixture of rotamers) □δ □8.38 and 8.49 (s, 1H), 8.46 (m, 1H), 8.08-8.10 and 8.18-8.29 (m, 2H), 7.61 and 7.72 (d, J=8 Hz, 1H), 7.52 (m, 1H), 7.26-7.32 (m, 2H), 4.01 (m, 1H), 3.19-3.68 (m, 3H), 2.97 (m, 1H), 2.82 and 2.94 (s, 3H), 2.28-2.32 (m, 2H), 1.68-2.02 (m, 2H); CIMS (Methane) m/z 363 [C21H22N4O2+Hr; HPLC (Method A) 96.7%, tR 16.4 min.; anal. calculated for C21H22N4O2.2.1HCl. 1.5H2O: C, 54.12; H, 5.86; N, 12.02; Cl, 15.98. Found: C, 54.13; H, 6.03; N, 12.37; Cl, 15.71.
    • 13. Cyclopropyl-[6-(1-methylpiperidin-4-ylcarbonyl)-pyridin-2-yl]-carboxamide dihydrochloride salt
  • Figure US20170044136A1-20170216-C00035
  • Add cyclopropylcarbonyl chloride (0.08 mL, 0.83 mmol) dropwise to a solution of 2-amino(6-pyridyl)-1-methyl(4-piperidyl)-ketone (221 mg, 0.76 mmol, provided by Eli Lilly) and triethylamine (0.32 mL, 2.3 mmol) in CH2Cl2 (5 mL) cooled in an ice bath. Warm the reaction mixture to room temperature and stir for 3 hr. Extract the reaction mixture with CH2Cl2 and H2O and adjust the pH of the aqueous layer to 11 with Na2CO3. Separate the layers and extract he aqueous layer with CH2Cl2 (2×50 mL). Combine the organic fractions, dry (Na2SO4), filter and concentrate in vacuo. Purify the concentrate by chromatography on a silica gel column, eluting with a gradient of CH2Cl2/methanol (95:5 to 90:10) to obtain the free base of the title compound (180 mg, 83%). 1H NMR (CDCl3, complex mixture of rotamers) □ δ □8.81 (bs, 1H), 8.39 (d, J=8 Hz, 1H), 7.82 (t, J=8 Hz, 1H), 7.71 (d, J=8 Hz, 1H), 3.50 (m, 1H), 3.13-3.21 (m, 2H), 2.51 (s, 3H), 2.37-2.48 (m, 4H), 1.95-2.04 (m, 2H), 1.55 and 1.82 (m, 1H), 0.75-0.81, 0.90-0.99 and 1.10-1.14 (m, 4H); APCI MS m/z 288 [C16H21N3O2+H]+.
  • Add 2.0M HCl in diethyl ether (0.95 mL, 1.9 mmol) to a solution of the free base (180 mg, 0.626 mmol) in diethyl ether (10 mL) and methanol (3 mL). After 2 hr. the reaction was filtered to afford the title compound as a light yellow solid. Rf 0.47 (93:7:1 CHCl3/methanol/NH4OH); m.p. 140-148° C.; 1H NMR (CD3OD, complex mixture of rotamers) δ □8.24 and 8.50 (m, 1H), 8.05-8.08 (m, 1H), 7.52 and 7.64 (d, J=8.0 Hz, 1H), 3.98 and 4.16 (m, 1H), 3.62-3.66 (m, 1H), 3.20-3.28 and 3.44-3.56 (m, 2H), 2.91-3.04 (m, 1H), 2.80 and 2.93 (s, 3H), 2.13-2.29 (m, 2H), 1.57-1.79 and 1.92-2.06 (m, 3H), 1.01-1.21 (m, 4H); CIMS (Methane) m/z 288 [C16H21N3O2+Hr; HPLC (Method A)>99%, tR 14.9 min.; anal. calculated for C16H21N3O2.2.3HCl.2.3H2O: C, 46.57; H, 6.81; N, 10.18; Cl, 19.76. Found: C, 46.43; H, 6.55; N, 10.00; Cl, 19.62.
    • 14. 2-Methylprop-1-yl-N-[6-(1-methylpiperidin-4-ylcarbonyl)-pyridin-2-yl]-carboxamide dihydrochloride salt
  • Figure US20170044136A1-20170216-C00036
    • ALB 7533
  • (i) Free base: Add 3-methylbutanoyl chloride (0.11 mL, 0.90 mmol) dropwise to a solution of 2-amino-6-(1-methylpiperidin-4-ylcarbonyl)pyridine (132 mg, 0.45 mmol) and triethylamine (0.19 mL, 1.4 mmol) in CH2Cl2 (5 mL) cooled in an ice bath. Warm the reaction mixture to room temperature and stir for 3 hr. Dilute the reaction with CH2Cl2 and wash with saturated NaHCO3 (50 mL). Extract the aqueous layer with CH2Cl2 (2×25 mL). Combine the organic fractions, dry (Na2SO4), filter and concentrate in vacuo. Purify the product by chromatography on a silica gel column, eluting with CH2Cl2/methanol (95:5) to obtain the free base of the title compound (88 mg, 64%). 1H NMR (CDCl3) δ 8.44 (d, J=8.0 Hz, 1H), 7.81-7.86 (m, 1H), 7.73 (d, J=7.1 Hz, 1H), 3.50 (m, 1H), 3.00-3.18 (m, 2H), 2.18-2.46 (m, 7H), 1.92-2.01 (m, 2H), 1.52-1.71 (m, 3H), 1.05 (d, J=6.6 Hz, 6H); CIMS (Methane) m/z 304 [C17H25N3O2+H]+.
  • (ii) Dihydrochloride salt: Add 2.0M HCl in diethyl ether (0.36 mL, 0.73 mmol) to a solution of the free base (88 mg, 0.29 mmol) in diethyl ether (5 mL) and methanol (2 mL). After 2 hr., concentrate the reaction mixture in vacuo to obtain the title compound as a brown solid. Rf 0.58 (93:7:1 CHCl3/methanol/NH4OH); m.p. 93-95° C.; 1H NMR (CD3OD, complex mixture of rotamers) □ δ □8.35 (m, 1H), 7.95 (m, 1H), 7.77 (m, 1H), 4.06 and 4.25 (m, 1H), 3.43-3.52 and 3.61-3.65 (m, 2H), 3.18-3.28 (m, 2H), 2.81-2.94 (m, 3H), 2.21-2.37 (m, 5H), 1.90-2.02 (m, 2H), 1.03-1.05 (m, 6H); CIMS (Methane) m/z 304 [C17H25N3O2+H]+; HPLC 98.4%, Symmetry® series C18 column, Waters Corporation, Milford, Mass. (4.6×250 mm); anal. calculated for C17H25N3O2.1.9HCl.1.2H2O: C, 51.79; H, 7.49; N, 10.66; Cl, 17.08. found: C, 51.78; H, 7.64; N, 10.35; Cl, 17.07.
    • 15. 2,4,6-Trifluoro-N-methyl-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide hydrochloride salt (H19-A01377-159, LY 2004686)
  • Figure US20170044136A1-20170216-C00037
  • Dissolve 2,6-dibromopyridine (3.6 g, 15.3 mmol) in anhydrous dichloromethane (90 mL) under nitrogen atmosphere. Cool the reaction mixture to −78° C. Add a solution of n-butyl lithium in hexane very slowly via a syringe (1.6 M, 10.5 mL, 16.9 mmol). After the addition is complete, stir the reaction at −78° C. for 1 hr. Add a solution of 4-(methoxy-methyl-aminocarbonyl)-piperidine-1-carboxylic acid tert-butyl ester (2 g, 7.3 mmol) in anhydrous dichloromethane (10 mL) dropwise to the reaction mixture. Stir the reaction at −78° C. for 2 hrs., then allow it to slowly warm to room temperature overnight. Quench the reaction with 0.1 N aqueous NaOH. Dilute the solution with dichloromethane (100 mL), transfer into a separation funnel and shake with 0.1 N NaOH (60 mL). Separate the organic layer and dry it over anhydrous sodium sulfate. Evaporate the solvent under reduced pressure. Further purify the residue by chromatography on silica gel column (10%-30% ethyl acetate/hexane) to obtain 2-bromo-6-(1-t-butoxycarbonylpiperidin-4-ylcarbonyl)-pyridine (2.7 g, quantitative yield). Mass spectrum (ion spray): m/z 370 (M+1).
  • Heat a mixture of 2-bromo-6-(1-t-butoxycarbonylpiperidin-4-ylcarbonyl)-pyridine (152 mg, 0.41 mmol), N-methyl-2,4,6-trifluorobenzamide (92.6 mg, 0.49 mmol), Pd2(dba)3 (9.2 mg, 0.01 mmol), BINAP (12.4 mg, 0.02 mmol), sodium t-butoxide (55 mg, 0.57 mmol) in anhydrous toluene (10 mL) at 85° C. for 16 hrs. Cool the reaction to room temperature and add another aliquot of N-methyl-2,4,6-trifluorobenzamide, Pd2(dba)3, BINAP and sodium t-butoxide in the same amount. Re-heat the reaction at 85° C. for 16 more hours. Extract the reaction mixture with ethyl acetate and aqueous NaOH (0.1N). Collect and dry the organic layers. Concentrate and purify the crude product by chromatography (silica gel, 10%-30% ethyl acetate/hexane) to obtain 2,4,6-trifluoro-N-methyl-N-[6-(1-t-butoxycarbonyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide (86 mg, 44% yield).
  • Dissolve the 2,4,6-trifluoro-N-methyl-N-[6-(1-t-butoxycarbonyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide in 50% trifluoroacetic acid/CH2Cl2 (24 mL) and stir for 45 min. Remove volatiles under reduced pressure and extract with ethyl acetate and aqueous NaOH (2M). Combine the organic layers and dry with sodium sulfate. Concentrate and purify the residue by chromatography (silica gel/6% of (2M NH3 in methanol)/CH2Cl2) to afford 2,4,6-trifluoro-N-methyl-N-[6-(piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide (77 mg, 85% yield).
  • Dissolve the 2,4,6-trifluoro-N-methyl-N-[6-(piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide (77 mg, 0.20 mmol) in methanol (10 mL), add 37% aqueous formaldehyde (0.16 mL, 2.0 mmol), glacial acetic acid (0.34 mL, 6.0 mmol) and NaBH3CN (21.9 mg, 0.35 mmol). Stir the reaction mixture at room temperature. Extract the mixture with ethyl acetate and aqueous NaOH (2M) to obtain 2,4,6-trifluoro-N-methyl-N-[6-(a-hydroxy-(1-methylpiperidin-4-ylcarbonyl)-methyl)-pyridin-2-yl]-benzamide. Dissolve the 2,4,6-trifluoro-N-methyl-N-[6-(α-hydroxy-(1-methylpiperidin-4-ylcarbonyl)-methyl)-pyridin-2-yl]-benzamide in anhydrous CH2Cl2 (12 mL) and treat under N2 with Dess-Martin reagent (127 mg, 0.30 mmol) for 1 hr. Extract with ethyl acetate and 2M aqueous NaOH. Collect and dry the organic layers. Concentrate and purify the residue by chromatography (silica gel/6% of (2M NH3 in methanol)/CH2Cl2) to afford the free amine of the title compound (60.2 mg, 77% yield). Dissolve the free base in methanol (10 mL) and treat with ammonium chloride (0.032 g). Concentrate and dry under vacuum to obtain the title compound. LY 2004686 Mass spectrum (ion spray): m/z=392.0 (M+1); 1H NMR (methanol-d4): 7.85 (m, 2H), 7.50 (m, 1H), 6.80 (m, 2H), 3.75 (m, 1H), 3.52 (d, 2H), 3.47 (s, 3H), 3.20 (t, 2H), 2.94 (s, 3H), 2.03 (d, 2H), 1.83 (m, 2H).
    • 16. 2,4,6-Trifluoro-N-ethyl-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide hydrochloride salt (H19-A01377-163, LY 2020146)H19-A01377-163 (LY 2020146)
  • Figure US20170044136A1-20170216-C00038
  • Dissolve 2,6-dibromopyridine (5.5 g, 23.2 mmol) in anhydrous dichloromethane (140 mL) under a nitrogen atmosphere. Cool the reaction mixture to −78° C. Add a solution of n-butyl lithium in hexane (1.6 M, 15.8 mL, 25.3 mmol) very slowly via a syringe. After the addition is complete, stir the reaction at −78° C. for 1 hr. Add a solution of 1-methyl-N-methyl-N-methoxy-piperidine-4-carboxamide (2 g, 11 mmol) in anhydrous dichloromethane (10 mL) dropwise to the reaction mixture. Stir the reaction at −78° C. for 2 hrs, and then allow the mixture to slowly warm to room temperature overnight. Quench the reaction with 0.1 N NaOH. Dilute the solution with dichloromethane (100 mL), transfer into a separatory funnel and shake with 2 N NaOH (50 mL). Separate the organic layer, dry it over anhydrous sodium sulfate, and then evaporate the solvent under reduced pressure. Further purify the residue by chromatography on asilica gel column (6%, 2M NH3 in methanol/CH2Cl2) to obtain 2-bromo-6-(1-methylpiperidin-4-ylcarbonyl)-pyridine e (2.3 g, 74% yield). Mass spectrum (ion spray): m/z 283 (M+1).
  • Combine 2-bromo-6-(1-methylpiperidin-4-ylcarbonyl)-pyridin (189 mg, 0.67 mmol), N-ethyl-2,4,6-trifluorobenzamide (162 mg, 0.80 mmol), Pd2(dba)3 (14.6 mg, 0.016 mmol), BINAP (19.9 mg, 0.032 mmol), sodium t-butoxide (90.2 mg, 0.94 mmol) and anhydrous toluene (10 mL), and heat the mixture at 85° C. for 16 hr. under a nitrogen atmosphere. Cool the reaction to room temperature and add additional N-ethyl-2,4,6-trifluorobenzamide, Pd2(dba)3, BINAP, sodium t-butoxide in the same amounts. Re-heat the reaction at 85° C. for 16 more hours. Extract with ethyl acetate and aqueous NaOH (0.1N). Collect and dry the organic layers. Concentrate and purify the residue by chromatography (silica gel, 10%-30% ethyl acetate/hexanes) to obtain the free base of the title compound of LY 2020146 (100 mg, 37% yield). Dissolve the free base in methanol (10 mL) and treat with ammonium chloride (0.032 g). Concentrate and dry under vacuum to obtain the title compound. LY 2020146 Mass spectrum (ion spray): m/z=406.1 (M+1); 1H NMR (methanol-d4): 7.94 (m, 2H), 7.54 (m, 1H), 6.88 (m, 2H), 4.12 (q, 2H), 3.86 (m, 1H), 3.77 (d, 2H), 3.18 (t, 2H), 2.94 (s, 3H), 2.15 (d, 2H), 1.92 (m, 2H).
    • 17. 2,4,6-Trifluoro-N-[6-(piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide LY 636773 MN4-A01246-118-1
  • Figure US20170044136A1-20170216-C00039
  • Add 1-chloroethyl chloroformate (0.8 g) into a solution of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide (0.216 g) in dichloroethane (10 mL) and heat at reflux for 1 hr. Then add more 1-chloroethyl chloroformate (1 mL) and heat at reflux overnight. Add methanol (10 mL) to the reaction mixture, concentrate to a small volume, dilute with methanol again, load onto an SCX column (10 g), wash with methanol, and elute with 2M NH3-methanol, evaporate and purify on a silica gel column (CH2Cl2 with 2 M NH3 in methanol) to obtain the title compound (61 mg). Mass spectrum (electric spray) m/z=364 (M+1); 1H NMR (CDCl3): 8.55 (d, J=8.1 Hz, 1H), 7.92 (dd, J=8.0, 8.0 Hz 1H), 7.84(1H, J=8.0 Hz, 1H), 6.81 (m, 3H), 3.89 (m, 1H), 3.12 (br d, 2H), 2.81 (m, 2H), 1.85 (m, 2H), 1.74 (br, 2H), 1.61 (m, 2H). (file: mn4-a01246-118)
  • Add 0.17 mL of 1N HCl in ether into a solution of the free base in methylene chloride-methanol, evaporate the solvent and dry under vacuum to obtain the monohydrochloride salt. (LY 636774, MN4-A01246-118-2)
    • 18. 2,4,6-Trifluoro-N-[6-(1-ethylpiperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide LY 2030068 MN4-A01700-74-1 Bai-Ping Ying & Dan Kohlman
  • Figure US20170044136A1-20170216-C00040
  • Mix 2,4,6-trifluoro-N-[6-(piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide (26 mg), acetaldehyde (42 mg), sodium cyanoborohydride (10 mg) and trifluoroacetic acid (16.4 mg) in methanol (2 mL) in a sealed tube and heat in an oil bath at 90° C. overnight. Dilute with methanol and load on a SCX column (10 g), wash with methanol, elute the product with 2M NH3-methanol, evaporate, purify on a silica gel column (4 g, solvent: dichloromethane-2M NH3 in methanol, gradient) to obtain the title compound (8.4 mg). Mass spectrum (electrospray) m/z=392 (M+1); 1H NMR (CDCl3): 8.51 (d, 1H), 8.42 (br, 1H), 7.92 (t, 1H), 7.82 (dd, 1H), 6.84 (m, 2H), 3.63 (m, 1H), 3.02 (m, 2H), 2.44 (m, 2H), 2.04 (m, 2H), 1.87 (m, 4H), 1.60 (m, 5H), 1.11 (t, J=6.8 Hz, 3H). (file: mn4-a01700-74)
  • Dissolve the free base (8.4 mg) in dichloromethane-methanol and add 0.02 mL of 1N HCl in ether, evaporate and dry in vacuum to give the hydrochloride salt. LY 2030069 MN4-A01700-74-2
    • 19. 2,4,6-Trifluoro-N-[6-(1-propylpiperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide LY 2029650 MN4-A01700-72-1
  • Figure US20170044136A1-20170216-C00041
  • Mix 2,4,6-trifluoro-N-[6-(piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide (50 mg), propionaldehyde (80 mg), sodium triacetoxyborohydride (38 mg) and acetic acid (21 mg) with dichloromethane (5 mL) and stir for 1.5 hrs. Dilute with methanol and load on a SCX column (10 g), wash with methanol, elute the product with 2M NH3-methanol. Purify the product on a silica gel column (10 g, dichloromethane/2M NH3 in methanol, gradient) to obtain the title compound as a free base (26 mg). Mass spectrum (electrospray) m/z=406 (M+1); 1H NMR (CDCl3): 8.52 (d, 1H), 8.38 (br, 1H), 7.92 (t, 1H), 7.82 (dd, 1H), 6.82 (m, 2H), 3.61 (br, 1H), 3.00 (m, 2H), 2.34 (m, 2H), 2.11 (m, 2H), 1.87 (m, 3H), 1.60 (m, 5H), 0.90 (t, J=7.3 Hz, 3H). (file: mn4-a01700-72)
  • Dissolve the free base (26 mg) in dichloromethane-methanol and add 0.064 mL of 1N HCl in ether, evaporate and dry under vacuum to obtain the hydrochloride salt. LY 2029652 MN4-A01700-72-2
    • 20. 2,4,6-Trifluoro-N-[6-(1-cyclopropylmethyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide dihydrochloride salt LY2029823 GH8-A01546-104D (PX114282)
  • Figure US20170044136A1-20170216-C00042
  • Combine 2,4,6-trifluoro-N-[6-(piperidin-4-ylcarbonyl)pyridin-2-yl]benzamide (0.05 g, 0.138 mmol), cyclopropylmethanal (0.10 g, 1.38 mmol) and dichloromethane (5 mL), and stir at ambient temperature. After 15 minutes, add glacial acetic acid (0.02 mL, 0.35 mmol) followed by sodium-triacetoxyborohydride (0.038 g, 0.18 mmol) with stirring. After 3 hrs., dilute the reaction mixture with methanol (5 mL) and load on an SCX column (10 g). Wash the column with methanol, elute with 2M ammonia/methanol, and concentrate the eluent. Purify the residue by flash chromatography, eluting with 10% ammonia/methanol in dichloromethane, to obtain the free base of the title compound (0.045 g, 77%). Dissolve the free base in dichloromethane (5 mL), treat with 1M hydrogen chloride in diethylether (0.25 mL), and concentrate the mixture to obtain the dihydrochloride salt. M.p.=140° C.; HRMS: Obs. m/z 418.1743; Calc. m/z 418.1742; 1H NMR (CDCl3): 11.51 (bs, 1H), 10.34 (bs, 1H), 8.38 (m, 1H), 8.11 (m, 1H), 7.78 (d, 1H), 7.42 (m, 2H), 3.79 (m, 1H), 3.64 (m, 2H), 2.98 (m, 4H), 2.17 (m, 2H), 1.99 (m, 2H), 1.13 (m, 1H), 0.65 (m, 2H), 0.39 (m, 2H).
    • Preparations 3. N-Methylisonipecotic acid 4. 415028
  • Figure US20170044136A1-20170216-C00043
  • Load isonipicotic acid (028608, 1 kg, 7.74 mol), water (10 L), formaldehyde (37% solution in water, 720 g, 8.87 mol, 1.15 eq.) and wet Pd/C catalyst (10%; 55% paste, 100 g) into a stainless steel hydrogenation reactor. Pressurize the reactor with H2 (3 bar) and stir the reaction mixture overnight at 200-300 rpm at 16-25° C. Stop the reaction and filter off the catalyst. Wash the filtrate with water (500 ml) and concentrate under vacuum. Distill off the remaining water from the residue using ethanol (2×1 L). Dry the solid overnight under vacuum at 50° C. to obtain the title product as an off-white solid (1087 g, 98.1% yield).
    • 4. N-Methylisonipecotyl chloride hydrochloride(Notebook 0793, p 068)
  • Figure US20170044136A1-20170216-C00044
  • Suspend N-methylisonipicotic acid (415028, 365 g, 2.55 mol) in CH2Cl2 (3500 ml) and add a catalytic quantity of DMF (2 ml). Add oxalyl chloride (435 g, 3.42 mol, 1.35 eq.) to the reaction mixture maintaining the temperature at 20° C. Heat the suspension under reflux for 2 hrs. Cool the reaction mixture and concentrate on a rotary evaporator. Resuspend the residue in toluene (1000 ml), evaporate and dry under vacuum to yield the title product (489 g, 96%) as an off-white solid residue, which is used without further purification in the next reaction step.
    • 5. N,N′-Dimethyl-N-methylisonipecotamide
  • Figure US20170044136A1-20170216-C00045
  • Resuspend N-methylisonipecotyl chloride hydrochloride (489 g, 2.54 mol) in anhydrous THF (5000 mL) and cool the suspension to 0-5° C. Add a solution of dimethylamine in THF (2M, 2500 ml, 2 eq.) and triethylamine (775 g, 3 eq.) dropwise to the reaction mixture maintaining the temperature below 7° C. Stir the suspension for 3 hrs. at this temperature and then allow the reaction mixture to warm to 20° C. overnight. Then cool the reaction mixture to 5° C. and 30% NaOH (600 mL) and add CH2Cl2 (2 L). Separate the organic layer from the sticky solid that is formed and redissolve the solid in water (2 L). Extract the solution with CH2Cl2 (2 L). Combine the organic fractions, concentrate to about 3500 mL, and wash twice with water (500 mL). Dry the organic layer with Na2SO4, filter, and concentrate to dryness. Dry the red oil under vacuum at room temperature to produce the title product (378.7 g, 90% yield). Treat with ether and evaporate to dryness to obtain the product as a solid.
    • 6. 2-Bromo-6-(1-methylpiperid-4-ylcarbonyl)-pyridine (Notebook 0793, p 173)
  • Figure US20170044136A1-20170216-C00046
  • Cool methyl-ten-butyl ether (MTBE) (50 mL) (Tmass=−75° C.) under a nitrogen atmosphere, and add n-butyl litium (2.5M in n-hexane, 35 mL, 0.875 mol) to give a white suspension. Add 2,6-Dibromopyridine (20.9 g, 0.088 mol) in MTBE (210 mL) dropwise to the suspension at a rate that maintains the Tmass under −65° C. (40 min). Stir the resulting yellow heterogeneous solution at −70° C. for 20 min. to produce a green homogeneous solution. Then add N′,N-dimethyl-N-methylisonipecotamide (10 g, 0.0587 mol) in MTBE (100 mL) dropwise at a rate that maintains the Tmass under −65° C. (20 min). After the addition is completed, agitate the mixture at −75° C. for 1 hour. Quench the reaction mixture with saturated ammonium chloride (30 mL) at 0-10° C. Neutralize the reaction mixture (pH=7) with 37% HCl (15 mL) and add additional water (50 mL). Decant the aqueous phase and extract with CH2Cl2 (3×500 mL). Combine the organic layers and wash with acidic water (pH=2) (3×500 mL). Then basify the aqueous phase with 30% NaOH (pH=12) and extract the mixture with ethyl acetate (2×500 mL). Combine the organic layers, dry with MgSO4, concentrate under reduced pressure, and then vacuum dry at room temperature to provide the title product as an oil (16 g, 96% yield). Mass spectrum (electrospray) m/z=283-285 (M+1); 1H NMR: (400 MHz, CHLOROFORM-D) ppm 1.76 (m, 2H) 1.91 (m, 2H) 2.14 (m, 2H) 2.30 (s, 3H) 2.90 (d, J=11.85 Hz, 2H) 3.71 (m, 1H) 7.62 (d, J=7.54 Hz, 1H) 7.67 (t, J=7.54 Hz, 1H) 7.95 (d, J=7.54 Hz, 1H); 13C-NMR: (100.61 MHz, Chloroform-D) ppm 28.08; 41.68; 46.36; 55.08; 121.26; 131.61; 139.25; 141.24; 153.59; 202.23.
    • 7. 2-Amino-(6-(1-methylpiperidin-4-ylcarbonyl)-pyridine (Notebook 0910, p 030)
  • Figure US20170044136A1-20170216-C00047
  • Load 2-bromo-6-(1-methylpiperidin-4-ylcarbonyl)-piperidine (20 g, 70.67 mmol, 1 eq) in 73.6 ml of 7M NH3/ethylene glycol (530 mmol, 7.5 eq) into a 130 ml pressure autoclave, and add Cu2O (101 mg, 0.706 mmol, 0.01 eq) as a catalyst. Seal the autoclave and heat the reaction mixture to 85° C. at about 50 psi (345 kPa) for 20 hrs. Cool the reaction mixture to room temperature, transfer the organic layer to a 250 ml flask, and place the flask under reduce pressure to remove ammonia. Add water (70 mL) and of 30% NaOH (38 mL) and then extract the mixture with methyl t-butyl ether (MTBE)(5×100 ml). Combine the organic fractions and then dry with MgSO4, filter, and concentrate under reduce pressure to obtain crude 2-amino-(6-(1-methylpiperidin-4-ylcarbonyl)-pyridine (18.5 g). Purification of 2-amino(6-pyridyl)-1-methyl(4-piperidyl)-ketone (Notebook 0910, p 036)
  • Resuspend the crude 2-amino-(6-(1-methylpiperidin-4-ylcarbonyl)-pyridine (14.5 g, 66.2 mmol) in ethanol (30 mL), add 2.5M HCl/ethanol (100 mL), stir the mixture for 30 minutes, and then remove the solvent under reduce pressure. Resuspend the resulting solid in 125 ml isopropanol and heat under reflux for 30 minutes. Cool the reaction mixture to room temperature, filtered-off the precipitate, rinse with 20 ml isopropanol, and dry under vacuum at 50° C. to obtain 2-amino-(6-(1-methylpiperidin-4-ylcarbonyl)-pyridine 2HCl (11 g, 63% yield corrected by HPLC % w/w).
    • Neutralization of 647714 2HCl (Notebook 0910, p 164)
  • Resuspend the 2-amino-(6-(1-methylpiperidin-4-ylcarbonyl)-pyridine 2HCl (129.5 g) in ethyl acetate (100 mL) and add 10M NaOH (50 mL) and water (50 mL) to neutralize the suspension. Separate the organic layer and extract the aqueous phase with ethyl acetate (2×150 mL). Combine the organic layers, dry with MgSO4, filter, and concentrate under reduce pressure to obtain the title product (21 g).
    • EXAMPLES 21. 2,4,6-Trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide (Notebook 0910, p 066)
  • Figure US20170044136A1-20170216-C00048
  • Add triethylamine (10.67 mL, 76.70 mmol, 2.4 eq) to a solution of 2-amino-(6-(1-methylpiperidin-4-ylcarbonyl)-pyridine (7 g, 31.96 mmol, 1 eq) in anhydrous THF (100 mL) under a nitrogen atmosphere. Add 2,4,6-triflubenzoylchloride (7.46 g, 5 mL, 38.35 mmol, 1.20 eq) dropwise at room temperature. After 2 hrs., add additional 2,4,6-triflubenzoylchloride (0.75 mL, 0.15 eq) and triethylamine (1.32 mL, 0.3 eq) to the reaction mixture and agitate the mixture for an additional 3 hrs. Quench the reaction with distilled water (10 mL) and 30% NaOH (15 mL). Stir the resulting biphasic system for 1 hour and then separate the phases. Extract the organic fraction by adding H2O (75 mL) and acetic acid (12 mL), followed by cyclohexane (70 mL). Wash the organic fraction with H2O (50 mL) containing acetic acid (1 mL). Combine all the aqueous fractions and washes and neutralize the mixture with 30% NaOH (15 mL). Extract with methyl-tert-butyl ether (MTBE) (3×50 mL). Combine the organic fractions and dry with MgSO4, filter, concentrate under reduce pressure, and vacuum dry at room temperature, to obtain the title compound as a light-brown solid (11.031 g, 91% yield). Mass spectrum (Electrospray) m/z=378 (M+1); 1H NMR (250 MHz, Chloroform-D) ppm 1.54 (m, 2H) 2.02 (m, 2H) 2.13 (t, J=11.48 Hz, 2H) 2.29 (s, 3H) 2.80 (m, J=11.96 Hz, 1H) 3.56 (m, 1H) 4.26 (d, J=7.87 Hz, 1H) 6.17 (d, J=8.50 Hz, 1H) 6.75 (m, 2H) 7.45 (t, J=7.87 Hz, 1H) 7.53 (m, 1H) 7.95 (s, 1H); 13C-NMR: (62.90 MHz, Chloroform-D) ppm 202.78; 162.6 (dm C-F-couplings); 162.0 (m C-F-couplings); 160.1 (m C-F-couplings); 158.1; 150.0; 139.7; 119.3; 117.9; 110.2 (m C-F-couplings); 100.9 (m C-F-couplings); 55.2; 46.5; 41.9; 28.1
    • 22. 2,4,6-Trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide mono-hydrochloride salt (587815) (Notebook 0910, p 131)
  • Figure US20170044136A1-20170216-C00049
  • Dissolve 2,4,6-trifluoro-N-[6-(1-methylpiperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide-free base (5 g, 23.26 mmol) in isopropanol (50 mL) at room temperature and add a solution of 3.3 M diethylether/HCl (8 mL). Heat the reaction mixture under reflux for 30 minutes. Cool the reaction mixture to room temperature and agitate for 2 hrs. Filter the resulting white precipitate and rinse with isopropanol (5 mL). Dry the residual solid under reduce pressure at 40° C. overnight to obtain the title compound (5.12 g, 93% yield). M.p. 223-224° C. (sublimation); 1H NMR (400 MHz, d6-DMSO) d ppm 1.94 (m, 2H) 2.14 (m, J=11.15 Hz, 2H) 2.74 (s, 3H) 2.99 (m, J=9.19 Hz, 2H) 3.49 (m, J=11.15 Hz, 2H) 3.77 (m, 1H) 7.41 (t, J=8.71 Hz, 2H) 7.78 (d, J=7.43 Hz, 1H) 8.10 (t, J=7.92 Hz, 1H) 8.37 (d, J=6.85 Hz, 1H) 10.50 (s, 1H) 11.51 (s, 1H); 13C-NMR: (100.61 MHz, Chloroform-D) ppm 200.7; 130.6-158.0 (m, C-F-couplings); 150.4; 150.1; 140.2; 118.5; 118.2; 111.9; 101.3 (t, C-F couplings); 52.8; 42.6; 25.2
    • 23. 2,4,6-Trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemi-succinate salt 683974 (Notebook 0910, p 134)
  • Figure US20170044136A1-20170216-C00050
  • Add succinic acid (0.25 g, 2.148 mmol, 0.5 eq) to a solution of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide-free base (1.62 g, 4.297 mmol, 1 eq) in acetone (16.2 mL), at room temperature. Warm the solution under reflux for 30 minutes. Cool the solution to room temperature and filter off the resulting white precipitate. Rinse the precipitate with acetone (0.2 mL) and dry under vacuum at 50° C. for 16 hours to provide the title compound (1.5 g, 80% yield). M.p. 198.5° C.; mass spectrum (Electrospray) m/z=495.45 mass spec. presumed from data in C.S.document, pg 19.
  • The following examples are prepared by combinatorial chemistry techniques as follows:
    • Examples 24-54
  • Figure US20170044136A1-20170216-C00051
  • Combine R-acid (300 μL of 0.5M solution in dimethylformamide (DMF)), HATU (57 mg, 0.15 mmol), collidine (19 μL, 0.15 mmol), 2-amino-(6-(1-methylpiperidin-4-ylcarbonyl)-pyridine and DMF (1.5 mL), and agitate for 48 hr. Dilute the reaction mixture with 10% acetic acid in methanol (0.5 mL). Load the resulting reaction mixture onto a 2 g SCX column Wash the column thoroughly with methanol and then elute with 1 M ammonia in methanol. Concentrate the eluent and further purify the product by high-throughput mass guided chromatography. This procedure is repeated in parallel for examples 24-54.
    • Examples 55-58
  • Figure US20170044136A1-20170216-C00052
  • Heat R-acid chloride (300 μL of 0.5M solution in pyridine) to 55° C., add 2-amino-(6-(1-methylpiperidin-4-ylcarbonyl)-pyridine (200 μL of 0.5M solution in pyridine), and continue heating the reaction mixture for 24 hr. Concentrate the reaction mixture and then dilute with 10% Acetic acid in methanol (0.5 mL) and methanol (0.5 mL). Load the resulting reaction mixture directly onto a 2 g SCX column Thoroughly wash the column with methanol and then elute the column with 1 M ammonia in methanol. Concentrate the eluent and then further purify the product by high-throughput mass guided chromatography. This procedure is repeated in parallel for examples 55-58.
    • Examples 59-71
  • Figure US20170044136A1-20170216-C00053
  • Heat 2-amino-(6-(1-methylpiperidin-4-ylcarbonyl)-pyridine (200 μL of 0.5M solution in pyridine) to 55° C. then add R-acid chloride (0.10 mmol), heat for 2 hr. Concentrate the reaction mixture and then dilute with 10% Acetic acid in methanol (0.5 mL) and methanol (0.5 mL). Load the resulting reaction mixture directly onto a 2 g SCX column Thoroughly wash the column with methanol and then elute the column with 1 M ammonia in methanol. Concentrate the eluent and then further purify the product by high-throughput mass guided chromatography. This procedure is repeated in parallel for examples 59-71.
  • Recombinant chemistry compounds are characterized by liquid chromatography/mass spectroscopy on a Shimadzu QP8000™. Examples 24-45 and 55-58 are run with a Metachem™ C18 column (monochrom 3 micron, 2.5×25 cm) using a 10-90% solvent B gradient in 4.5 min., where solvent A is 0.1% trifluoroacetic acid in water and solvent B is 0.1% trifluoroacetic acid in acetonitrile. Examples 46-54 and 59-71 are run with a Metachem™ C18 column (monochrom 5 micron, 4.6×50 cm) using a 10-80% solvent B gradient in 9 min, where solvent A is 0.1% trifluoroacetic acid in water and solvent B is 0.08% trifluoroacetic acid in acetonitrile.
  •
    24 N-[6-(1-Methyl- piperidin-4- ylcarbonyl)-pyridin-2- yl]-thiophene-2- amide
    Figure US20170044136A1-20170216-C00054
         		LCMS Rf 2.871 min at 254 nm, 2.871 min at 190 nm, m/e 330 (M + 1).
    25 N-[6-(1-Methyl- piperidin-4- ylcarbonyl)-pyridin-2- yl]-furan-2-amide
    Figure US20170044136A1-20170216-C00055
         		LCMS Rf 2.454 min at 254 nm, 2.454 min at 190 nm, m/e 314 (M + 1).
    26 2-Chloro-N-[6-(1- methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00056
         		LCMS Rf 3.080 min at 254 nm, 3.080 min at 190 nm, m/e 358 (M + 1).
    27 N-[6-(1-Methyl- piperidin-4- ylcarbonyl)-pyridin-2- yl]-furan-3-amide
    Figure US20170044136A1-20170216-C00057
         		LCMS Rf 2.448 min at 254 nm, 2.448 min at 190 nm, m/e 314 (M + 1).
    28 3,4-Difluoro-N-[6-(1- methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00058
         		LCMS Rf 4.47 min at 254 nm, m/e 360 (M + 1).
    29 N-[6-(1-Methyl- piperidin-4- ylcarbonyl)-pyridin-2- yl]-isonicotinamide
    Figure US20170044136A1-20170216-C00059
         		LCMS Rf 2.890 min at 254 nm, 2.890 min at 190 nm, m/e 325 (M + 1).
    30 2-Methyl-N-[6-(1- methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00060
         		LCMS Rf 3.092 min at 254 nm, 3.092 min at 190 nm, m/e 338 (M + 1).
    31 2-Bromo-N-[6-(1- methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00061
         		LCMS Rf 3.132 min at 254 nm, 3.132 min at 190 nm, m/e 402 (M + 1).
    32 2-trifluoromethoxy-N- [6-(1-methyl- piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00062
         		LCMS Rf 2.771 min at 254 nm, 2.771 min at 190 nm, m/e 330 (M + 1).
    33 2-Fluoro-N-[6-(1- methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-isonicotinamide
    Figure US20170044136A1-20170216-C00063
         		LCMS Rf 2.669 min at 254 nm, 2.669 min at 190 nm, m/e 343 (M + 1).
    34 4-Chloro-2-methoxy- N-[6-(1-methyl- piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00064
         		LCMS Rf 3.665 min at 254 nm, 3.664 min at 190 nm, m/e 387 (M + 1).
    35 2-Ethoxy-N-[6-(1- methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00065
         		LCMS Rf 3.519 min at 254 nm, 3.520 min at 190 nm, m/e 367 (M + 1).
    36 2-Phenoxy-N-[6-(1- methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00066
         		LCMS Rf 3.841 min at 254 nm, 3.838 min at 190 nm, m/e 415 (M + 1).
    37 2-Methoxy-5-chloro- N-[6-(1-methyl- piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00067
         		LCMS Rf 3.661 min at 254 nm, 3.666 min at 190 nm, m/e 387 (M + 1).
    38 2-Methoxy-4- methylsulfanyl-N-[6- (1-methylpiperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00068
         		LCMS Rf 3.683 min at 254 nm, 3.692 min at 190 nm, m/e 399 (M + 1).
    39 N-[6-(1-Methyl- piperidin-4- ylcarbonyl)-pyridin-2- yl]-2,3- Dihydrobenzofuran-7- amide
    Figure US20170044136A1-20170216-C00069
         		LCMS Rf 3.381 min at 254 nm, 3.381 min at 190 nm, m/e 365 (M + 1).
    40 2-Benzyloxy-N-[6-(1- methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00070
         		LCMS Rf 4.086 min at 254 nm, 4.089 min at 190 nm, m/e 429 (M + 1).
    41 2-Propoxy-N-[6-(1- methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00071
         		LCMS Rf 3.811 min at 254 nm, 3.813 min at 190 nm, m/e 381 (M + 1).
    42 2,2-Difluoro-N-[6-(1- methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]- benzo[1,3]dioxole-4- amide
    Figure US20170044136A1-20170216-C00072
         		LCMS Rf 3.531 min at 254 nm, 3.534 min at 190 nm, m/e 403 (M + 1).
    43 2-(2-Methoxy- ethoxy)-4-methoxy-N- [6-(1-methyl- piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00073
         		LCMS Rf 3.552 min at 254 nm, 3.556 min at 190 nm, m/e 427 (M + 1).
    44 2-Methoxy-5-bromo- N-[6-(1-methyl- piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00074
         		LCMS Rf 3.742 min at 254 nm, 3.742 min at 190 nm, m/e 432 (M + 1).
    45 2-(4,6-Dimethoxy- pyrimidin-2-yloxy)-N- [6-(1-methyl- piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00075
         		LCMS Rf 3.428 min at 254 nm, 3.425 min at 190 nm, m/e 477 (M + 1).
    46 2-Ethoxy-N-[6-(1- methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-nicotinamide
    Figure US20170044136A1-20170216-C00076
         		LCMS Rf 1.56 min at 254 nm, m/e 368 (M + 1).
    47 2-Phenoxy-N-[6-(1- methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-nicotinamide
    Figure US20170044136A1-20170216-C00077
         		LCMS Rf 1.61 min at 254 nm, m/e 416 (M + 1).
    48 3-Acetyl-N-[6-(1- methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-thiazolidine-4- amide
    Figure US20170044136A1-20170216-C00078
         		LCMS Rf 1.23 min at 254 nm, m/e 376 (M + 1).
    49 2-Phenylsulfanyl-N- [6-(1-methyl- piperidin-4- ylcarbonyl)-pyridin-2- yl]-nicotinamide
    Figure US20170044136A1-20170216-C00079
         		LCMS Rf 1.59 min at 254 nm, m/e 432 (M + 1).
    50 2-(2,2,2- Trifluoroethoxy)-5- methoxy-N-[6-(1- methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00080
         		LCMS Rf 1.69 min at 254 nm, m/e 451 (M + 1).
    51 2-Methoxy-6-methyl- N-[6-(1-methyl- piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00081
         		LCMS Rf 1.50 min at 254 nm, m/e 367 (M + 1).
    52 4-Methoxycarbonyl- N-[6-(1-methyl- piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00082
         		LCMS Rf 1.53 min at 254 nm, m/e 381 (M + 1).
    53 N-[6-(1-Methyl- piperidin-4- ylcarbonyl)-pyridin-2- yl]- Cyclobutylformamide
    Figure US20170044136A1-20170216-C00083
         		LCMS Rf 1.31 min at 254 nm, m/e 301 (M + 1).
    54 2-(2-Chloro-1,1,2- trifluoroethoxy)-N-[6- (1-methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00084
         		LCMS Rf 1.64 min at 254 nm, m/e 455 (M + 1).
    55 N-[6-(1-Methyl- piperidin-4- ylcarbonyl)-pyridin-2- yl]-butanamide
    Figure US20170044136A1-20170216-C00085
         		LCMS Rf 2.23 min at 254 nm, m/e 290 (M + 1).
    56 N-[6-(1-methyl- piperidin-4- ylcarbonyl)-pyridin-2- yl]- cyclohexylformamide
    Figure US20170044136A1-20170216-C00086
         		LCMS Rf 4.23 min at 254 nm, m/e 330 (M + 1).
    57 N-[6-(1-Methyl- piperidin-4- ylcarbonyl)-pyridin-2- yl]-3-phenyl- propanamide
    Figure US20170044136A1-20170216-C00087
         		LCMS Rf 4.86 min at 254 nm, m/e 352 (M + 1).
    58 2,6-Difluoro-N-[6-(1- methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00088
         		LCMS Rf 4.05 min 254 nm, m/e 360 (M + 1).
    59 2-Chloro-N-[6-(1- methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00089
         		LCMS Rf 1.47 min at 254 nm, m/e 357 (M + 1).
    60 2,5-Difluoro-N-[6-(1- methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00090
         		LCMS Rf 1.52 min at 254 nm, m/e 359 (M + 1).
    61 3,4-Difluoro-N-[6-(1- methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00091
         		LCMS Rf 1.54 min at 254 nm, m/e 359 (M + 1).
    62 2-Trifluoromethyl-4- fluoro-N-[6-(1- methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00092
         		LCMS Rf 1.57 min at 254 nm, m/e 409 (M + 1).
    63 2-Fluoro-6- trifluoromethyl-N-[6- (1-methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00093
         		LCMS Rf 1.60 min at 254 nm, m/e 409 (M + 1).
    64 2,3,4-Trifluoro-N-[6- (1-methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00094
         		LCMS Rf 1.57 min at 254 nm, m/e 377 (M + 1).
    65 2,4,5-Trifluoro-N-[6- (1-methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00095
         		LCMS Rf 1.56 min at 254 nm, m/e 377 (M + 1).
    67 3-Chloro-N-[6-(1- methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-thiophene-2- amide
    Figure US20170044136A1-20170216-C00096
         		LCMS Rf 1.67 min at 254 nm, m/e 363 (M + 1).
    68 2,6-Dichloro-N-[6-(1- methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00097
         		LCMS Rf 1.57 min at 254 nm, m/e 391 (M + 1).
    69 2-Fluoro-4- trifluoromethyl-N-[6- (1-methyl-piperidin-4- ylcarbonyl)-pyridin-2- yl]-benzamide
    Figure US20170044136A1-20170216-C00098
         		LCMS Rf 1.67 min at 254 nm, m/e 409 (M + 1).
    70 N-[6-(1-methyl- piperidin-4- ylcarbonyl)-pyridin-2- yl]- Cyclopentylformamide
    Figure US20170044136A1-20170216-C00099
         		LCMS Rf 3.06 min at 254 nm, m/e 315 (M + 1).
    71 N-[6-(1-Methyl- piperidin-4- ylcarbonyl)-pyridin-2- yl]-nicotinamide
    Figure US20170044136A1-20170216-C00100
         		LCMS Rf 2.5 min at 254 nm, m/e 324 (M + 1).
    • Preparations
  • Figure US20170044136A1-20170216-C00101
    • 7. 1-Methyl-4-(pyrrolidin-1-yl-carbonyl)-piperidine
  • Add oxalyl chloride (5.08 mL, 0.058 mol) dropwise to a suspension of 1-methyl-4-carboxypiperidine HCl (10 g, 0.056 mol) in THF (100 mL) in the presence of a catalytic amount of DMF (0.1 mL) at room temperature. Stir for 1 hr. and then heat the mixture at reflux until gas emission stops (about 1 hr.). Cool the white suspension to 5° C. and add a solution of pyrrolidine (7.92 g, 0.111 mol) and triethylamine (16.9 g, 0.167 mol) dropwise over 30 min at a temperature between 5 and 13° C. Stir the suspension for 30 min. at 10° C. and then warm to room temperature. Quench the reaction mixture by adding 30% NaOH (20 mL, 0.2 mol) and water (10 mL). Decant the aqueous layer and extract with THF (200 mL). Combine the organic layers, dry over Na2CO3, and evaporate under vacuum at 40° C. Solubilize the resulting oil in cyclohexane (200 mL). Evaporate under reduced pressure at 40° C. to give a white solid (11 g). Heat the white solid (11 g) under reflux in cyclohexane (50 mL) until completely dissolved. Cool the solution to room temperature and stir at room temperature for 2 hr. Filter the suspension wash the crystals with cyclohexane (10 mL). Dry the white crystals under reduced pressure at 40° C. to provide the title intermediate (7.76 g, 75% yield).
    • 8. 2-Bromo-6-(1-methylpiperidin-4-ylcarbonyl)-pyridine
  • Add a solution of n-butyllithium (1.9M in n-hexane, 4 ml, 7.6 mmol) to a solution of 2,6-dibromopyridine (1.81 g, 7.64 mmol) in MTBE (20 mL) dropwise under nitrogen, over 20 min., maintaining the temperature between −72 and −67° C. Stir the yellow heterogeneous solution at −70° C. for 20 min. to provide a green homogeneous solution. Add a solution of 1-methyl-4-(pyrrolidin-1-yl-carbonyl)piperidine (1 g, 5.09 mmol) in 10 mL MTBE dropwise over 20 min., maintaining the temperature below −69° C. Stir the yellow mixture at −75° C. for 1 hr. Quench the reaction mixture with a saturated solution of ammonium chloride (5 mL) between 0 and 10° C. Acidify the mixture to pH 2 with fuming HCl (2 mL). Extract the organic layer. Wash the aqueous phase with MTBE (50 mL), make the aqueous layer basic with a solution of 30% NaOH, and extract with ethyl acetate (2×50 mL). Combine the organic layers, dry over MgSO4, and concentrate under reduced pressure at 40° C. to provide the title intermediate as an oil (1.23 g, 85% yield).
  • The compounds of this invention are useful for increasing activation of the 5-HT1F receptor. An increase in the activation of the 5-HT1F is useful for treating a variety of disorders which have been linked to decreased neurotransmission of serotonin in mammals, e.g., migraine headaches. See U.S. Pat. No. 5,708,008 demonstrating the nexus between activation of the 5-HT1F receptor and migraine. To demonstrate the use of the compounds of the present invention in the treatment of migraine, their ability to bind to the 5-HT1F receptor subtype was determined. The ability of the compounds of this invention to bind to the 5-HT1F receptor subtype was measured essentially as described in N. Adham, et al., Proceedings of the National 15 Academy of Sciences (USA), 90:408-412, 1993.
    • Membrane Preparation:
  • Membranes were prepared from transfected Ltk-cells (transfected with the human 5-HT1F receptor sequence) which were grown to 100% confluency. The cells were washed twice with phosphate-buffered saline, scraped from the culture dishes into 5 mL of ice-cold phosphate-buffered saline, and centrifuged at 200×g for 5 minutes at 4° C. The pellet was resuspended in 2.5 mL of ice-cold Tris buffer (20 mM Tris HCl, pH 7.4 at 23° C., 5 mM EDTA) and homogenized with a Wheaton tissue grinder. The lysate was subsequently centrifuged at 200×g for 5 minutes at 4° C. to pellet large fragments which were discarded. The supernatant was collected and centrifuged at 40,000×g for 20 minutes at 4° C. The resulting pellet was washed once in ice-cold Tris wash buffer and resuspended in a final buffer containing 50 mM Tris HCl and 0.5 mM EDTA, pH 7.4 at 23° C. Membrane preparations were kept on ice and utilized within two hours for the radioligand binding assays. Protein concentrations were determined by the method of Bradford. Anal. Biochem., 72:248-254, 1976.
    • Radioligand Binding:
  • [3H] 5-HT binding was performed using slight modifications of the 5-HT1D assay conditions reported by Herrick-Davis and Titeler (J. Neurochem., 50:1624-1631, 1988) with the omission of masking ligands. Radioligand binding studies were achieved at 37° C. in a total volume of 250 μL of buffer (50 mM Tris, 10 mM MgCl2, 0.2 mM EDTA, 10 μM pargyline, 0.1% ascorbate, pH 7.4 at 37° C.) in 96 well microtiter plates. Saturation studies were conducted using [3H] 5-HT at 12 different concentrations ranging from 0.5 nM to 100 nM. Displacement studies were performed using 4.5-5.5 nM [3H] 5-HT. The binding profile of drugs in competition experiments was accomplished using 6-12 concentrations of compound. Incubation times were 30 minutes for both saturation and displacement studies based upon initial investigations which determined equilibrium binding conditions. Nonspecific binding was defined in the presence of 10 μM 5-HT. Binding was initiated by the addition of 50 μL membrane homogenates (10-20 μg). The reaction was terminated by rapid filtration through presoaked (0.5% poylethyleneimine) filters using 48R Brandel Cell Harvester (Gaithersburg, Md.). Subsequently, filters were washed for 5 seconds with ice cold buffer (50 mM Tris HCl, pH=7.4 at 4° C.), dried and placed into vials containing 2.5 mL Readi-Safe (Beckman, Fullerton, Calif.) and radioactivity was measured using a Beckman LS 5000TA liquid scintillation counter. The efficiency of counting of [3H] 5-HT averaged between 45-50%. Binding data was analyzed by computer-assisted nonlinear regression analysis (Accufit and Accucomp, Lunden Software, Chagrin Falls, Ohio). IC50 values were converted to Ki values using the Cheng-Prusoff equation. Biochem. Pharmacol., 22:3099-3108 (1973). All experiments were performed in triplicate. Representative compounds of the present invention were found to have high affinity for the 5-HT1F receptor as measured by the procedure described above, as for example Ki's of less than or equal to 300 nM. Preferred compounds of the present invention have Ki's of less than or equal to 100 nM. A yet more preferred embodiment provides compounds having a Ki of less than or equal to 50 nM.
    • Selectivity for the 5-HT1F Receptor
  • Compounds of the prevent invention are relatively selective for the 5-HT1F receptor, particularly in comparison to other 5-HT receptor subtypes, specifically other receptors in the 5-HT1 subclass, as for example, but without limitation, the 5-HT1A, 5-HT1B, 5-HT1D, and 5-HT1E receptor subtypes. Affinity for these other receptor subtypes can readily be determined by slight modification of the above described radioligand receptor binding assays using cells transfected with the desired receptor subtype in place of cells transfected with the 5-HT1F receptor subtype. The binding affinities of representative compounds of the present invention were determined by such assays and were found to be selective for the 5-HT1F receptor; that is the affinities of the compounds for the 5-HT1F receptor were on the whole, higher than for other receptor subtypes, particular for the 5-HT1B and 5-HT1D receptor subtypes.
  • Measurement of cAMP Formation
  • As was reported by R. L. Weinshank, et al., WO93/14201, the 5-HT1F receptor is functionally coupled to a G-protein as measured by the ability of serotonin and serotonergic drugs to inhibit forskolin stimulated cAMP production in NIH3T3 cells transfected with the 5-HT1F receptor. Adenylate cyclase activity was determined using standard techniques. A maximal effect is achieved by serotonin. An Emax is determined by dividing the inhibition of a test compound by the maximal effect and determining a percent inhibition. N. Adham, et al., supra; R. L. Weinshank, et al., Proceedings of the National Academy of Sciences (USA), 89:3630-3634, 1992; and the references cited therein.
  • Human 5-HT1F receptor transfected NIH3T3 cells (estimated Bmax from one point competition studies=488 fmol/mg of protein) were incubated in DMEM, 5 mM theophylline, 10 mM HEPES (4-[2-hydroxyethyl]-1-piperazineethanesulfonic acid) and 10 μM pargyline for 20 minutes at 37° C., 5% CO2. Drug dose-effect curves were then conducted by adding 6 different final concentrations of drug, followed immediately by the addition of forskolin (10 μM). Subsequently, the cells were incubated for an additional 10 minutes at 37° C., 5% CO2. The medium was aspirated and the reaction was stopped by the addition of 100 mM HCl. To demonstrate competitive antagonism, a dose-response curve for 5-HT was measured in parallel, using a fixed dose of methiothepin (0.32 μM). The plates were stored at 4° C. for 15 minutes and then centrifuged for 5 minutes at 500×g to pellet cellular debris, and the supernatant was aliquoted and stored at −20° C. before assessment of cAMP formation by radioimmunoassay (cAMP radioimmunoassay kit; Advanced Magnetics, Cambridge, Mass.). Radioactivity was quantified using a Packard COBRA Auto Gamma counter, equipped with data reduction software. Representative compounds of the present invention were tested and found to be agonists of the 5-HT1F receptor in the cAMP assay described above.
    • Protein Extravasation Assay
  • The following test was performed to determine the ability of compounds of the present invention to inhibit protein extravasation, which test is also a functional assay for the neuronal mechanism of migraine.
  • Harlan Sprague-Dawley rats (225-325 g) or guinea pigs from Charles River Laboratories (225-325 g) were anesthetized with sodium pentobarbital intraperitoneally (65 mg/kg or 45 mg/kg respectively) and placed in a stereotaxic frame (David Kopf Instruments) with the incisor bar set at −3.5 mm for rats or -4.0 mm for guinea pigs. Following a midline sagital scalp incision, two pairs of bilateral holes were drilled through the skull (6 mm posterially, 2.0 and 4.0 mm laterally in rats; 4 mm posteriorly and 3.2 and 5.2 mm laterally in guinea pigs, all coordinates referenced to bregma). Pairs of stainless steel stimulating electrodes, insulated except at the ends (Rhodes Medical Systems, Inc.), were lowered through the holes in both hemispheres to a depth of 9 mm (rats) or 10.5 mm (guinea pigs) from dura.
  • The femoral vein was exposed and a dose of the test compound was injected intravenously (1 mL/kg). Approximately 7 minutes later, a 50 mg/kg dose of Evans Blue, a fluorescent dye, was also injected intravenously. The Evans Blue complexed with proteins in the blood and functioned as a marker for protein extravasation. Exactly 10 minutes post-injection of the test compound, the left trigeminal ganglion was stimulated for 3 minutes at a current intensity of 1.0 mA (5 Hz, 4 msec duration) with a Model 273 potentiostat/galvanostat (EG&G Princeton Applied Research).
  • Fifteen minutes following stimulation, the animals were killed and exsanguinated with 20 mL of saline. The top of the skull was removed to facilitate the collection of the dural membranes. The membrane samples were removed from both hemispheres, rinsed with water, and spread flat on microscopic slides. Once dried, the tissues were coverslipped with a 70% glycerol/water solution.
  • A fluorescence microscope (Zeiss) equipped with a grating monchromator and a spectrophotometer was used to quantify the amount of Evans Blue dye in each sample. An excitation wavelength of approximately 535 nm was utilized and the emission intensity at 600 nm was determined. The microscope was equipped with a motorized stage and also interfaced with a personal computer. This facilitated the computer-controlled movement of the stage with fluorescence measurements at 25 points (500 μm steps) on each dural sample. The mean and standard deviation of the measurements were determined by the computer.
  • The extravasation induced by the electrical stimulation of the trigeminal ganglion was an ipsilateral effect (i.e. occurs only on the side of the dura in which the trigeminal ganglion was stimulated). This allows the other (unstimulated) half of the dura to be used as a control. The ratio of the amount of extravasation in the dura from the stimulated side compared to the unstimulated side was calculated. Saline controls yielded a ratio of approximately 2.0 in rats and 1.8 in guinea pigs. In contrast, a compound which effectively prevented the extravasation in the dura from the stimulated side would have a ratio of approximately 1.0. A dose-response curve was generated and the dose that inhibited the extravasation by 50% (ID50) was approximated. Representative compounds of the present invention were assayed by the above procedure and were found to significantly inhibit neuronal protein extravasation. All compounds of the present invention tested had ID50's of less than or equal to _ nM/Kg.
    • Rabbit Saphenous Vein Contraction
  • Representative compounds of the present invention were tested in a rabbit saphenous vein contraction assay to measure their ability to mediate vasoconstriction.
  • Male New Zealand White rabbits (3-6 lbs) (Hazleton, Kalamazoo, Mich.) were sacrificed by a lethal dose of sodium pentobarbital (325 mg) injected into the ear vein. Tissues were dissected free of connective tissue, cannulated in situ with polyethylene tubing (PESO, outside diameter=0.97 mm) and placed in petri dishes containing modified Krebs solution (described infra). The tips of two 30-gauge stainless steel hypodermic needles bent into an L-shape were slipped into the polyetylene tubing. Vessels were gently pushed from the cannula onto the needles. The needles were then separated so that the lower one was attached with thread to a stationary glass rod and the upper one was tied with thread to the transducer.
  • Tissues were mounted in organ baths containing 10 mL of modified Krebs solution of the following composition: 118.2 mMol NaCl, 4.6 mMol KCl, 1.6 mMol CaCl2.H2O, 1.2 mMol KH2PO4, 1.2 mMol MgSO4, 10.0 mMol dextrose and 24.8 mMol NaHCO3. Tissue bath solutions were maintained at 37° C. and aerated with 95% O2 and 5% CO2. An initial optimum resting force of 1 gm was applied to the saphenous vein. Isometric contractions were recorded as changes in grams of force on a Beckman Dynograph with Statham UC-3 transducers and microscale accessory attachments. Tissues were allowed to equilibrate 1 to 2 hours before exposure to drugs. Cumulative agonist concentration-response curves were generated in tissues and no tissue was used to generate more than two agonist concentration-response curves. Results are expressed as a mean EC50 and the maximal response expressed as a percentage of the maximal tissue contraction response to 67 mM KCl administered initially to each tissue.
  • This vasoconstriction assay measures two important parameters, saphenous vein contraction (EC50) and maximal contraction as a % maximal KCl response (%max KCl). The saphenous vein contraction (EC50) is a measure of the dose required to contract tissue to 50% of the maximal response that the specific compound is capable of mediating. The maximal response that the saphenous vein is capable of exhibiting is measured after administration of a high concentration (67 mM) of KCl. The % maximal KCl contraction is the ratio of the maximal response that the specific compound is capable of mediating divided by the maximal response that the tissue can produce upon stimulation with KCl. For purposes of this application, a compound may be considered to not have significant vasoconstrictive activity if it produces a maximal contraction of less than or equal to 5% of the contraction produced by the 67 mM KCl positive control at compound concentrations of up to 100 μM.
  • Representative compounds of the present invention were tested with the above saphenous vein assay and found to not be significantly vasoconstrictive. All compounds of the present invention tested had an EC50 of less than or equal to _ mM and a %max KCl of less than or equal to _ in this assay. This contrasts greatly with prior art compounds for the treatment of migraine targeting the neural vasoconstrictive model for migraine treatment, which compounds were selected on the basis of strong vasoconstrictive activity, as for example, sumatriptan, which has an EC50 of 0.66 mM and a %max KCl of 64.20 in this assay.
    • Specifidity Index
  • The specificity of compounds of the present invention for 5-HT1F mediated inhibition of neuronal protein extravasation versus vasoconstrictive activity can be expressed with a Specificity Index, which is the ratio of vasoconstriction to efficacy in inhibiting neuronal protein extravasation:
  • Specificity Index = Corrected Vasoconstriction EC 50 ( M ) Extravasation ID 50 ( mMol / kg )
  • The Corrected Vasoconstriction takes into consideration the maximal contraction relative to KCl for each individual compound, and is defined as the vasoconstriction EC50 value divided by the %max KCl.
  • For example, sumatriptan has a corrected vasoconstriction EC50 of 1.03×10−8 M (0.66 mM EC50÷ 64.20%max KCl) and an extravasation inhibition ID50 of 2.6×10−8 mMol/Kg, giving a Specificity Index of 0.40. Compounds of the present invention have Specificity Indexes of greater than or equal to 10. (10 picked for being a lower number in dependent claim of X09150.)
  • Thus the procedure for determining the Specificity Index of any given compound is as follows:
  • 1. Measure the affinity of the compound for the 5-HT1F receptor using the radioligand binding method described above;
  • 2. Once affinity for the 5-HT1F receptor is established, determine whether the compound is an agonist, partial agonist or antagonist of the 5-HT1F receptor by its response in the above described cAMP assay;
  • 3. If the compound is shown to be an agonist or partial agonist with an Emax of at least about 50%, measure efficacy of the compound in inhibition of protein extravasation and saphenous vein contraction using the above described assays; and
  • 4. Calculate the Specificity Index as shown above.
  • While compounds with a Specificity Index greater than 1 are useful for the methods and uses of the present invention, larger values for the Specificity Index are preferred. A larger Specificity Index indicates greater specificity for efficacy in inhibition of neuronal protein extravasation over vasoconstriction. Thus, preferred compounds have a Specificity Index of greater than or equal to 10 (at least 10), preferably greater than or equal to 100 (at least 100). More preferred compounds have a Specificity Index of greater than or equal to 1000 (at least 1000), and yet more preferred compounds have Specificity Indexes greater than or equal to 5000 (at least 5000).
    • Formulations
  • The type of formulation used for the administration of the compounds employed in the methods of the present invention may be dictated by the particular compounds selected, the type of pharmacokinetic profile desired from the route of administration, and the state of the patient.
  • Formulations amenable to oral, sublingual, nasal or injectable administration are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound. See, e.g., REMINGTON'S PHARMACEUTICAL SCIENCES, (16th ed. 1980).
  • In general, a formulation of the present invention includes an active ingredient (a compound of formula I) and is usually mixed with an excipient, diluted by an excipient or enclosed within such a carrier which can be in the form of a capsule, sachet, paper or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the formulations can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing for example up to 10% by weight of the active compound, soft and hard gelatin capsules, gels, suppositories, sterile injectable solutions, and sterile packaged powders.
  • In preparing a formulation, it may be necessary to mill the active compound to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it ordinarily is milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size is normally adjusted by milling to provide a substantially uniform distribution in the formulation, e.g., about 40 mesh. In one embodiment of the present invention, the particle size range is between about 0.1 μm to about 100 μm.
  • Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxybenzoates; sweetening agents; and flavoring agents. The compounds of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
  • The following formulation examples are illustrative only and are not intended to limit the scope of the present invention. The term “active ingredient” refers to a compound of formula I.
    • Formulation Example 1
  • Hard Gelatin Capsules
    Ingredient Quantity (mg/capsule)
    2,4,6-Trifluoro-N-[6-(1-methyl-piperidine- 30.0
    4-carbonyl)-pyridin-2-yl]-benzamide
    hydrochloric acid salt LY587815
    Starch 305.0
    Magnesium stearate 5.0
  • The above ingredients are mixed and filled into hard gelatin capsules in 340 mg quantities.
    • Formulation Example 2
  • Tablet
    Ingredient Quantity (mg/tablet)
    2-Chloro-6-fluoro-N-[6-(1-methyl-piperidine- 25.0
    4-carbonyl)-pyridin-2-yl]-benzamide
    mono-hydrochloric acid salt LY622824
    Cellulose, microcrystalline 200.0
    Colloidal silicon dioxide 10.0
    Stearic acid 5.0
  • The components are blended and compressed to form tablets, each weighing 240 mg.
    • Formulation Example 3
  • Dry Powder Inhaler
    Ingredient Weight %
    2,4,6-Trifluoro-N-methyl-N-[6-(piperidine- 5
    4-carbonyl)-pyridin-2-yl]-benzamideLY2004686
    Lactose 95
  • The active ingredient is mixed with the lactose and the mixture is added to a dry powder inhaling appliance.
    • Formulation Example 4
  • Tablet
    Ingredient Quantity (mg/tablet)
    2-Fluoro-N-[6-(1-methyl-piperidine-4- 30.0
    carbonyl)-pyridin-2-yl]-isonicotinamide LY558431
    Starch 45.0
    Microcrystalline cellulose 35.0
    Polyvinylpyrrolidone 4.0
    (as 10% solution in water)
    Sodium carboxymethyl starch 4.5
    Magnesium stearate 0.5
    Talc 1.0
    Total 120 mg
  • The active ingredient, starch and cellulose are passed through a No. 20 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders, which are then passed through a 16 mesh U.S. sieve. The granules so produced are dried at 50° C.-60° C. and passed through a 16 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 30 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 120 mg.
    • Formulation Example 5
  • Capsules
    Ingredient Quantity (mg/capsule)
    Furan-3-carboxylic acid[6-(1-methyl-piperidine- 40.0
    4-carbonyl)-pyridin-2-yl]-amide LY558422
    Starch 109.0
    Magnesium stearate 1.0
    Total 150.0 mg
  • The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 150 mg quantities.
    • Formulation Example 6
  • Suspensions
    Ingredient Amount
    4-Fluoro-N-[6-(1-methyl-piperidine-4-carbonyl)- 50.0 mg
    pyridin-2-yl]-2-trifluoromethyl-benzamide
    mono-hydrochloric acid salt LY586554
    Xanthan gum  4.0 mg
    Sodium carboxymethyl cellulose (11%) 50.0 mg
    Microcrystalline cellulose (89%)
    Sucrose 1.75 g
    Sodium benzoate 10.0 mg
    Flavor and color q.v.
    Purified water to  5.0 ml
  • The active ingredient, sucrose and xanthan gum are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of the microcrystalline cellulose and sodium carboxymethyl cellulose in water. The sodium benzoate, flavor, and color are diluted with some of the water and added with stirring. Sufficient water is then added to produce the required volume.
    • Formulation Example 7
  • Capsules
    Ingredient Quantity (mg/capsule)
    4-Chloro-2-methoxy-N-[6-(1-methyl-piperidine- 15.0
    4-carbonyl)-pyridin-2-yl]-benzamide DZ13
    Starch 407.0
    Magnesium stearate 3.0
    Total 425.0 mg
  • The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 425 mg quantities.
    • Formulation Example 8
  • Intravenous Formulation
    Ingredient Quantity
    2-Ethoxy-N-[6-(1-methyl-piperidine- 250.0 mg
    4-carbonyl)-pyridin-2-yl]-benzamide DZ14
    Isotonic saline  1000 ml
    • Formulation Example 9
  • Sublingual or Buccal Tablets
    Ingredient Quantity (mg/tablet)
    2,4,6-Trifluoro-N-[6-(1-methyl-piperidine- 10.0
    4-carbonyl)-pyridin-2-yl]-benzamide
    hemi-succinnic acid salt LY683974
    Glycerol 210.5
    Water 143.0
    Sodium citrate 4.5
    Polyvinyl alcohol 26.5
    Polyvinylpyrrolidone 15.5
    Total 410.0 mg
  • The glycerol, water, sodium citrate, polyvinyl alcohol, and polyvinylpyrrolidone are admixed together by continuous stirring and maintaining the temperature at about 90° C. When the polymers have gone into solution, the solution is cooled to about 50-55° C. and the active ingredient is slowly admixed. The homogenous mixture is poured into forms made of an inert material to produce a drug-containing diffusion matrix having a thickness of about 2-4 mm. This diffusion matrix is then cut to form individual tablets having the appropriate size.
    • Formulation Example 9
  • Sublingual or Buccal Tablets
    Ingredient Quantity (mg/tablet)
    2,4,6-Trifluoro-N-[6-(1-methyl-piperidine- 5.0 (freebase equivalent)
    4-carbonyl)-pyridin-2-yl]-benzamide
    hemi-succinnic acid salt LY683974
    Mannitol 20
    Gelatine 2.0
    Water add to total volume of 100 μL
    Total 27.0 mg
  • The compound was dissolved in water containing 20% mannitol and 2% gelatine to provide a stock solution at a concentration of 50 mg/mL (free base equivalent). The solution was aliquoted into forms holding 100 μL solution each. The formulation was then frozen at −20° C. for 3 hours and freeze dried.
    • Formulation Example 8
  • Intravenous Formulation
    Quantity per
    Ingredient 1.0 mL Formulation
    2,4,6-Trifluoro-N-[6-(1-methyl-piperidine- 1.16 mg
    4-carbonyl)-pyridin-2-yl]-benzamide
    hemi-succinnic acid salt DZ14
    Mannitol parenteral 50.0 mg
    Water for injection: q.s. to  1.0 mL
  • The compound and mannitol are dissolved in water and then water is added to obtain the desired final volume. The solution is then sterile filtered and aseptically filled into suitable vials.
  • While it is possible to administer a compound employed in the methods of this invention directly without any formulation, the compounds are usually administered in the form of pharmaceutical formulations comprising a pharmaceutically acceptable excipient and at least one active ingredient. These formulations can be administered by a variety of routes including oral, buccal, rectal, intranasal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. Many of the compounds employed in the methods of this invention are effective as both injectable and oral compositions.
  • In order to administer transdermally, a transdermal delivery device (“patch”) is needed. Such transdermal patches may be used to provide continuous or discontinuous infusion of a compound of the present invention in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Pat. No. 5,023,252. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
  • Frequently, it will be desirable or necessary to introduce the pharmaceutical composition to the brain, either directly or indirectly. Direct techniques usually involve placement of a drug delivery catheter into the host's ventricular system to bypass the blood-brain barrier. One such implantable delivery system, used for the transport of biological factors to specific anatomical regions of the body, is described in U.S. Pat. No. 5,011,472, which is herein incorporated by reference. The delivery of hydrophilic drugs may be enhanced by intra-arterial infusion of hypertonic solutions which can transiently open the blood-brain barrier.
  • In one preferred embodiment of the present invention, there is provided a pharmaceutical formulation comprising at least one active compound as described above in a formulation adapted for buccal and/or sublingual, or nasal administration. This embodiment provides administration of the active compound in a manner that avoids gastric complications, such as first pass metabolism by the gastric system and/or through the liver. This administration route may also reduce adsorption times, providing more rapid onset of therapeutic benefit. The compounds of the present invention may provide particularly favorable solubility profiles to facilitate sublingual/buccal formulations. Such formulations typically require relatively high concentrations of active ingredients to deliver sufficient amounts of active ingredients to the limited surface area of the sublingual/buccal mucosa for the relatively short durations the formulation is in contact with the surface area, to allow the absorption of the active ingredient. Thus, the very high activity of the compounds of the present invention combined with their high solubilities, facilitate their suitability for sublingual/buccal formulation.
  • A compound of formula I is preferably formulated in a unit dosage form, each dosage containing from about 0.001 to about 100 mg, more usually about 1.0 to about 30 mg, of the active ingredient. The term “unit dosage form” refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient as described above.
  • The compounds are generally effective over a wide dosage range. For examples, dosages per day normally fall within the range of about 0.0001 to about 30 mg/kg of body weight. In the treatment of adult humans, the range of about 0.1 to about 15 mg/kg/day, in single or divided dose, is especially preferred. However, it will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way. In some instances dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several smaller doses for administration throughout the day.

Claims (20)

What is claimed is:
1. A compound of formula I:
Figure US20170044136A1-20170216-C00102
or a pharmaceutically acceptable acid addition salt thereof, where;
R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;
R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II
Figure US20170044136A1-20170216-C00103
R3 is hydrogen or C1-C3 alkyl;
R4 is hydrogen, halo, or C1-C3 alkyl;
R5 is hydrogen or C1-C3 alkyl;
R6 is hydrogen or C1-C6 alkyl; and
n is an integer from 1 to 6 inclusively.
2. The compound claim 1, wherein R5 is hydrogen and R4 is hydrogen or halogen.
3. The compound of claim 2, wherein R4 is hydrogen.
4. The Compound of claim 1, wherein R2 is hydrogen or C1-C3 alkyl.
5. The compound of claim 1, wherein R1 is phenyl, substituted phenyl, heterocycle, or substituted heterocycle.
6. The compound of claim 1, wherein R1 is phenyl, substituted phenyl, heterocycle or substituted heterocycle, wherein the heterocycle moiety is selected from the group consisting of furanyl, thiophenyl, pyrrolyl, pyrrolidinyl, pyridinyl, N-methylpyrrolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, triazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, thiazolidinyl, N-acetylthiazolidinyl, pyrimidinyl, pyrazinyl, pyridazinyl, isoquinolinyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, quinolinyl, benzofuranyl, benzothiophenyl, and indolyl, and wherein substituted is taken to mean the ring moiety is substituted with one to three halo substituents; or substituted with one to two substituents independently selected from the group consisting of halo, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 alkylthio, wherein each alkyl, alkoxy and alkylthio substituent can be further substituted independently with C1-C2 alkoxy or with one to five halo groups each independently selected from fluoro and chloro; or substituted with one substituent selected from the group consisting of phenyloxy, benzyloxy, phenylthio, benzylthio, and pyrimidinyloxy, wherein the phenyloxy, benzyloxy, phenylthio, benzylthio, or pyrimidinyloxy moiety can be further substituted with one to two substituents selected from the group consisting of halo, C1-C2 alkyl, and C1-C2 alkoxy; or substituted with one substituent selected from the group consisting of C1-C4 acyl and C1-C4 alkoxycarbonyl, and further substituted with zero to one substituent selected from the group consisting of halo, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 alkylthio.
7. The compound of claim 1, wherein R1 is phenyl, substituted phenyl, heterocycle or substituted heterocycle, wherein the heterocycle moiety is selected from the group consisting of pyridinyl, indolyl, benzofuranyl, furanyl, thiophenyl, benzodioxolyl, and thiazolidinyl, and wherein substituted is taken to mean the ring moiety is substituted with one to three halo substituents; or substituted with one to two substituents independently selected from the group consisting of halo, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 alkylthio, wherein each alkyl, alkoxy and alkylthio substituent can be further substituted independently with C1-C2 alkoxy or with one to five halo groups each independently selected from fluoro and chloro; or substituted with one substituent selected from the group consisting of phenyloxy, benzyloxy, phenylthio, benzylthio, and pyrimidinyloxy, wherein the phenyloxy, benzyloxy, phenylthio, benzylthio, or pyrimidinyloxy moiety can be further substituted with one to two substituents selected from the group consisting of halo, C1-C2 alkyl, and C1-C2 alkoxy; or substituted with one substituent selected from the group consisting of C1-C4 acyl and C1-C4 alkoxycarbonyl, and further substituted with zero to one substituent selected from the group consisting of halo, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 alkylthio.
8. A method for activating 5-HT1F receptors in a mammal comprising administering to a mammal in need of such activation an effective amount of a compound of formula I:
Figure US20170044136A1-20170216-C00104
or a pharmaceutically acceptable acid addition salt thereof, where;
R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl heterocycle, or substituted heterocycle;
R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II
Figure US20170044136A1-20170216-C00105
R3 is hydrogen or C1-C3 alkyl;
R4 is hydrogen, halo, or C1-C3 alkyl;
R5 is hydrogen or C1-C3 alkyl;
R6 is hydrogen or C1-C6 alkyl; and
n is an integer from 1 to 6 inclusively.
9. The method according to claim 8, wherein the mammal is a human.
10. A method for the treatment or prevention of migraine in a mammal comprising administering to a mammal in need of such treatment or prevention an effective amount of a compound of formula I:
Figure US20170044136A1-20170216-C00106
or a pharmaceutically acceptable acid addition salt thereof, where;
R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, -substituted phenyl, heterocycle, or substituted heterocycle;
R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II
Figure US20170044136A1-20170216-C00107
R3 is hydrogen or C1-C3 alkyl;
R4 is hydrogen, halo, or C1-C3 alkyl;
R5 is hydrogen or C1-C3 alkyl;
R6 is hydrogen or C1-C6 alkyl; and
n is an integer front 1 to 6 inclusively.
11. The method according to claim 10, wherein the mammal is a human.
12. The compound of claim 5, wherein R5 is hydrogen and R4 is hydrogen or halogen.
13. The compound of claim 12, wherein R4 is hydrogen.
14. The compound of claim 5, wherein R2 is hydrogen or C1-C3 alkyl.
15. The compound of claim 6, wherein R5 is hydrogen and R4 is hydrogen or halogen.
16. The compound of claim 15, wherein R4 is hydrogen.
17. The compound of claim 6, wherein R2 is hydrogen or C1-C3 alkyl.
18. The compound of claim 7, wherein R5 is hydrogen and R4 is hydrogen or halogen.
19. The compound of claim 18, wherein R4 is hydrogen.
20. The compound of claim 7, wherein R2 is hydrogen or C1-C3 alkyl.
US15/091,776 2002-03-29 2016-04-06 Pyridinoylpiperidines As 5-HT1F Agonists Abandoned US20170044136A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/091,776 US20170044136A1 (en) 2002-03-29 2016-04-06 Pyridinoylpiperidines As 5-HT1F Agonists

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US36908802P 2002-03-29 2002-03-29
PCT/US2003/008455 WO2003084949A1 (en) 2002-03-29 2003-03-27 Pyridinoylpiperidines as 5-ht1f agonists
US10/509,770 US7423050B2 (en) 2002-03-29 2003-03-27 Pyridinoylpiperidines as 5-HT1F agonists
US12/221,919 US20090209563A1 (en) 2002-03-29 2008-08-07 Pyridinoylpiperidines as 5-HT1F agonists
US13/363,895 US8748459B2 (en) 2002-03-29 2012-02-01 Pyridinoylpiperidines as 5-HT1F agonists
US14/296,911 US20150376178A1 (en) 2002-03-29 2014-06-05 Pyridinoylpiperidines As 5-HT1F Agonists
US15/091,776 US20170044136A1 (en) 2002-03-29 2016-04-06 Pyridinoylpiperidines As 5-HT1F Agonists

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/296,911 Continuation US20150376178A1 (en) 2002-03-29 2014-06-05 Pyridinoylpiperidines As 5-HT1F Agonists

Publications (1)

Publication Number Publication Date
US20170044136A1 true US20170044136A1 (en) 2017-02-16

Family

ID=28791923

Family Applications (6)

Application Number Title Priority Date Filing Date
US10/509,770 Active 2030-02-27 US7423050B2 (en) 2002-03-29 2003-03-27 Pyridinoylpiperidines as 5-HT1F agonists
US12/220,225 Expired - Lifetime US8044207B2 (en) 2002-03-29 2008-07-22 Pyridinoylpiperidines as 5-HT1F agonists
US12/221,919 Abandoned US20090209563A1 (en) 2002-03-29 2008-08-07 Pyridinoylpiperidines as 5-HT1F agonists
US13/363,895 Expired - Lifetime US8748459B2 (en) 2002-03-29 2012-02-01 Pyridinoylpiperidines as 5-HT1F agonists
US14/296,911 Abandoned US20150376178A1 (en) 2002-03-29 2014-06-05 Pyridinoylpiperidines As 5-HT1F Agonists
US15/091,776 Abandoned US20170044136A1 (en) 2002-03-29 2016-04-06 Pyridinoylpiperidines As 5-HT1F Agonists

Family Applications Before (5)

Application Number Title Priority Date Filing Date
US10/509,770 Active 2030-02-27 US7423050B2 (en) 2002-03-29 2003-03-27 Pyridinoylpiperidines as 5-HT1F agonists
US12/220,225 Expired - Lifetime US8044207B2 (en) 2002-03-29 2008-07-22 Pyridinoylpiperidines as 5-HT1F agonists
US12/221,919 Abandoned US20090209563A1 (en) 2002-03-29 2008-08-07 Pyridinoylpiperidines as 5-HT1F agonists
US13/363,895 Expired - Lifetime US8748459B2 (en) 2002-03-29 2012-02-01 Pyridinoylpiperidines as 5-HT1F agonists
US14/296,911 Abandoned US20150376178A1 (en) 2002-03-29 2014-06-05 Pyridinoylpiperidines As 5-HT1F Agonists

Country Status (31)

Country Link
US (6) US7423050B2 (en)
EP (1) EP1492786B1 (en)
JP (2) JP4493345B2 (en)
KR (1) KR100985995B1 (en)
CN (1) CN100352817C (en)
AR (1) AR039150A1 (en)
AT (1) ATE341543T1 (en)
AU (1) AU2003224719B2 (en)
BR (1) BRPI0308495B8 (en)
CA (2) CA2478229C (en)
CR (1) CR7496A (en)
CY (1) CY1105899T1 (en)
DE (1) DE60308850T2 (en)
DK (1) DK1492786T3 (en)
EA (1) EA007966B1 (en)
EC (1) ECSP045317A (en)
EG (1) EG25226A (en)
ES (1) ES2277074T3 (en)
HR (1) HRP20040883B1 (en)
IL (1) IL163928A0 (en)
MX (1) MXPA04009497A (en)
MY (1) MY134666A (en)
NO (1) NO330394B1 (en)
NZ (1) NZ534952A (en)
PE (1) PE20030976A1 (en)
PL (1) PL210019B1 (en)
PT (1) PT1492786E (en)
TW (1) TWI263497B (en)
UA (1) UA77504C2 (en)
WO (1) WO2003084949A1 (en)
ZA (1) ZA200407666B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10899770B2 (en) 2017-02-20 2021-01-26 Hangzhou Solipharma Co., Ltd. Crystal form of ACP-196 salt and preparation method, pharmaceutical composition, and use thereof

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263497B (en) * 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
BRPI0409211A (en) 2003-04-18 2006-03-28 Lilly Co Eli compound, pharmaceutical composition, methods for activating 5-ht1f receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal, and, use of a compound
AU2003903597A0 (en) * 2003-07-11 2003-07-24 Jakov Vaisman Treatment of premature ejaculation
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
ES2291978T3 (en) * 2003-12-17 2008-03-01 Eli Lilly And Company COMPOUNDS OF (4-AMINOCICLOHEXEN-1-IL) PHENYL AND (4-AMINOCICLOHEXEN-1-IL) PIRIDINYL SUBSTITUTED AS AGONISTS OF 5-HT1F.
WO2006022442A1 (en) * 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. Novel heterocyclic amide derivatives having dihydroorotate dehydrogenase inhibiting activity
EP1794130A1 (en) * 2004-09-20 2007-06-13 Biolipox AB Pyrazole compounds useful in the treatment of inflammation
US20070225318A1 (en) * 2004-09-20 2007-09-27 Biolipox Ab Pyrazole Compounds Useful In The Treatment Of Inflammation
US20060178349A1 (en) * 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
TW200800911A (en) * 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
TW200732320A (en) * 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
EA200801108A1 (en) * 2005-10-31 2008-10-30 Биолипокс Аб TRIAZOLE, SUITABLE FOR THE TREATMENT OF INFLAMMATION
WO2007052000A1 (en) * 2005-11-01 2007-05-10 Biolipox Ab Pyrazoles useful in the treatment of inflammation
AU2007216563B2 (en) 2006-02-17 2012-08-09 F. Hoffmann-La Roche Ag Benzoyl-piperidine derivatives as 5HT2/D3 modulators
NO2413933T3 (en) 2009-04-02 2018-03-31
US8429652B2 (en) 2009-06-22 2013-04-23 Citrix Systems, Inc. Systems and methods for spillover in a multi-core system
WO2011123654A1 (en) * 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
US20120129842A1 (en) 2010-11-18 2012-05-24 Paul Francis Jackson Bisthiazole inhibitors of pro-matrix metalloproteinase activation
CN102993086A (en) * 2012-10-11 2013-03-27 南通市华峰化工有限责任公司 Method for synthesizing 2,6-dibromo pyridine
WO2018010345A1 (en) * 2016-07-15 2018-01-18 杭州领业医药科技有限公司 Crystalline form of receptor agonist, and manufacturing method and pharmaceutical composition thereof
PE20191148A1 (en) 2016-09-23 2019-09-02 Teva Pharmaceuticals Int Gmbh TREATMENT OF REFRACTORY MIGRANA
CN108137605B (en) 2016-10-05 2021-07-13 杭州领业医药科技有限公司 Crystal form of ACP-196, its preparation method and pharmaceutical composition
US11014892B2 (en) 2016-11-02 2021-05-25 Musc Foundation For Research Development 5HT1F receptor agonists and mitochondrial biogenesis
JP2020500936A (en) 2016-12-06 2020-01-16 コルシド ファーマシューティカルズ，インコーポレイテッド Compositions and methods relating to pyridinoylpiperidine 5-HT1F agonists
SG10201912846PA (en) * 2017-01-13 2020-02-27 Sumitomo Dainippon Pharma Co Ltd Therapeutic agent for non-motor symptoms associated with parkinson's disease
EP3601216B1 (en) * 2017-03-21 2023-10-25 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same for the treatment of hepatitis b virus infection
TWI754772B (en) 2017-09-06 2022-02-11 美商美國禮來大藥廠 Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine
CN110386918B (en) * 2018-04-23 2020-06-09 新发药业有限公司 Preparation method of 5-HT1F agonist compound
CA3107145A1 (en) * 2018-08-24 2020-02-27 Sunshine Lake Pharma Co., Ltd. Pyridinylmethylenepiperidine derivatives and uses thereof
TWI826514B (en) 2018-09-04 2023-12-21 美商美國禮來大藥廠 Chronic nightly dosing of lasmiditan for migraine prevention
WO2020095171A1 (en) * 2018-11-05 2020-05-14 Glenmark Life Sciences Limited, Glenmark Pharmaceuticals Limited Process for preparation of lasmiditan
ES2801774B2 (en) * 2019-07-01 2022-03-30 Moehs Iberica Sl 2,2-DIMETHYL-N-[6-(1-METHYL-PIPERIDIN-4-CARBONIL)-PYRIDIN-2-IL]-PROPIONAMIDE, PROCEDURE FOR THE PREPARATION OF (6-AMINO-PYRIDIN-2-IL)-( 1-METHYL-PIPERIDIN-4-IL)-METHANONE USING SAID COMPOUND AND USE OF SAID COMPOUND IN THE PREPARATION OF LASMIDITAN
TWI829107B (en) * 2019-07-09 2024-01-11 美商美國禮來大藥廠 Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate
CN110981854B (en) * 2019-09-10 2023-03-28 南京三元阳普医药科技有限公司 Synthesis method of 2-amino-6- (1-alkyl piperidine-4-carbonyl) pyridine compound
CN111187251B (en) * 2019-11-22 2023-06-09 广东东阳光药业有限公司 Pyridylpiperidine derivatives and uses thereof
CN111187252B (en) * 2019-11-22 2023-06-09 广东东阳光药业有限公司 Pyridinoyl azaspiroheptane derivatives and their use
CN110845402B (en) * 2019-11-22 2023-05-09 广东东阳光药业有限公司 Pyridine methylene piperazine derivatives and uses thereof
WO2021097781A1 (en) * 2019-11-22 2021-05-27 广东东阳光药业有限公司 Pyridine methylene piperidine derivative and use thereof
IT201900023937A1 (en) 2019-12-13 2021-06-13 Olon Spa Process for the preparation of Lasmiditan and a synthetic intermediate
CN113045540B (en) * 2019-12-27 2024-02-13 上海天慈国际药业有限公司 Preparation method of masmipide
EP4096662A4 (en) * 2020-01-31 2024-02-14 Glenmark Life Sciences Limited METHOD FOR PRODUCING LASMIDITAN
CN113637003B (en) * 2020-05-11 2024-03-19 鲁南制药集团股份有限公司 Method for preparing 2-amino-6- (piperidine-4-acyl) pyridine derivative
CN111943930B (en) * 2020-08-25 2022-11-01 南京三元阳普医药科技有限公司 Synthesis process of Lasmidinan
WO2022079591A1 (en) * 2020-10-14 2022-04-21 Alembic Pharmaceuticals Limited Pharmaceutical composition of lasmiditan and process of preparation thereof
CN114573555A (en) * 2020-11-30 2022-06-03 上海天慈国际药业有限公司 Preparation method of compound for treating migraine
CN114685439B (en) * 2020-12-30 2025-07-22 鲁南制药集团股份有限公司 Lasemidi Process for the preparation of tam
WO2022236004A1 (en) 2021-05-07 2022-11-10 Eli Lilly And Company Taste masked compostions of 2,4,6-trifluoro- n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2- ylj-benzamide hemisuccinate, and orally disentegrating tablet comprising the same
CN115594665A (en) * 2021-07-08 2023-01-13 北京万全德众医药生物技术有限公司（Cn） New preparation method of Lasmidiptan
IT202100023861A1 (en) 2021-09-16 2023-03-16 Procos Spa PROCESS FOR THE PREPARATION OF (6-ALOPYRIDIN-2-IL)(1-METHYLPIPERIDIN-4-IL)METHANONE
CN113866318B (en) * 2021-10-21 2023-07-04 佛山奕安赛医药科技有限公司 Detection method of (6-aminopyridine-2-yl) (1-methylpiperidine-4-yl) methanone dihydrochloride
CN116239569A (en) * 2021-12-07 2023-06-09 山东新时代药业有限公司 A kind of Lasmidestan hemisuccinate crystal form and preparation method thereof
CN116239570A (en) * 2021-12-08 2023-06-09 山东新时代药业有限公司 A new crystal form of lasmidiptan hemisuccinate
WO2023152081A1 (en) 2022-02-09 2023-08-17 Inke, S.A. Process for preparing pyridinoylpiperidines 5-ht1f agonists and salts thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US677428A (en) * 1900-04-28 1901-07-02 Chicago Handle Bar Co Steering device for bicycles.
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
JPH03255426A (en) 1990-03-06 1991-11-14 Toshiba Corp Organic nonlinear optical material
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5360735A (en) 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells
US5521196A (en) 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5698571A (en) 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US5521197A (en) 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
EA001113B1 (en) 1995-03-20 2000-10-30 Эли Лилли Энд Компани 5-substituted -3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles and their pharmaceutically acceptable salts and solvates, pharmaceutical composition on their basem method for activation of 5-ht receptors, and method for inhibition of neuronal protein extravasation
CA2234166A1 (en) 1995-10-10 1997-04-17 Patric James Hahn N-¬2-substituted-3-(2-aminoethyl)-1h-indol-5-yl|-amides: new 5-ht1f agonists
US6153754A (en) * 1995-12-21 2000-11-28 Albany Molecular Research, Inc. Process for production of piperidine derivatives
WO1997036867A1 (en) * 1996-03-29 1997-10-09 Pfizer Inc. Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-ht1a- and/or 5-ht1d receptors
US5708187A (en) 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
WO1998008502A1 (en) 1996-08-28 1998-03-05 Eli Lilly And Company SUBSTITUTED 1,2,3,4-TETRAHYDRO-2-DIBENZOFURANAMINES AND 2-AMINOCYCLOHEPTA[b]BENZOFURANS
WO1998011895A1 (en) * 1996-09-18 1998-03-26 Eli Lilly And Company A method for the prevention of migraine
AU4652697A (en) 1996-10-08 1998-05-05 Eli Lilly And Company New serotonin 5-ht1f agonists
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
EP0875513A1 (en) 1997-04-14 1998-11-04 Eli Lilly And Company Substituted heteroaromatic 5-HT 1F agonists
ID23053A (en) 1997-06-04 2000-01-20 Lilly Co Eli CARBOXAMIDE USED AS A 5-HT <IF> AGONIST
US5905084A (en) 1997-11-14 1999-05-18 Eli Lilly And Company 5-HTIF -agonists effective in treating migraine
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6303627B1 (en) * 1998-06-19 2001-10-16 Eli Lilly And Company Inhibitors of serotonin reuptake
WO2000000490A2 (en) 1998-06-26 2000-01-06 Eli Lilly And Company 5-ht1f agonists
EP1089993B1 (en) * 1998-06-30 2003-10-22 Eli Lilly And Company 5-ht1f agonists
WO2000034266A1 (en) 1998-12-11 2000-06-15 Eli Lilly And Company Indole derivatives and their use as 5-ht1f agonists
US6777428B1 (en) * 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
WO2000047559A2 (en) * 1999-02-10 2000-08-17 Eli Lilly And Company 5-ht1f agonists
AU3354000A (en) 1999-02-26 2000-09-14 Eli Lilly And Company 5-ht1f agonists
EP1299334B1 (en) 2000-07-13 2008-01-16 MERCK PATENT GmbH Chiral compounds i
US6650463B2 (en) 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
US20050080112A1 (en) 2001-06-22 2005-04-14 Madsen Lars Siim Compounds for use in disorders associated with mast cell or basophil acitvity
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
US6900210B2 (en) 2002-11-22 2005-05-31 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
BRPI0409211A (en) * 2003-04-18 2006-03-28 Lilly Co Eli compound, pharmaceutical composition, methods for activating 5-ht1f receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal, and, use of a compound
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
WO2005007621A2 (en) 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2006048771A1 (en) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510143D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
MX2007006109A (en) 2004-12-01 2007-10-04 Devgen Nv 5-CARBOXAMIDO SUBSTITUTED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE Kv FAMILY.
KR20060067738A (en) 2004-12-15 2006-06-20 주식회사 대웅제약 Novel N-arylamide derivatives exhibiting potent analgesic effects as antagonists of vanilloid receptors and pharmaceutical compositions containing them
US20060178349A1 (en) 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
DE102005016634A1 (en) 2005-04-12 2006-10-19 Merck Patent Gmbh Novel aza heterocycles as kinase inhibitors
KR100976063B1 (en) 2007-03-16 2010-08-17 동아제약주식회사 Novel benzamide derivative compounds and preparation methods thereof
NO2413933T3 (en) 2009-04-02 2018-03-31
WO2011123654A1 (en) 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10899770B2 (en) 2017-02-20 2021-01-26 Hangzhou Solipharma Co., Ltd. Crystal form of ACP-196 salt and preparation method, pharmaceutical composition, and use thereof

Also Published As

Publication number Publication date
JP2010159272A (en) 2010-07-22
US20080300407A1 (en) 2008-12-04
IL163928A0 (en) 2005-12-18
US7423050B2 (en) 2008-09-09
PL210019B1 (en) 2011-11-30
CA2694410A1 (en) 2003-10-16
CY1105899T1 (en) 2011-02-02
ECSP045317A (en) 2004-11-26
TW200306186A (en) 2003-11-16
AU2003224719B2 (en) 2008-08-14
EG25226A (en) 2011-11-17
US20050222206A1 (en) 2005-10-06
US20090209563A1 (en) 2009-08-20
DE60308850T2 (en) 2007-05-24
US20120329820A1 (en) 2012-12-27
UA77504C2 (en) 2006-12-15
KR20040094872A (en) 2004-11-10
NZ534952A (en) 2005-11-25
ES2277074T3 (en) 2007-07-01
WO2003084949A1 (en) 2003-10-16
CN100352817C (en) 2007-12-05
CA2694410C (en) 2013-01-29
NO20044654L (en) 2004-10-28
TWI263497B (en) 2006-10-11
MY134666A (en) 2007-12-31
US20150376178A1 (en) 2015-12-31
HK1073464A1 (en) 2005-10-07
HRP20040883B1 (en) 2012-11-30
BRPI0308495B1 (en) 2015-07-07
EA200401282A1 (en) 2005-02-24
PE20030976A1 (en) 2003-11-12
KR100985995B1 (en) 2010-10-06
AU2003224719A1 (en) 2003-10-20
JP2005530722A (en) 2005-10-13
CA2478229A1 (en) 2003-10-16
MXPA04009497A (en) 2005-06-08
DE60308850D1 (en) 2006-11-16
EA007966B1 (en) 2007-02-27
ATE341543T1 (en) 2006-10-15
HRP20040883A2 (en) 2004-12-31
ZA200407666B (en) 2006-02-22
PL372845A1 (en) 2005-08-08
EP1492786A1 (en) 2005-01-05
CR7496A (en) 2004-11-27
CN1642939A (en) 2005-07-20
PT1492786E (en) 2007-01-31
US8748459B2 (en) 2014-06-10
BR0308495A (en) 2005-02-01
BRPI0308495B8 (en) 2021-05-25
US8044207B2 (en) 2011-10-25
AR039150A1 (en) 2005-02-09
EP1492786B1 (en) 2006-10-04
CA2478229C (en) 2011-03-22
JP4493345B2 (en) 2010-06-30
NO330394B1 (en) 2011-04-04
DK1492786T3 (en) 2007-02-12

Similar Documents

Publication Publication Date Title
US8748459B2 (en) Pyridinoylpiperidines as 5-HT1F agonists
US7608629B2 (en) (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists
US7803813B2 (en) Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists
HK1073464B (en) Pyridinoylpiperidines as 5-ht1f agonists
US7312236B2 (en) Substituted (4-aminocyclohexen-1-yl)phenyl and (4-aminocyclohexen-1-yl)pyridinyl compounds as 5-HT1F agonists

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION